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ABSTRACT 
	  
	  F-­‐box	  proteins	  are	  the	  substrate-­‐recognition	  components	  of	  the	  SCF	  E3	  ubiquitin	  ligases	   that	   catalyze	   the	   ubiquitylation	   of	   many	   key	   cell	   cycle	   regulators.	  Functional	  studies	  indicate	  that	  the	  ubiquitin-­‐proteasome	  system	  participates	  in	  the	   control	   of	   nearly	   all	   cellular	   processes	   through	   the	   timely	   degradation	   of	  short-­‐lived	  regulatory	  proteins.	  Accordingly,	  altered	  protein	  degradation	  due	  to	  defective	  E3	   ligases	  has	  been	  shown	  to	  underlie	  many	  human	  diseases,	  such	  as	  cancer.	  The	  studies	  in	  this	  thesis	  have	  focused	  on	  the	  functional	  characterization	  of	   two	   F-­‐box	   proteins,	   FBXW7/hCDC4	   and	   FBXO28,	   in	   ubiquitylation	   and	  degradation	   of	   the	   cell	   cycle	   regulatory	   proteins,	   cyclin	   E	   and	   Myc,	   and	   their	  potential	  deregulation	  in	  cancer.	  The	  tumor	  suppressor	  protein	  FBXW7/hCDC4	  has	  been	  linked	  to	  human	  tumorigenesis	   through	   the	   targeted	   degradation	   of	   several	   important	  oncoproteins,	   including	  cyclin	  E.	  The	  ubiquitin-­‐dependent	  turnover	  of	  cyclin	  E1	  is	  regulated	  by	  phosphorylation	  and	  isomerization	  of	  cyclin	  E1,	  and	  executed	  by	  the	   concerted	   actions	   of	   the	   FBXW7/hCDC4-­‐α	   and	   -­‐γ	   isoforms.	   Our	   results	  demonstrate	   that	   this	   two-­‐isoform	   dependence	   is	   not	   employed	   in	   conditions	  where	  cyclin	  E1	  levels	  are	  elevated.	  Under	  these	  circumstances,	  cyclin	  E1	  can	  be	  ubiquitylated	   by	   FBXW7/hCDC4-­‐α	   alone,	   perhaps	   through	   an	   alternative	  pathway	  that	  does	  not	  require	  isomerization.	  In	  the	  second	  study,	  we	  report	  that	  cyclin	   E2	   is	   targeted	   for	   ubiquitin-­‐dependent	   proteolysis	   by	   SCFFBXW7/hCDC4.	  Interestingly,	   we	   found	   that	   cyclin	   E1	   enhances	   the	   ubiquitin-­‐dependent	  proteolysis	   of	   cyclin	   E2,	   suggesting	   a	  mechanism	  by	  which	   cyclin	   E1	   regulates	  the	   abundance	   of	   cyclin	   E2,	   allowing	   it	   to	   possibly	   perform	   non-­‐redundant	  functions	  in	  cell	  cycle	  control.	  	  In	  the	  last	  two	  studies	  we	  characterized	  the	  novel	  F-­‐box	  protein,	  FBXO28,	  initially	   identified	   in	   an	   RNAi	   screen	   for	   F-­‐box	   genes	   that	   regulate	   cell	  proliferation.	   We	   show	   that	   SCFFBXO28	   targets	   Myc	   for	   ubiquitylation,	   without	  altering	  Myc	   protein	   turnover.	   Instead,	   FBXO28	  was	   found	   to	   be	   an	   important	  regulator	   of	   Myc-­‐driven	   transcription	   through	   the	   ubiquitin-­‐dependent	  recruitment	   of	   a	   transcriptional	   cofactor	   to	   Myc	   target	   gene	   promoters.	   In	  addition,	   we	   found	   that	   FBXO28	   is	   a	   nuclear	   substrate	   for	   cyclin-­‐CDK	  phosphorylation	  and	  that	  phosphorylation	  of	  FBXO28	  is	  significantly	  associated	  with	  poor	  prognosis	   in	  patients	  with	  primary	  breast	   cancer.	   FBXO28	  may	   thus	  constitute	   an	   important	   player	   in	   cell	   proliferation	   and	   Myc	   pathways	   during	  tumorigenesis.	  	  In	   summary,	   in	   this	   thesis	   we	   present	   different	   mechanisms	   by	   which	  SCF-­‐mediated	   ubiquitylation	   can	   regulate	   proliferation,	   thus	   linking	   ubiquitin-­‐mediated	  processes	  to	  proliferative	  pathways	  often	  altered	  in	  human	  cancer.	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1.	  LIST	  OF	  ABBREVIATIONS	  
	  
	  APC/C	  	   anaphase-­‐promoting	  complex/Cyclosome	  	  ATP	   	   adenosine	  triphosphate	  BCSS	   	   breast	  cancer-­‐specific	  survival	  bHLH/LZ	   basic	  helix-­‐loop-­‐helix	  leucine	  zipper	  	  B-­‐ALL	   	   B-­‐cell	  acute	  lymphoblastic	  leukemia/lymphoma	  BIM	   	   BCL2	  interacting	  mediator	  of	  cell	  death	  BRCA	   	   breast	  cancer	  susceptibility	  gene	  CBP	   	   CREB-­‐binding	  protein	  CDK	   	   cyclin-­‐dependent	  kinase	  ChIP	   	   chromatin	  immunoprecipitation	  Cip/Kip	   cdk	  interacting	  protein/cdk	  inhibitory	  protein	  CKI	   	   CDK	  inhibitor	  CPD	   	   CDC4	  phosphodegron	  D-­‐box	   	   destruction	  box	  DNA	   	   deoxyribonucleic	  acid	  DNMT3a	   DNA-­‐methyltransferase	  3a	  DUB	   	   deubiquitylating	  enzyme	  ER	   	   estrogen	  receptor	  GSK3	   	   glycogen	  synthase	  kinase	  3	   	  HAT	   	   histone	  acetyltransferase	  hCDC4	  	   human	  cell	  division	  cycle	  4	  HDAC	   	   histone	  deacetylase	  HECT	   	   homologous	  to	  the	  E6-­‐AP	  carboxyl	  terminus	  HER2	   	   human	  epidermal	  growth	  factor	  receptor	  2	  HUWE1	   HECT,	  UBA	  and	  WWE	  domain-­‐containing	  protein	  1	  INK4	   	   inhibitor	  of	  CDK4	  K	   	   lysine	  Mad	   	   Max	  dimerizer	  Max	   	   Myc-­‐associated	  protein	  X	  MBI/II	  	   myc	  box	  I	  or	  myc	  box	  II	  MCM	   	   minichromosome	  maintenance	   	  Mdm2	  	   mouse	  double	  minute	  2	  MEFs	   	   mouse	  embryonic	  fibroblasts	  Mga	   	   Max	  gene-­‐associated	  protein	  Miz1	   	   Myc-­‐interacting	  zinc	  finger	  protein	  1	  Mnt	   	   Max-­‐interacting	  protein	  mRNA	  	   messenger	  ribonucleic	  acid	  Mule	   	   Mcl-­‐1	  ubiquitination	  ligase	  E2	  Mxi1	   	   max	  interactor	  1	  NF	   	   nuclear	  fraction	  NF-­‐κB	   	   nuclear	  factor-­‐kappa	  B	  NLS	   	   nuclear	  localization	  signal	  OS	   	   overall	  survival	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2.	  LITERATURE	  REVIEW	  
	  
	  
The	  work	  presented	   in	   this	   thesis	   focuses	  on	  the	  roles	  of	  protein	  ubiquitylation	   in	  
the	   control	   of	   proliferative	   pathways	   often	   operating	   at	   an	   increased	   rate	   to	  
promote	  cancer.	  I	  hope	  that	  the	  topics	  that	  I	  have	  chosen	  to	  cover	  in	  this	  literature	  
review	  will	   reflect	   this.	   Since	   understanding	   the	   biology	   of	   cancer	   has	   ultimately	  




2.1.	  CANCER:	  THE	  PRICE	  OF	  MULTICELLULARITY	  
	  	  Most	  of	  us	  have	  a	  very	  clear	  reaction	  to	  the	  term	  cancer:	  fear.	  We	  consider	  cancer	  as	  a	  terrible	  and	  painful	  disease	  that	  greatly	  shortens	  the	  lifespan	  of	  the	  affected	  person.	   However,	   for	   the	  most	   part,	   we	   have	   a	   less	   clear	   idea	   of	   what	   cancer	  really	  is.	  Cancer	  can	  be	  broadly	  defined	  as	  a	  genetic	  disease	  that	  arises	  from	  the	  unrestrained	  and	  destructive	  proliferation	  of	  cells	  that	  is	  irresponsive	  to	  external	  signals.	   But	   how	   do	   normal	   cells	   become	   cancer	   cells?	   Normal	   physiology	   of	  multicellular	   organisms	   requires	   the	   continuous	   renewal	   of	   cell	   populations,	  largely	   accomplished	   by	   cell	   growth	   (defined	   as	   an	   increase	   in	   cell	  mass),	   cell	  division,	   and	   the	   programmed	   elimination	   of	   cells	   (termed	   apoptosis)	   in	  response	   to	   environmental	   cues.	   The	   tight	   control	   of	   these	   processes	   is	   thus	  essential	   to	   the	   proper	   functioning	   of	   the	   organism	   and	   perturbation	   of	   the	  cellular	   balance	   between	   life	   and	   death	   can	   have	   devastating	   consequences	   to	  the	   organism	   as	   a	   whole.	   Occasionally,	   a	   cell	   acquires	   a	   set	   of	   advantageous	  changes	  that	  allows	  it	  to	  escape	  normal	  regulation,	  and	  to	  grow	  and	  proliferate	  autonomously,	   invading	   other	   tissues	   and	   organs.	   These	   changes,	   called	  
mutations	  and/or	  epigenetic	  changes,	  simultaneously	  affect	  two	  groups	  of	  genes:	  those	   that	  promote	  cell	   growth	  and	  proliferation,	   evading	  cell	  death,	  known	  as	  
oncogenes,	   and	   those	   that	   restrain	   proliferative	   events	   and	   induce	   death	   by	  apoptosis,	   called	   tumor	   suppressor	   genes	   (TSGs).	   Through	   a	   combination	   of	  sufficiently	   advantageous	   mutations,	   cells	   ultimately	   acquire	   an	   array	   of	  functional	   capabilities,	   commonly	   referred	   to	   as	   the	  hallmarks	   of	   cancer.	   These	  include:	   (1)	  sustaining	  proliferative	  signalling,	   (2)	  evading	  growth	  suppressors,	  (3)	   resisting	   cell	   death,	   (4)	   enabling	   replicative	   immortality,	   (5)	   inducing	  angiogenesis,	   (6)	   activating	   tissue	   invasion	  and	  metastasis,	   (7)	   reprogramming	  of	  energy	  metabolism,	  and	  (8)	  evading	   immune	  destruction	  [1].	  The	  genes	   that	  are	  altered	  and	   result	   in	  disturbance	  of	   these	  processes	  differ	  between	   tumors	  from	   different	   tissue	   types,	   but	   the	   acquired	   traits	   are	   remarkably	   consistent	  across	   cancers.	   Therefore,	   rather	   than	   being	   a	   single	   disease,	   the	   term	   cancer	  encompasses	  hundreds	  of	  different	  diseases,	  each	  with	  its	  own	  set	  of	  risk	  factors	  and	  epidemiology,	  which	  can	  arise	   from	  most	  cell	   types	  and	  organs.	  Hence,	   the	  requisite	   to	   the	   preservation	   of	   a	   long	   life	  with	   tissues	   that	   regenerate	   comes	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with	   the	   ever-­‐present	   risk	   of	   initiating	   processes	   that	   might	   result	   in	   fatal	  malignancy.	  
	  
	  
Given	  that	  in	  Paper	  III	  and,	  in	  particular,	  in	  Paper	  IV,	  we	  examine	  the	  expression	  of	  
the	  F-­box	  protein,	  FBXO28,	  in	  breast	  cancers,	  I	  owe	  the	  reader	  a	  short	  description	  
of	  this	  type	  of	  cancer.	  	  	  	  
2.1.1.	  On	  breast	  cancer	  	  Breast	   carcinogenesis	   arises	   from	  a	  multi-­‐step	  process	   in	  which	  normal	  breast	  epithelium	   evolves	   into	   an	   invasive	   cancer	   that	   can	   eventually	   spread	   via	   the	  lymphatic	  and	  vascular	  systems	  to	  give	  rise	  to	  distant	  metastases	  [2].	  The	  steps	  in	   the	  development	  of	  breast	   cancer	   seem	  to	  correlate	   to	  genetic	  alterations	   in	  either	  oncogenes	  or	  tumor	  suppressor	  genes.	  	  Breast	   cancer	   can	   be	   divided	   into	   two	   major	   groups:	   sporadic	   and	  hereditary	   breast	   cancer.	   In	   sporadic	   breast	   cancer,	   mutations	   are	   acquired	  during	   the	   individual’s	   lifetime,	   and	   occur	   in	   somatic	   cells	   without	   underlying	  changes	   in	   germ	   cells.	   Early	   mutations	   in	   sporadic	   breast	   cancer	   include	  mutational	   activation	   of	   oncogenes,	   with	   concomitant	   overexpression	   of	   the	  oncoprotein,	  such	  as	  c-­‐Myc,	  cyclin	  D1,	  and	  HER2/neu	  [2-­‐5].	  In	  hereditary	  breast	  cancer,	  the	  individual	  is	  born	  with	  a	  mutation	  (germline	  mutation)	  in	  one	  copy	  of	  a	   tumor	   suppressor	   gene	   (TSG)	   that,	   in	   combination	   with	   inactivation	   of	   the	  second	  copy,	  or	  allele,	  can	  support	  cancer	  development.	  This	  is	  called	  Knudson’s	  “two-­‐hit-­‐hypothesis”	   of	   carcinogenesis	   [6].	   The	   most	   prominent	   predisposing	  mutations	   in	   hereditary	   breast	   cancer	   occur	   in	   the	   BRCA1	   and	   BRCA2	   genes	  (breast	   cancer	   susceptibility	   gene	   1	   and	   breast	   cancer	   susceptibility	   gene	   2,	  respectively).	   The	  products	   of	   these	  TSGs	  play	   critical	   roles	   in	  maintaining	   the	  integrity	  of	  the	  cellular	  genome	  through	  DNA	  repair.	  Women	  carrying	  germline	  BRCA1	  or	  BRCA2	  mutations	  have	  an	  increased	  lifetime	  risk	  for	  breast	  	  (50-­‐90%	  and	   40-­‐80%,	   respectively)	   and	   ovarian	   (20-­‐50%	   and	   10-­‐20%,	   respectively)	  cancers	  [7].	  	  Breast	   cancer	   classification	   assigns	   breast	   cancers	   into	   several	   different	  categories	  based	  on	  multiple	  parameters.	  The	  purpose	  of	  the	  classification	  is	  to	  aid	  in	  the	  selection	  of	  the	  best	  treatment	  approach	  for	  each	  individual	  patient.	  A	  typical	   classification	   usually	   considers	   the	   following	   features:	   the	  histolopathological	  type,	  the	  grade	  of	  the	  tumor,	  the	  stage	  of	  the	  tumor,	  and	  the	  expression	   of	   proteins	   and	   genes.	   The	   general	   architecture	   of	   breast	   tumors	  determines	   their	  histological	   type.	   In	  general,	  breast	  cancers	  are	  derived	   from	  glandular	   tissue,	   and	   can	   be	   divided	   into	   ductal	   and	   lobular	   carcinomas,	   with	  invasive	   ductal	   carcinomas	   being	   the	   most	   common	   form	   of	   invasive	   breast	  cancer.	  Tumor	  histological	  grade	  defines	  cellular	  differentiation,	  reflecting	  how	  much	   the	   tumor	   cells	   differ	   from	   the	   cells	   in	   the	   normal	   surrounding	   tissue.	  Grading	   is	   generally	   performed	   using	   the	   guidelines	   proposed	   by	   Bloom	   and	  Richardson,	  and	  later	  modified	  by	  Elston	  and	  Ellis	  [8,	  9].	  The	  histological	  grade	  is	  based	   on	   three	   features:	   tubule	   formation,	   nuclear	   pleomorphism	   (abnormal	  nuclei),	  and	  mitotic	  count	  (as	  a	  measure	  of	  proliferation	  rate),	  and	  divides	  breast	  tumors	  into	  three	  categories:	  grade	  I,	  II	  and	  III.	  Grade	  score	  increases	  with	  lack	  of	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cellular	   differentiation,	   such	   that	   well-­‐differentiated	   cells	   are	   found	   in	   grade	   I	  tumors	   (low-­‐grade),	   moderately	   differentiated	   cells	   in	   grade	   II	   tumors	  (moderate	   grade),	   and	   poorly	   differentiated	   cells	   in	   grade	   III	   tumors	   (high-­‐grade).	   Moreover,	   breast	   cancer	   staging	   is	   performed	   using	   the	   TNM	  classification	   that	   describes	   the	   size	   of	   the	   tumor	   (T),	   the	   involvement	   of	   local	  lymph	   nodes	   (N),	   and	   the	   existence	   of	   distant	  metastases	   (M).	   Finally,	   routine	  pathological	   classification	   of	   breast	   cancer	   also	   defines	   the	   receptor	   status	  (estrogen	   and	   progesterone	   receptors),	   gene	   amplifications	   and	   expression	   of	  the	   HER2/neu	   gene,	   and	   occasionally	   the	   status	   of	   the	   p53	   tumor	   suppressor	  gene.	  	   Overexpression	  of	   the	  estrogen	  receptor	  (ER)	   is	  also	  a	   frequent	  event	   in	  breast	   cancer	   [10].	   An	   increased	   risk	   for	   breast	   cancer	   is	   associated	  with	   high	  levels	   of	   estrogen	   in	   the	   blood	   plasma,	   either	   endogenous	   estrogen	   or	   from	  exogenous	  sources	  such	  as	  hormone-­‐replacement	  therapy	  [11].	  Recent	  advances	  in	   gene	   expression	   profiling	   have	   further	   stratified	   breast	   cancers	   into	  “molecular	   subtypes”	  based	  on	  patterns	  of	   gene	  expression.	  These	   include	   two	  main	  subtypes	  of	  ER-­‐positive	  tumors,	  termed	  luminal	  A	  and	  luminal	  B.	  As	  a	  rule,	  luminal	   A	   tumors	   have	   low	   expression	   of	   proliferation-­‐related	   genes,	   thus	  carrying	   the	   best	   prognosis	   of	   all	   breast	   cancer	   subtypes,	   whereas	   the	   less	  common	   luminal	   B	   tumors	   are	   highly	   proliferative,	   and	   have	   therefore	   poor	  prognosis.	  It	   is	  worth	  noting	  that	  these	  classifications	  are	  constantly	  being	  updated	  as	  our	  knowledge	  of	  breast	  cancer	  biology	  and	  prognosis	  develops.	  
	  
I	  hope	  that,	  as	  the	  thesis	  proceeds,	  it	  becomes	  apparent	  to	  the	  reader	  that	  genetic	  
aberrations	   resulting	   in	   deregulated	   proteolytic	   pathways	   contribute	   to	   the	  
aetiology	  of	  cancer	  of	  the	  breast	  and	  other	  tissues.	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2.2.1.	  Cycling	  in	  the	  lane	  
	  To	   divide	   is	   a	   challenging	   task	   for	   a	   cell.	   It	   entails	   the	   progression	   through	   a	  complex	  sequence	  of	  events	  that	  will	  ultimately	  culminate	  in	  cell	  growth	  and	  the	  production	  of	  two	  daughter	  cells.	  In	  order	  for	  the	  cell	  to	  maintain	  its	  functional	  integrity,	  these	  events	  need	  to	  be	  tightly	  controlled	  every	  step	  of	  the	  way.	  Failure	  to	   do	   so	   can	   have	   devastating	   consequences,	   leading	   to	   mutations	   in	   critical	  genes,	   excessive	   proliferation	   and	   cellular	   transformation.	   In	   order	   to	  understand	  how	  cancer	  cells	  acquire	  the	  ability	  to	  proliferate	  uncontrollably,	  we	  need	  to	  appreciate	  how	  a	  normal	  cell	  divides.	  	  Two	  main	  events	  characterize	  the	  cell	  cycle:	  DNA	  replication	  and	  nuclear	  division.	  However,	  for	  the	  cell	  to	  accomplish	  these	  tasks,	  it	  must	  pass	  through	  a	  series	  of	  unidirectionally	  steps,	  or	  phases,	  that	  make	  up	  the	  cell	  division	  cycle,	  or	  simply	   the	  cell	   cycle.	  The	  cell	  cycle	   is	  divided	   into	   four	  major	  phases:	  G1,	  S,	  G2,	  and	   M.	   Duplication	   of	   DNA,	   or	   chromosomal	   replication,	   occurs	   during	   the	   S	  phase	   (synthesis	   phase),	   preceded	   by	   a	   gap	   phase	   called	   G1.	   In	   G1,	   the	   cell	  receives	   and	   translates	   signals	   from	   its	   surrounding	   and	   makes	   the	   critical	  decision	   to	   progress	   through	   cell	   cycle	   and	   initiate	   DNA	   synthesis.	   S	   phase	   is	  followed	  by	  a	  second	  gap	  phase,	  G2,	  in	  preparation	  for	  cell	  division,	  also	  known	  as	  mitosis	  (M).	  Cells	  in	  G1	  that	  are	  not	  committed	  to	  cell	  division	  can	  withdraw	  from	  the	  cell	  cycle	  and	  enter	  a	  resting	  state	  termed	  G0.	  However,	  resting	  cells	  can	  be	  stimulated	  to	  re-­‐enter	  the	  cell	  cycle	  in	  response	  to	  external	  growth	  promoting	  signals.	  Once	  committed	  to	  divide,	  the	  cell	  must	  proceed	  through	  all	  the	  phases	  of	  the	  cell	  cycle	  without	  additional	  growth	  stimulatory	  signals.	  This	  “point	  of	  no	  return”	   has	   been	   referred	   to	   as	   the	   restriction	   point	   [12,	   13].	   Deregulation	   of	  factors	  that	  control	  the	  restriction	  point	  are	  thought	  to	  be	  of	  major	   importance	  for	  cancer	  development.	  	   The	   driving	   force	   promoting	   the	   transition	   from	  one	   cell	   cycle	   phase	   to	  the	  next	  is	  governed	  by	  the	  activation	  of	  key	  regulatory	  protein	  kinases,	  known	  as	   cyclin-­‐dependent	   kinases	   (CDKs).	   CDKs	   are	   a	   family	   of	   serine/threonine	  protein	   kinases	   that,	   when	   activated,	   induce	   downstream	   processes	   by	  phosphorylating	  proteins	   essential	   for	   the	   forward	  movement	  of	   the	   cell	   cycle.	  Activation	  of	  CDKs	  is	  dependent	  on	  binding	  to	  specific	  cyclin	  proteins.	  While	  CDK	  protein	   levels	   are	   stable	   throughout	   the	   cell	   cycle,	   cyclin	   levels	   rise	   and	   fall	  periodically	  during	  the	  cell	  cycle.	  Cyclins	  are	  short-­‐lived	  proteins	  regulated	  at	  the	  level	  of	  transcription	  and	  protein	  stability	  [14,	  15].	  In	  this	  way,	  the	  abundance	  of	  cyclins	  determines	  the	  timing	  of	  CDK	  activation.	  Different	  cyclins	  are	  expressed	  at	  different	  stages	  of	   the	  cell	   cycle;	   the	  D-­‐type	  cyclins	   (Cyclins	  D1,	  D2,	  and	  D3)	  associate	  with	   CDK4	   and	   CDK6	   and	   are	   essential	   for	   entry	   into	   G1.	   Unlike	   the	  other	  cyclins,	  D-­‐type	  cyclins	  are	  not	  synthesized	  periodically,	  but	  are	  expressed	  as	  long	  as	  growth	  stimulatory	  signals	  are	  present	  [16].	  E-­‐cyclins	  are	  another	  type	  of	  G1	  cyclins,	  which	  associate	  with	  CDK2	  to	  regulate	  the	  transition	  from	  G1	  to	  S-­‐phase	   [17].	  Cyclin	  A-­‐CDK2	  association	   is	   required	  during	  S-­‐phase,	  while	   in	   late	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G2	  cyclin	  A	  binds	  to	  CDK1	  to	  promote	  M-­‐phase	  entry	  [18,	  19].	  Finally,	  cyclin	  B-­‐CDK1	  complexes	  are	  responsible	  for	  the	  regulation	  of	  mitosis	  [20].	  	   Cyclin-­‐CDK	  activity	  can	  be	  antagonized	  by	  a	  group	  of	  proteins	  called	  CDK	  inhibitors	   (CKIs).	   There	   are	   two	   major	   families	   of	   CKIs:	   the	   INK4	   (named	   as	  inhibitors	   of	   CDK4)	   and	   the	   Cip/Kip	   (cdk	   interacting	   protein/cdk	   inhibitory	  protein)	   families	   [21].	   The	   INK4	   proteins	   (p15INK4b,	   p16INK4a,	   p18INK4c,	   and	  p19INK4d)	  specifically	  inactivate	  CDK4	  and	  CDK6	  by	  preventing	  cyclin	  association	  and	   inhibiting	   their	   catalytic	   activities	   [22,	   23],	  whereas	   the	   Cip/Kip	   family	   of	  inhibitors	   (p21Cip1,	   p27Kip1,	   and	  p57Kip2)	   have	   the	  potential	   to	   inhibit	   all	   cyclin-­‐CDK	  complexes.	  The	  expression	  and	  activities	  of	  CKIs	  are	  tightly	  regulated	  at	  the	  level	  of	   transcription,	  phosphorylation	  by	  other	  kinases,	  and	  by	  degradation	  by	  the	  ubiquitin	  proteasome	  system.	  	  One	  of	  the	  major	  targets	  of	  cyclin	  D-­‐CDK4/6	  is	  the	  Retinoblastoma	  tumor	  suppressor	  protein,	  Rb.	  The	  Rb	  family	  includes	  three	  members,	  Rb1/p105,	  p107,	  and	   Rb2/p130,	   collectively	   referred	   to	   as	   “pocket	   proteins”.	   The	   Rb	   proteins	  repress	   transition	   from	  G1	   to	  S	  phase	  by	   inhibiting	   transcription	   factors	  of	   the	  E2F	   family	  whose	  activity	   is	   required	   for	  S-­‐phase	  progression	   [24].	  Thus,	   in	   its	  hypophosphorylated,	   active	   state,	   Rb	   inhibits	   cell	   cycle	   progression;	   however,	  upon	   growth	   factor	   stimulation,	   Rb	   is	   inactivated	   by	   G1	   CDK-­‐dependent	  phosphorylation,	   leading	   to	   the	   dissociation	   of	   E2F/DP	   transcription	   factors	  from	  Rb	  and	  transcriptional	  induction	  of	  a	  large	  set	  of	  genes	  required	  for	  S-­‐phase	  progression,	   including	   cyclin	   E,	   cyclin	   A,	   CDK1,	   CDK2	   and	   thymidine	   synthase	  [24,	   25].	   Rb	   remains	   inactive	   for	   the	   remainder	   of	   the	   cell	   cycle	   by	   virtue	   of	  phosphorylation	   by	   cyclin	   E-­‐CDK2	   [26].	   During	   G1/S	   transition,	   the	   cyclin	   E-­‐CDK2	   complex	   phosphorylates	   its	   inhibitor	   p27Kip1,	   inducing	   its	   proteasomal	  degradation	   by	   the	   SCFSKP2	   ubiquitin	   ligase	   [27,	   28].	   Both	   cyclin	   E-­‐CDK2	   and	  cyclin	   A-­‐CDK2	   complexes	   play	   essential	   roles	   in	   DNA	   replication.	   As	   S-­‐phase	  progression	   continues,	   cyclin	   E	   is	   destroyed	   by	   the	   ubiquitin	   ligase	   SCFFbxw7	  (discussed	  further	  in	  Section	  2.4.3.),	  and	  the	  level	  of	  mitotic	  cyclins	  begin	  to	  rise.	  The	   activity	   of	   cyclin	   A-­‐CDK1	   is	   of	   particular	   importance	   in	   G2/M	   transition,	  while	   its	   degradation	   is	   necessary	   for	   M-­‐phase	   completion	   [29,	   30].	   Finally,	  cyclin	  B-­‐CDK1	  complexes	   initiate	  essential	  processes	   including	  condensation	  of	  the	   chromosomes,	   mitotic	   spindle	   assembly	   and	   breakdown	   of	   the	   nuclear	  envelope,	   ultimately	   leading	   to	   cell	   division.	   At	   this	   point,	   the	   anaphase-­‐promoting	   complex	   (APC/C)	   degrades	   cyclin	   B,	   which	   is	   necessary	   for	  mitotic	  exit	  and	  entry	  into	  the	  next	  G1	  phase	  (reviewed	  in	  [31,	  32]).	  	  	  	  
“Cycling	  in	  the	  lane”	  is	  analogous	  to	  the	  regulated	  progression	  of	  a	  cell	  through	  the	  
cell	   cycle,	   with	   “stop”	   and	   “go	   ahead”	   signals	   in	   place	   at	   each	   cell	   cycle	   phase.	  
However,	  when,	  for	  example	  the	  signals	  are	  misplaced,	  the	  cell	  starts	  cycling	  non-­
stop.	  The	  next	   section	  gives	  a	   few	  examples	  of	   regulators	   that,	  when	  altered,	   can	  
promote	  uncontrolled	  proliferation.	  	  
	  
2.2.2	  Cycling	  round	  and	  round:	  	  When	  the	  cell	  cycle	  is	  out	  of	  control	  
	  In	  cancer,	  alterations	  in	  the	  molecular	  machinery	  that	  regulates	  cell	  growth	  and	  cell	   division	   cooperate	   to	   promote	   unrestrained	   cell	   proliferation	   that	   is	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irresponsive	   to	  regulatory	  cues.	  Mutations	  have	  been	  described	   in	  genes	  acting	  at	   multiple	   levels	   of	   cell	   proliferative	   pathways,	   including	   CDKs,	   cyclins,	   CKIs,	  and	   CDK	   substrates.	   The	   RB1	   gene	   is	   frequently	   mutated	   in	   human	  retinoblastoma	  and	  many	  other	  tumors	  [33],	  and	  alterations	  of	  at	   least	  one	  CKI	  are	  found	  in	  nearly	  all	  human	  cancers	  [34].	  For	  instance,	  decreased	  expression	  of	  p27Kip1,	   through	   increased	   proteasome-­‐dependent	   proteolysis,	   is	   a	   frequent	  event	  in	  various	  human	  cancers,	  and	  is	  a	  strong	  indicator	  of	  poor	  prognosis	  [35,	  36].	   Indeed,	   overexpression	   of	   SKP2,	   the	   E3	   ligase	   responsible	   for	   p27Kip1	  degradation,	   is	   a	   major	   contributor	   to	   human	   malignancy	   [37].	   Moreover,	  whereas	   cyclin	  E	   has	   been	   found	   to	   be	   amplified	   and	  overexpressed	   in	   a	  wide	  range	  of	  cancers	  [38],	  its	  overexpression	  has	  also	  been	  attributed	  to	  inactivation	  of	   the	   FBXW7/hCDC4	   protein	   that	   is	   responsible	   for	   its	   ubiquitin-­‐dependent	  proteasomal	   degradation	   [39,	   40].	   These	   examples	   highlight	   the	   importance	   of	  regulated	  protein	  abundance	  in	  normal	  cell	  cycle	  control.	  Targeting	  of	  cyclin	  E	  for	  
ubiquitin-­mediated	  degradation	  by	  FBXW7/hCDC4	  the	  basis	  of	  Papers	  I	  and	  II,	  and	  
will	  be	  discussed	  in	  greater	  detail	  throughout	  section	  2.4.	  	  Abnormal	  activation	  of	   the	  Myc	  proto-­‐oncogene	   is	  also	  a	   frequent	  event	  leading	  to	  dysregulation	  of	  cellular	  homeostasis.	  Briefly,	  Myc	  drives	  proliferation	  and	  inhibits	  cell	  differentiation	  by	  stimulating	  the	  expression	  of	  several	  positive	  regulators	   of	   the	   cell	   cycle,	   including	   cyclin	   D2,	   CDK4	   and	   E2F2	   [41-­‐43].	  Accordingly,	   the	  MYC	   oncogene	   is	   deregulated	   in	   multiple	   human	   cancers	   by	  different	   mechanisms	   including	   amplification,	   point	   mutation,	   chromosomal	  translocation,	   or	   increased	   protein	   stability	   [44].	   The	   functions	   of	   Myc	   will	   be	  
explored	  in	  section	  2.5.,	  and	  Paper	  III	  will	  describe	  a	  novel	  regulator	  of	  Myc	  activity.	  All	  of	  the	  above-­‐described	  alterations	  have	  the	  same	  functional	  outcome:	  to	   increase	   cell	   cycle	   progression,	   often	   by	   shutting	   down	   terminal	  differentiation	   and	   cell	   death	   pathways.	   This	   unchecked	   cell	   division	   will	  ultimately	  result	  in	  the	  accumulation	  of	  malignant	  cells	  with	  the	  acquired	  ability	  to	  proliferate	  autonomously,	  thus	  promoting	  tumor	  formation.	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2.3.	  UBIQUITIN-­‐MEDIATED	  PROTEOLYSIS	  
 
 
2.3.1.	  One-­‐way	  cycling:	  a	  role	  for	  the	  ubiquitin-­‐proteasome	  system	  	  As	   we	   learned	   in	   the	   previous	   section,	   the	   cell	   cycle	   consists	   of	   an	   orderly	  sequence	   of	   events	   characterized	   by	   the	   periodic	   synthesis	   and	   destruction	   of	  key	   regulatory	   proteins	   within	   a	   defined	   window	   of	   time.	   The	   ubiquitin-­‐proteasome	   system	   (UPS)	   is	   responsible	   for	   the	   targeted	   degradation	   of	  numerous	  cell	  cycle	  proteins,	  including	  cyclins	  and	  CDK	  inhibitors	  (CKIs)	  [45].	  	  The	  tasks	  of	  many	  of	  the	  proteins	  required	  for	  cell	  cycle	  progression	  are	  often	  limited	  to	  a	  precise	  period	  of	  time.	  Cyclins	  are	  great	  examples	  of	  how	  cell-­‐cycle	   transitions	   are	   regulated	   by	   the	   sharp	   activation	   of	   specific	   CDKs	  programmed	   to	   phosphorylate	   a	   defined	   set	   of	   substrates.	   Understandably,	  chronic	  activation	  of	  CDKs	  leading	  to	  phosphorylation	  of	  the	  wrong	  substrates	  at	  the	   wrong	   time	   can	   have	   deleterious	   consequences	   for	   the	   cell.	   Proteolysis	   of	  cyclins	  via	   the	  UPS	   is	   thus	   important	   for	  preventing	  continuous	  CDK	  activation	  and	   ensuring	   the	  proper	   execution	  of	   cell-­‐cycle	   functions.	  Degradation	  of	  CKIs,	  negative	  regulators	  of	  the	  CDKs,	  by	  the	  UPS	  is	  also	  instrumental	  in	  the	  rapid	  and	  irreversible	   transition	   from	  one	  cell-­‐cycle	  phase	   to	   the	  next.	  Undoubtedly,	   cell-­‐cycle	   control	   and	   ubiquitin-­‐mediated	   proteolysis	   are	   intricately	   dependent	  processes.	   The	   importance	   of	   this	   system	   in	   the	   pathogenesis	   of	  many	   human	  tumors	   is	   underpinned	   by	   growing	   evidence	   of	   direct	   alterations	   found	   in	   the	  components	  that	  regulate	  the	  UPS.	  	  
	  
2.3.2.	  The	  process	  of	  tagging	  	   	  Besides	  its	  crucial	  role	  in	  cell	  cycle	  regulation,	  major	  roles	  of	  the	  UPS	  also	  include	  clearance	   of	  misfolded	   proteins,	   immune	   response,	   cell	   survival,	   inflammatory	  responses,	  protein	  trafficking,	  signaling	  and	  gene	  transcription	  [46-­‐48].	  	  Ubiquitin	   is	   a	   highly	   conserved	   protein	   of	   76	   amino	   acids	   that	   is	  ubiquitously	  expressed,	   thus	  giving	  rise	   to	   its	  name.	   It	   is	   translated	  as	  a	   fusion	  product,	  either	  fused	  to	  a	  ribosomal	  protein	  or	  as	  a	  linear	  repeat	  comprised	  of	  a	  chain	   of	   ubiquitin	   molecules	   linked	   together.	   Single	   ubiquitin	   monomers	   are	  produced	   through	   cleavage	   of	   the	   fusion	   proteins	   by	   ubiquitin	   C-­‐terminal	  hydrolases	   [49].	  While	  ubiquitin	  protein	   is	  highly	  abundant	  due	   to	  constitutive	  expression,	  stability	  and	  recycling,	  the	  pool	  of	  free	  ubiquitin	  molecules	  is	  rather	  limited	   [50].	   This	   is	   because	   the	   majority	   of	   ubiquitin	   is	   found	   conjugated	   to	  target	   proteins,	   reflecting	   the	   extensive	   usage	   of	   ubiquitin	   in	   diverse	   cellular	  processes.	  Consequently,	  there	  is	  a	  dynamic	  equilibrium	  between	  assembly	  and	  disassembly	   of	   ubiquitin	   molecules	   through	   the	   opposing	   actions	   of	  ubiquitylation	  and	  deubiquitylation	  enzymes.	  	  	   Ubiquitin	   regulates	   protein	   turnover	   in	   the	   cell	   by	   “tagging”	   specific	  proteins	   for	   degradation.	  Whereas	   the	  majority	   of	   the	   proteins	   in	   the	   cell	   are	  long-­‐lived,	   short-­‐lived	   proteins	   are	   typically	   regulatory	   proteins	   or	   abnormal	  proteins	   that	  need	  to	  be	  removed.	  Thus,	  by	  eliminating	  such	  proteins,	  cells	  can	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rapidly	  turn	  on	  or	  off	  specific	  biological	  process.	  This	   is	  a	  very	  effective	  way	  to	  irreversibly	   regulate	  protein	  activity,	  but	   is	  also	  energetically	  expensive,	  as	   the	  protein	  needs	  to	  be	  re-­‐synthesized	  if	  needed	  again.	  Furthermore,	   the	  processes	  of	  ubiquitin	  conjugation	  and	  proteasomal	  degradation	  require	  energy	  in	  the	  form	  of	  ATP.	  But	  why	  is	  this,	  since	  no	  energy	  is	  needed	  for	  hydrolysis	  of	  proteins?	  The	  reason	  for	  this	  is	  that	  specialized	  machinery	  needs	  to	  be	  engaged	  in	  the	  specific	  tagging	  of	  proteins	  for	  ubiquitin-­‐mediated	  proteolysis.	  It	  was	  this	  discovery,	  that	  regulated	   protein	   degradation	   was	   an	   energy-­‐dependent	   process	   catalyzed	   by	  the	  covalent	  attachment	  of	  multiple	  ubiquitin	  molecules	  and	  degradation	  in	  the	  proteasome,	   that	  awarded	  Aaron	  Ciechanover,	  Avram	  Hershko,	  and	   Irwin	  Rose	  the	  Nobel	  Prize	  in	  chemistry	  in	  2004	  [51,	  52].	  	   The	  biological	  system	  responsible	  for	  conjugation	  of	  ubiquitin	  to	  specific	  target	   proteins	   (also	   known	   as	   ubiquitylation)	   is	   regulated	   by	   the	   sequential	  action	   of	   three	   key	   enzymes:	   a	   ubiquitin-­‐activating	   enzyme	   (E1),	   a	   ubiquitin-­‐conjugating	  enzyme	  (E2),	  and	  a	  ubiquitin	  ligase	  (E3).	  The	  E1	  enzyme	  generates	  a	  high-­‐energy	  thioester	  bond	  between	  E1	  and	  ubiquitin,	  activating	  ubiquitin	  in	  an	  ATP-­‐dependent	  reaction.	  In	  the	  second	  reaction,	  ubiquitin	  is	  transferred	  from	  E1	  to	   the	   active	   site	   cysteine	   of	   an	   E2	   ubiquitin-­‐conjugating	   enzyme.	   Finally,	  ubiquitin	  is	  ¨tagged¨	  to	  a	  specific	  lysine	  residue	  in	  the	  protein	  substrate	  with	  the	  help	   of	   an	   E3	   ubiquitin	   ligase.	   In	   some	   cases,	   the	   activated	   ubiquitin	   can	   be	  alternatively	  conjugated	  to	  the	  N-­‐terminal	  residue	  of	  the	  protein,	  conforming	  to	  the	  so-­‐called	  “N-­‐end	  rule”	  [53].	  E3	  ubiquitin	  ligases	  generally	  function	  in	  concert	  with	   E2s,	   and	   they	   are	   particularly	   important	   in	   the	   recognition	   of	   a	   specific	  substrate.	   Successive	   rounds	   of	   ubiquitylation	   ligation,	   linking	   additional	  ubiquitin	   molecules	   together	   in	   chains	   of	   different	   lengths,	   result	   in	   the	  formation	  of	  polyubiquitin	  chains	  on	  the	  substrate.	  While	  there	  are	  two	  E1s	  and	  approximately	  forty	  E2	  enzymes	  [54],	  it	  is	  estimated	  that	  hundreds	  of	  E3	  ligases	  exist	   in	   the	   human	   proteome.	   Targeting	   of	   substrates	   by	   E3	   ligases	   is	   both	  specific	   and	   versatile:	   one	   given	   E3	   ligase	   can	   ubiquitylate	   several	   different	  substrates,	  and	  the	  same	  substrate	  can	  be	  recognized	  by	  various	  E3	  ligases	  [55].	  	   E3	   ligases	   can	   be	   divided	   into	   two	   discrete	   groups	   on	   the	   basis	   of	  structural	  motifs	  and	  biochemical	  function:	  The	  HECT-­‐type	  and	  the	  RING-­‐finger-­‐type	   [56].	   The	   HECT	   (homologous	   to	   E6AP	   C-­‐Terminus)	   domain	   E3s	   are	  structurally	  similar	  to	  E6-­‐AP,	  which	  degrades	  the	  p53	  tumor	  suppressor	  by	  HPV	  E6.	   During	   the	   transfer	   of	   ubiquitin	   to	   the	   target	   substrate,	   HECT	   ligases	  themselves	  form	  a	  transient	  linkage	  with	  ubiquitin	  through	  a	  conserved	  cysteine	  residue,	   before	   catalyzing	   the	   subsequent	   ubiquitin	   conjugation.	   In	   contrast,	  RING	  (Really	  Interesting	  New	  Gene)	  E3	  ligases	  do	  not	  directly	  participate	  in	  the	  ubiquitylation	  reaction;	  by	  interacting	  with	  the	  E2	  via	  the	  RING	  domain,	  they	  act	  as	  scaffolds	  to	  facilitate	  the	  transfer	  of	  ubiquitin	  to	  substrates	  [57].	  	   The	  RING	  E3s	  constitute	  the	  largest	  family	  of	  ubiquitin	  ligases	  and	  can	  be	  further	  divided	  into	  two	  groups:	  single	  subunit	  ligases,	  where	  individual	  proteins	  interact	   with	   both	   the	   E2	   and	   the	   substrate,	   or	   multi-­‐subunit	   complexes	  composed	   of	   distinct	   RING	   and	   substrate	   adaptors	   to	   recruit	   the	   E2	   and	  substrate,	  respectively.	  Mdm2,	  the	  ubiquitin	  ligase	  responsible	  for	  destruction	  of	  p53,	  is	  an	  example	  of	  single-­‐subunit	  RING	  enzymes	  [58].	  Two	  canonical	  examples	  of	  multisubunit	  RING	  E3	  ligases	  are	  the	  SCF	  (SKP1/Cullin/F-­‐box)	  and	  the	  APC/C	  (Anaphase	   Promoting	   Complex/Cyclosome),	   each	   of	   which	   utilizes	   multiple	  substrate-­‐binding	  subunits	  and	  the	  same	  core	  ligase	  to	  target	  specific	  substrates.	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Figure	  1.	  A	  simplified	  overview	  of	  the	  interplay	  between	  SCF	  and	  APC/C	  E3	  ubiquitin	  
ligases	   in	   cell	   cycle	   regulation.	   Shown	   are	   examples	   of	   two	   SCF	   ligases,	   SKP2	   and	  
CDC4,	  in	  the	  ubiquitin-­mediated	  degradation	  of	  p27	  and	  cyclin	  E,	  respectively.	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Despite	  their	  differences,	   it	   is	  clear	  that	  there	   is	  a	   tight	   interplay	  between	  the	   APC/C	   and	   SCF	   E3	   ligase	   complexes	   in	   the	   control	   of	   cell-­‐cycle	   regulators	  [61-­‐63],	  as	  well	  as	  in	  regulating	  the	  activities	  of	  one	  another	  [64].	  However,	  and	  as	  mentioned,	  genetic	  alterations	  in	  these	  multisubunit	  E3	  ligases	  are	  frequently	  associated	   with	   cancer	   development,	   though	   they	   have	   been	   found	   to	   be	  significantly	  higher	  for	  the	  SCF	  complex	  than	  for	  the	  APC/C	  [59],	  likely	  as	  a	  result	  of	  the	  flexibility	  discussed	  above.	  
	  
	  
We	  will	  soon	  explore	  the	  SCF-­type	  E3	  ligases	  in	  greater	  detail.	  After	  all,	  they	  are	  the	  
central	  players	  in	  this	  thesis.	  But	  first,	  let	  us	  look	  into	  the	  fate	  of	  ubiquitin	  and	  the	  
tagged	  substrates.	  	  
	  
2.3.3.	  Chained	  by	  Ub	  	  The	   functional	   outcome	   of	   protein	   ubiquitylation	   depends	   primarily	   on	   two	  factors:	   the	   length	   of	   the	   ubiquitin	   chain,	   and	   the	   type	   of	   ubiquitin	   linkage.	  Ubiquitin	  can	  modify	  substrate	  proteins	  as	  a	  single	  moiety	  (monoubiquitylation)	  or	   can	   be	   conjugated	   to	   other	   ubiquitin	   molecules	   to	   form	   a	   chain	  (polyubiquitylation	  or	  multiubiquitylation).	  Monoubiquitylation	   is	  not	  normally	  implicated	   in	   degradation,	   but	   has	   been	   shown	   to	   control	   numerous	   cellular	  processes	  such	  as	  receptor	  transport,	  histone	  regulation	  and	  DNA	  repair	  [65,	  66].	  Furthermore,	   monoubiquitin	   modifications	   can	   serve	   as	   protein	   interaction	  surfaces,	  as	  several	  proteins	  contain	  domains	  (e.g	  UBM,	  UIM)	  that	  allow	  them	  to	  interact	  with	  ubiquitin	  molecules.	  Ubiquitin	  itself	  contains	  seven	  lysine	  residues	  (K6,	  K11,	  K27,	  K29,	  K33,	  K48,	  and	  K63)	  all	  of	  which	  can	  function	  as	  receptor	  sites	  for	  another	  ubiquitin	  molecule	  to	  form	  polyubiquitin	  chains	  of	  different	  linkages.	  Attachment	   of	   four	   or	   more	   ubiquitin	   chains	   through	   K48	   linkages	   typically	  targets	   a	   protein	   for	   proteasomal	   degradation,	   whereas	   polyubiquitin	   chains	  linked	   through	   other	   lysines	   often	   perform	   nonproteolytic	   functions	   ([67,	   68]	  and	  reviewed	   in	   [69]).	  K63-­‐linked	  chains,	   for	   instance,	  have	  been	   implicated	   in	  signal	   transduction	  through	  the	  NF-­‐κB	  pathway,	  receptor	  endocytosis	  and	  DNA	  repair	  (Reviewed	  in	  [70,	  71]).	  Protein	   ubiquitylation	   can	   be	   reversed	   by	   the	   action	   of	   isopeptidases	  called	   deubiquitylation	   enzymes,	   or	   DUBs.	   These	   proteins	   are	   responsible	   for	  processing	   of	   monomeric	   ubiquitin	  molecules	   from	   precursor	   ubiquitin	   fusion	  proteins,	   proofreading	   ubiquitin-­‐protein	   conjugates	   and	   recycling	   ubiquitin.	  Moreover,	  DUBs	  can	  regulate	   the	  UPS	  by	  rescuing	  substrates	   from	  degradation	  (Reviewed	  in	  [72]).	  
	  
	  
2.3.4.	  Execution	  by	  the	  26S	  proteasome	  	  Proteins	   that	   are	   modified	   by	   polyubiquitin	   chains	   of	   an	   appropriate	   type	   of	  linkage	  are	  ultimately	  presented	  to	   the	  26S	  proteasome.	  Proteasomes	  are	   large	  multisubunit	  complexes	  of	  about	  2000	  kDa	  in	  molecular	  mass,	  composed	  of	  one	  20S	  core	  particle	  carrying	   the	  proteolytic	  activity,	  and	  two	  19S	  regulatory	  caps	  [55].	  In	  order	  for	  a	  protein	  to	  access	  the	  core	  particle,	  it	  must	  first	  be	  recognized	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by	   the	   19S	   regulatory	   subunit.	   Recognition	   is	   mediated	   by	   binding	   to	   the	  polyubiquitin	  chain	  on	  the	  target	  protein,	  and	  the	  substrate	   is	   then	  unfolded	   in	  an	   ATP-­‐dependent	   fashion.	   The	   pores	   that	   lead	   to	   the	   central	   proteolytic	  chamber	  of	  the	  20S	  core	  particle	  are	  so	  narrow,	  that	  only	  unfolded	  polypeptides	  are	  able	  to	  pass	  through	  [73].	  The	  20S	  core	  particle	  consists	  of	  four	  heptameric	  ring	  structures	  stacked	  on	  top	  of	  each	  other	   forming	  a	  barrel-­‐shaped	  structure.	  Within	   this	   barrel	   a	   set	   of	   catalytic	   subunits	   with	   chymotrypsin,	   trypsin	   and	  peptidyl-­‐glutamyl	   peptide	   hydrolysing	   specificities	   break	   down	   proteins	   into	  small	   peptides.	   Ubiquitin	   chains	   are	   not	   degraded	   in	   the	   process,	   but	   are	  detached	  from	  ubiquitin-­‐protein	  conjugates	  by	  proteasome-­‐associated	  DUBs,	   to	  be	  re-­‐used	  by	  the	  UPS	  [72].	  	  	  
Now	   that	   we	   know	   how	   a	   protein	   is	   targeted	   and	   degraded	   by	   the	   ubiquitin-­
proteasome	   system,	   let	   us	   take	   a	   step	   back	   to	   explore	   how	   the	   SCF	   E3	   ligases	  
recognize	  their	  substrates.	  	  
	  
	  





Figure	  2.	  Illustration	  of	  the	  components	  of	  the	  SCF	  E3	  ligase,	  showing	  the	  interaction	  
with	   the	   substrate	   protein	   through	   the	   F-­box	   protein,	   as	   well	   as	   with	   the	   E2	  
ubiquitin-­conjugating	  enzyme	  via	  the	  RING	  protein	  RBX1.	  	  	  	  The	  RING-­‐finger	  type	  SCF	  ubiquitin	  ligase	  is	  composed	  of	  core	  components	  CUL1,	  SKP1	  and	  RBX1,	  and	  a	  variable	  F-­‐box	  protein.	  The	  cullin	  subunit	  CUL1	  functions	  as	   a	  molecular	   scaffold	   that	   simultaneously	   interacts	  with	   the	   adaptor	   subunit	  SKP1	   (S-­‐phase-­‐kinase-­‐associated	   protein-­‐1),	   and	   with	   the	   RING-­‐finger	   protein	  RBX1	  (also	  known	  as	  Roc1),	  which	  in	  turn	  recruits	  a	  specific	  E2	  enzyme,	  such	  as	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Ubc3,	   Ubc4	   or	   Ubc5.	   SKP1	  mediates	   the	   interaction	   between	   CUL1	   and	   one	   of	  many	  different	  F-­‐box	  proteins,	  which	  are	  responsible	  for	  substrate	  recognition.	  A	  graphical	  representation	  of	  the	  SCF	  complex	  is	  presented	  in	  Figure	  2.	  	  	   F-­‐box	  proteins	  are	  defined	  by	  the	  presence	  of	  a	  conserved	  F-­‐box	  domain	  through	  which	  they	  associate	  with	  SKP1	  [74].	  The	  F-­‐box	  motif,	  so	  named	  after	  its	  discovery	  in	  the	  first	  identified	  F-­‐box	  protein	  cyclin	  F,	  is	  generally	  found	  towards	  the	   amino-­‐terminus	   of	   the	   protein.	   F-­‐box	   proteins	   often	   recruit	   their	   specific	  substrates	   through	  a	  protein-­‐interaction	  domain	   that	   lies	   towards	   the	  carboxy-­‐terminus	   of	   the	   F-­‐box	   domain	   in	   the	   sequence.	   It	   is	   based	   on	   their	   substrate-­‐interaction	   domains	   that	   the	   F-­‐box	   proteins	   have	   been	   classified	   into	   three	  groups:	  those	  containing	  WD40	  repeats	  (FBXW),	  leucine-­‐rich	  repeats	  (FBXL)	  or	  other	   domains	   (FBXO)	   [75-­‐77].	   Typically,	   F-­‐box	   proteins	   specifically	   recognize	  phosphorylated	   substrates	   [78].	   For	   example	   the	   WD40	   substrate-­‐binding	  domain	  in	  the	  FBXW	  group	  is	  a	  β-­‐propeller	  structure	  that	  presumably	  recognizes	  specific	   Ser/Thr	   phosphorylation	   at	   consensus	   sequences,	   which	   have	   been	  dubbed	   phosphodegrons.	   Such	   consensus	   sequences	   have	   been	   identified	   for	  FBXW1	   (also	   known	   as	   β-­‐TrCP1)	   and	   FBXW7	   (CDC4)	   [79].	   To	   date,	  approximately	   70	   F-­‐box	   proteins	   have	   been	   identified	   in	   humans,	   but	   the	  functions	   of	   only	   a	   few	   have	   been	   described.	   Three	   well-­‐characterized	   F-­‐box	  proteins,	  in	  particular,	  target	  important	  substrates	  that	  implicate	  them	  in	  human	  malignancy.	  As	  mentioned,	  SKP2	  (FBXL1)	  targets	  key	  negative	  regulators	  of	  the	  cell	   cycle,	   including	   p27Kip1	   [28,	   80,	   81],	   p21Cip1	   [82,	   83],	   and	   p57Kip2	   [84]	   and	  p130	   [85]	   for	   degradation,	   thus	   promoting	   cell	   cycle	   progression	   (Figure	   1).	  SKP2	  has	  been	  demonstrated	  to	  be	  an	  oncogene	   in	  mouse	  models	  and	   is	   found	  overexpressed	   in	  many	   human	   cancers	   [86].	   β-­‐TrCP	   (FBXW1/11)	   functions	   in	  diverse	  pathways,	   targeting	   several	   cell	   cycle	  proteins	   such	  as	  Emi1/2	   [61,	  62,	  87],	  Wee1A	   [88]	   and	   CDC25A/B	   [89-­‐91],	   as	   well	   as	   the	   signalling	   proteins	   β-­‐catenin	   and	   IκB	   [37]	   for	   ubiquitin-­‐dependent	   proteolysis.	   Both	   mutation	   and	  overexpression	   of	   β-­‐TrCP	   have	   been	   reported	   in	   cancers	   [86].	   Finally,	  FBXW7/hCdc4	  promotes	  the	  degradation	  of	  positive	  regulators	  of	  the	  cell	  cycle	  such	  as	  Myc,	  Jun,	  Notch	  and	  cyclin	  E,	  and	  is	  often	  mutated	  in	  various	  tumor	  types	  [59]	  (shown	  in	  Figure	  1	  and	  discussed	  in	  greater	  detail	  in	  section	  2.4).	  Thus,	  by	  recruiting	  different	  substrate-­‐recognition	  factors	  (i.e.,	  the	  F-­‐box	  proteins)	  using	  a	  common	  core,	   SCF	  ubiquitin	   ligases	   are	   able	   to	   “cull”,	   or	   sort,	   a	  broad	  array	  of	  substrates	  involved	  in	  a	  variety	  of	  cellular	  functions.	  	  
	  	  
	  
Given	  that	  Papers	  I	  and	  II	  in	  this	  thesis	  will	  deal	  with	  the	  regulation	  of	  cyclin	  E	  by	  
the	   FBXW7/hCDC4	   E3	   ligase,	   we	   will	   now	   learn	   more	   about	   these	   proteins	   and	  
their	  involvement	  in	  cancer.	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2.4.	  FBXW7/hCDC4:	  MULTI-­‐TASKING	  IN	  TUMOR	  SUPPRESSION	  
 
 
2.4.1.	  The	  FBXW7/hCDC4	  protein	  	  The	  FBXW7	  gene	  (also	  known	  as	  FBW7	  or	  hCDC4	  in	  humans,	  Cdc4	  in	  S.	  cerevisiae,	  
Sel-­10	   in	  C.	   elegans,	   or	  Ago	   in	  Drosophila	  melanogaster)	   encodes	   three	   protein	  isoforms	   in	   humans,	   designated	   α,	   β,	   and	   γ,	   each	   containing	   a	   unique	   amino-­‐terminus,	   and	   a	   common	   carboxy-­‐terminal	   region.	   All	   three	   isoforms	   share	  motifs	  critical	  for	  recognition	  and	  ubiquitylation	  of	  substrates,	  namely	  the	  F-­‐box	  motif	   for	  recruitment	  of	  the	  SCF	  core	  proteins,	  the	  WD40	  repeats	  that	  form	  the	  typical	  β-­‐propeller	   structure	   for	   substrate	  binding,	  and	  a	  D-­‐domain	   that	  allows	  for	   dimerization	   [92].	   Each	   FBXW7/hCDC4	   isoform	   localizes	   to	   different	  subcellular	  compartments,	  mediated	  by	  signals	  in	  their	  unique	  N-­‐terminus.	  The	  α	  isoform	   is	   found	   in	   the	   nucleus,	   β	   in	   the	   cytosol	   and	   membrane	   of	   the	  endoplasmic	   reticulum	   [93],	   and	   γ	   is	   enriched	   in	   the	   nucleolus.	   Given	   that	   all	  three	   isoforms	   share	   the	   same	   substrate-­‐recognition	   domain,	   differential	  localization	   might	   be	   important	   for	   the	   compartmentalized	   targeting	   of	  substrates	   to	   specific	   locations	   in	   the	   cell.	   Substrate	   recognition	   by	  FBXW7/hCDC4	   is	   dependent	   on	   phosphorylation	   of	   the	   substrate	   within	   a	  consensus	   motif	   called	   the	   CDC4-­‐phosphodegron	   (CPD)	   [94].	   Comparison	  between	   known	   FBXW7/hCDC4	   substrates	   has	   allowed	   the	   identification	   of	   a	  defined	  CPD	  sequence:	  Φ-­‐X-­‐Φ-­‐Φ-­‐Φ-­‐pT/pS-­‐P-­‐P-­‐X-­‐pS/pT/E,	  where	  Φ	  corresponds	  to	   a	   hydrophobic	   amino	   acid	   and	   X	   to	   any	   amino	   acid	   [95].	   Many	   of	   the	  substrates	  contain	  clusters	  of	  phosphorylation	  sequences	   that	  deviate	   from	  the	  defined	   “ideal”	   CDP,	   but	   which	   still	   mediate	   binding	   to	   FBXW7/hCDC4.	  Therefore,	  efficiency	  of	  substrate	  recognition	  is	  determined	  both	  by	  the	  number	  of	   CPDs	   in	   the	   substrate,	   as	  well	   as	   their	   sequence	   similarity	   to	   the	   consensus	  CPD	  [45].	  	  
	  
	  
2.4.2.	  SCFFBXW7/hCDC4:	  One	  ligase,	  a	  multitude	  of	  substrates	  	  	  To	  date,	   the	  FBXW7/hCDC4-­‐containing	  SCF	  ubiquitin	   ligase,	   SCFFBXW7/hCDC4,	   has	  been	   reported	   to	   target	   more	   than	   20	   different	   proteins	   for	   ubiquitylation	   in	  different	   species.	   Substrates	   range	   from	   CDK	   inhibitors,	   such	   as	   the	   yeast	  proteins	  Sic1	  [96]	  and	  Far1	  [97],	  to	  transcription	  factors,	  like	  c-­‐Jun	  [98]	  and	  Myc	  [99,	  100];	  from	  signalling	  factors,	  such	  as	  Notch	  [101,	  102],	  to	  positive	  cell-­‐cycle	  regulatory	  proteins,	  such	  as	  cyclin	  E	  [39,	  40,	  103]	  an	  yeast	  Cdc6	  [104].	  Although	  the	  targets	  in	  mammalian	  cells	  regulate	  various	  biological	  processes,	  they	  seem	  to	   have	   one	   property	   in	   common:	   nearly	   all	   have	   been	   categorized	   as	  oncoproteins.	  Two	  of	   the	   substrates	  –	   cyclin	  E	   and	  Myc–	  are	   critically	   involved	   in	   cell	  cycle	  regulation	  and	  are	  often	  deregulated	  in	  cancer.	  Both	  cyclin	  E	  and	  Myc	  are	  of	  particular	   interest	   to	   the	   topics	   of	   this	   thesis,	   and	   thus	   are	   described	   more	  thoroughly	  in	  subsequent	  sections.	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2.4.3.	  The	  E-­‐cyclins:	  easy	  prey	  for	  SCFFBXW7/hCDC4	  	  E-­‐type	  cyclins	  (cyclin	  E1	  and	  cyclin	  E2)	  are	  expressed	   from	  late	  G1-­‐phase	  until	  the	  end	  of	  S-­‐phase	  of	   the	  mammalian	  cell	   cycle	  and,	   together	  with	   their	  kinase	  subunit	  CDK2,	  regulate	  passage	   from	  the	  G1	  restriction	  point	   into	  S-­‐phase.	  The	  cyclin	  E2	  gene	  was	  so	  named	  due	  to	  the	  presence	  of	  a	  characteristic	  cyclin	  box	  motif	   and	   a	   47%	   similarity	   to	   the	   original	   cyclin	   E	   (also	   known	   as	   cyclin	   E1)	  [105].	   Just	   like	   cyclin	  E1,	   cyclin	  E2	  binds	   and	  activates	  CDK2	   [105-­‐107].	  While	  most	   of	  what	  we	   know	  about	   cyclin	   E	   comes	   largely	   from	  extensive	   studies	   of	  cyclin	  E1,	  cyclin	  E1	  and	  cyclin	  E2	  have	  been	  described	  to	  have,	  for	  the	  most	  part,	  overlapping	  functions;	  hence,	  in	  this	  text	  I	  will	  refer	  to	  the	  E-­‐type	  cyclins	  simply	  as	  “cyclin	  E”,	  unless	  otherwise	  specified.	  Cyclin	  E-­‐CDK2	  complexes	  have	  direct	  roles	  in	  S-­‐phase	  entry	  and	  initiation	  of	   DNA	   replication	   by	   the	   stimulation	   of	   S-­‐phase	   genes,	   partly	   via	   the	   E2F	  transcription	   factors	   (explained	   below).	   Other	   S-­‐phase	   events	   controlled	   by	  cyclin	   E-­‐CDK2	   include	   modulation	   of	   DNA	   synthesis,	   recruitment	   of	   DNA	  polymerase	   α,	   loading	   of	   MCM	   proteins	   onto	   replication	   origins,	   centrosome	  duplication,	  among	  others	  (reviewed	  in	  [108]).	  Since	  most	   of	   the	   functions	  of	   cyclin	  E	   relate	   to	  DNA,	   cyclin	  E	   is	  mainly	  found	   to	   reside	   in	   the	   nucleus.	  Nuclear	   localization	   is	   partly	   dependent	   on	   the	  presence	   of	   a	   nuclear	   localization	   signal	   (NLS)	   in	   the	   cyclin	   E	   sequence,	   and	  nuclear	   shuttling	   by	   the	   proteins	   importin	   α	   and	   importin	   β	   [109].	   Moreover,	  CDK2,	  the	  catalytic	  partner	  of	  cyclin	  E,	  depends	  on	  interaction	  with	  cyclin	  E	  for	  nuclear	  import	  [108].	  Cyclin	  E	  is	  normally	  expressed	  periodically	  in	  the	  cell	  cycle,	  peaking	  at	  the	  G1	  to	  S	  transition.	  This	  periodicity	  is	  achieved	  by	  E2F-­‐dependent	  transcription	   in	   late	   G1	   and	   ubiquitin-­‐mediated	   proteolysis	   of	   active	   cyclin	   E-­‐CDK2	   complexes	   in	   early	   S-­‐phase	   [110].	   Complementary	  mechanisms,	   such	   as	  inhibition	  by	  CKIs	  p21Cip1	  and	  p27Kip1,	  are	  critical	  factors	  limiting	  cyclin	  E-­‐CDK2	  activities	  at	  the	  G1	  phase	  [21].	  As	  described	  in	  section	  2.2.	  of	  this	  thesis,	  the	  transcriptional	  activation	  of	  the	  cyclin	  E	  gene	  at	  the	  end	  of	  the	  G1-­‐phase	  is	  dependent	  on	  phosphorylation	  of	  the	   Rb	   transcriptional	   repressors	   by	   the	   cyclin	   D-­‐CDK4/6	   complexes.	  Phosphorylation	   of	   Rb	   activates	   E2F	   transcription	   factors,	   which	   can	  subsequently	   induce	   transcription	   of	   cyclin	   E.	   Since	   cyclin	   E-­‐CDK2	   can	   also	  phosphorylate	  the	  Rb	  family	  of	  proteins,	  increased	  cyclin	  E	  expression	  results	  in	  increased	  free	  E2F,	  further	  promoting	  expression	  of	  cyclin	  E	  [26,	  111-­‐113].	  This	  constitutes	   a	   positive	   feedback	   loop	   that	   allows	   cyclin	   E	   to	   stimulate	   its	   own	  expression.	  In	  contrast,	  transcription	  silencing	  of	  the	  cyclin	  E	  gene	  occurs	  by	  the	  assembly	   of	   repressive	   complexes	   containing	   hypophosphorylated	   Rb,	   histone	  deacetylase	  (HDAC),	  and	  the	  SWI/SNF	  chromatin	  remodelers	  together	  with	  E2F	  transcription	  factors	  bound	  to	  the	  cyclin	  E	  gene	  promoter	  [114].	  	  Not	   surprisingly,	   the	   proper	   regulation	   of	   cyclin	   E	   is	   important	   for	  maintaining	   genomic	   stability	   and	   its	   deregulation	   has	   been	   associated	  with	   a	  broad	   spectrum	   of	   human	   malignancies.	   As	   mentioned,	   the	   SCFFBXW7/CDC4	  ubiquitin	   ligase	   mediates	   the	   degradation	   of	   cyclin	   E1	   in	   a	   phosphorylation-­‐dependent	   fashion	   [39,	   40,	   103].	   Cyclin	   E1	   has	   two	   CDC4	   phosphodegrons	  (CPDs):	  one	  “ideal”	  high-­‐affinity	  CPD	  at	  the	  C-­‐terminus	  centered	  around	  residues	  Thr380	   and	   Ser384,	   and	   one	   N-­‐terminal	   low-­‐affinity	   CPD	   at	   Thr62	   [115-­‐118].	  Phosphorylation	   at	   Thr380	   and	   Ser384	   depends	   on	   autophosphorylation	   of	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cyclin	  E1	  by	  active	  cyclin	  E-­‐CDK2	  complexes,	  and	  by	  the	  GSK3	  kinase	  at	  Thr380	  [116,	  117].	  Since	  cyclin	  E1	  has	  an	  optimal	  CPD,	  a	  single	  phosphorylation	  event	  at	  Thr380	  within	  the	  high	  affinity	  CPD	  may	  be	  sufficient	  to	  induce	  ubiquitylation	  of	  cyclin	   E1	   by	   FBXW7/hCDC4	   [45].	   Nonetheless,	   phosphorylation	   of	   Ser384	   has	  been	  demonstrated	   to	   increase	   the	   efficiency	  of	   the	  binding	  between	   cyclin	  E1	  and	  FBXW7/hCDC4,	  as	  pSer384	  is	  capable	  of	  interacting	  with	  a	  basic	  surface	  on	  the	   interaction	   region	   of	   FBXW7/hCDC4	   [94].	   Interestingly,	   ubiquitylation	   of	  cyclin	   E1	   protein	   by	   SCFFBXW7/CDC4	   has	   been	   shown	   to	   involve	   the	   sequential	  action	  of	  the	  FBXW7/hCDC4-­‐α	  and	  -­‐γ	  isoforms,	  both	  in	  vitro	  and	  in	  vivo	  [119].	  In	  
vitro	   reconstitution	   experiments	   showed	   that	   the	   role	   of	   the	   FBXW7/hCDC4-­‐α	  isoform	   is	   to	   serve	   as	   a	   co-­‐factor	   for	   the	  prolyl	  cis-­trans	   isomerase	  Pin1	   in	   the	  isomerization	   of	   a	   non-­‐cannonical	   proline-­‐proline	   bond	   in	   the	   cyclin	   E1	   high-­‐affinity	   degron	   [119].	   This	   isomerization	   event	   constitutes	   a	   signal	   for	  subsequent	   binding	   and	   translocation	   of	   cyclin	   E1	   by	   the	   FBXW7/hCDC4-­‐γ	  isoform	   to	   the	   nucleolus	   where	   cyclin	   E1	   is	   subsequently	   multiubiquitylated	  ([120]	   and	   Bhaskaran	   et	   al.	   unpublished).	   The	   FBXW7/hCDC4-­‐β	   isoform	   does	  not	  seem	  to	  directly	  contribute	  to	  cyclin	  E1	  degradation	  in	  vivo,	  although	  it	  could	  theoretically	  regulate	  cytosolic	  cyclin	  E,	  which	  has	  been	  suggested	  [118].	  	  	  
Paper	   I	   explores	   the	   interplay	   between	   FBXW7/hCDC4-­α	   and	   –γ	   isoforms	   in	  
ubiquitylation	   of	   cyclin	   E1.	   The	   regulation	   of	   ubiquitin-­dependent	   proteolysis	   of	  
cyclin	  E2	  by	  FBXW7/hCDC4	  will	  be	  described	  in	  Paper	  II.	  	  
	  
2.4.4.	  Cyclin	  E	  in	  cancer	  	  Cyclin	  E	  is	  overexpressed	  in	  many	  human	  tumors	  and	  the	  cyclin	  E1	  gene	  (CCNE1)	  is	   sometimes	   amplified	   in	   cancers	   [121].	   However,	   more	   often,	   tumor	   cells	  display	   increased	   cyclin	   E1	   protein	   stability	   and	   loss	   of	   periodic	   expression.	  Unlike	   cyclin	  E1,	  which	   is	   expressed	  both	   in	  normal	   and	   tumor	   cells,	   cyclin	  E2	  expression	  has	  been	  reported	  to	  be	  very	  low	  to	  undetectable	  in	  non-­‐transformed	  cells,	  and	  to	  be	  elevated	  particularly	  in	  tumor	  cells,	  indicating	  an	  important	  role	  for	  cyclin	  E2	  in	  tumorigenesis	  [105].	  	  Overexpression	  of	  cyclin	  E	  has	  been	  shown	  to	   cause	   premature	   initiation	   of	   DNA	   synthesis,	   increased	   centrosomal	  duplication	   and	   genomic	   instability	   [122-­‐125].	   In	   breast	   carcinoma,	   increased	  levels	   of	   cyclin	   E	   have	   been	   correlated	   to	   poor	   prognosis	   and	   worse	   survival	  [126-­‐128].	   Evidence	   for	   an	   oncogenic	   function	   of	   cyclin	   E	   is	   also	   evident	   from	  mouse	  models	   [129].	   Finally,	   cyclin	   E	   has	   been	  demonstrated	   to	   transform	   rat	  embryonic	  fibroblasts	  in	  vitro,	  from	  the	  simultaneous	  expression	  of	  cyclin	  E	  and	  the	   constitutively	   form	  of	   the	  Ha-­‐Ras	   oncoprotein	   [130],	   supporting	   its	   role	   in	  tumorigenesis.	  As	   compared	   to	   many	   other	   oncoproteins,	   the	   major	   mechanism	   for	  deregulation	  of	   cyclin	  E	   in	  cancer	   is	   through	  decreased	   turnover	  by	   interfering	  with	   the	   cyclin	   E	   proteolytic	   pathway.	   Indeed,	   the	   main	   ligase	   for	   cyclin	   E,	  FBXW7/hCDC4	  is	  frequently	  inactivated	  in	  a	  broad	  spectrum	  of	  human	  tumors,	  with	   concominant	   cyclin	   E	   deregulation	   [40,	   131,	   132].	   This	   will	   the	   topic	   of	  section	  2.4.6.	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2.4.5.	  Regulators	  of	  FBXW7/hCDC4	  activity	  	  Given	   its	   critical	   function	  as	  a	  master	   regulator	  of	   various	   cell	   cycle	   regulatory	  proteins,	   it	   is	   not	   surprising	   that	   SCFFBXW7/CDC4	   activity	   is	   controlled	   by	   both	  positive	   and	   negative	   regulators.	   As	   mentioned,	   the	   prolyl	   isomerase	   Pin1	   in	  complex	   with	   FBXW7/hCDC4-­‐α	   promotes	   ubiquitylation	   of	   cyclin	   E1	   by	   the	  SCFFBXW7/hCDC4-­‐γ	   ligase	   [119,	   133].	   Importantly,	   a	  mutation	   in	   FBXW7/hCDC4-­‐α	  that	   abrogates	   binding	   to	   Pin1	   was	   found	   to	   increase	   cyclin	   E1	   stability,	  illustrating	   the	   requirement	   of	   Pin1	   for	   cyclin	   E1	   turnover	   [119].	   As	   will	   be	  described	   in	   section	   2.5.4.,	   ubiquitylation	   of	   the	   Myc	   oncoprotein	   is	   also	  regulated	  by	  Pin1,	  as	  well	  as	  by	  the	  protein	  phosphatase	  PP2A	  [134].	  A	  negative	  regulator	  of	  Myc	   and	   cyclin	  E1	  ubiquitylation	  by	   the	   SCFFBXW7/CDC4	   ligase	   is	   the	  deubiquitylating	  enzyme	  USP28	  (ubiquitin-­‐specific	  protease	  28)	  (also	  described	  in	   section	   2.5.4.)	   [135].	   It	   is	   not	   known	   whether	   USP28	   regulates	   the	  ubiquitylation	  of	  other	  FBXW7/hCDC4	  substrates,	  though	  it	  has	  been	  suggested.	  
	  
	  
2.4.6.	  FBXW7/hCDC4	  in	  cancer	  	  The	  fact	  FBXW7/hCDC4	  is	  implicated	  in	  the	  degradation	  of	  several	  oncoproteins	  and	  is	  frequently	  inactivated	  by	  mutations	  and	  chromosomal	  rearrangements	  in	  many	   cancers	   supports	   its	   function	   as	   a	   general	   TSG.	   An	   extensive	   screen	   of	  primary	  human	  tumors	  recently	  reported	  mutations	  in	  tumors	  of	  diverse	  origin,	  including	   those	  of	   the	   stomach,	  breast,	  blood,	   colon,	   endometrium,	   lung,	  ovary,	  pancreas,	   bile	   duct,	   and	   prostate,	   with	   an	   overall	   mutation	   frequency	   of	   ~6%	  [136].	  While	  mutations	  are	   found	   to	  occur	   throughout	   the	   coding	   region,	  more	  than	  half	  of	  the	  mutations	  are	  localized	  to	  six	  mutation	  hotspots	  corresponding	  to	  residues	  in	  the	  β-­‐propeller	  structure	  of	  the	  WD40	  repeats	  critical	  for	  substrate	  binding	  [40,	  94,	  95,	  136].	  Moreover,	  mutation	  of	  a	  single	  FBXW7/CDC4	  allele	   in	  mouse	   has	   been	   found	   to	   cooperate	   with	   inactivation	   of	   p53,	   suggesting	   that	  
FBXW7/CDC4	   is	   a	   haploinsufficient	   tumor	   suppressor	   (i.e.,	   loss	   of	   one	   copy	   is	  enough	  to	  cause	  disease)	  [137].	  However,	  recent	  data	  rather	  support	  a	  function	  for	   dominant-­‐negative	   mutations	   in	   the	   substrate-­‐binding	   domain	   of	  
FBW7/hCDC4.	  Dimerization	  of	  FBXW7/hCDC4	  proteins	  through	  their	  conserved	  D-­‐domains	   has	   also	   been	   suggested	   to	   promote	   ubiquitination	   activity,	  presumably	   by	   enhancing	   accessibility	   of	   the	   ligase	   to	   the	   different	   lysine	  residues	   on	   the	   substrate,	   resulting	   in	   more	   efficient	   polyubiquitylation	   [138-­‐141].	   Thus,	   an	   FBXW7/hCDC4	   mutant	   that	   forms	   a	   complex	   with	   wild-­‐type	  FBXW7/hCDC4	   may	   act	   in	   a	   dominant-­‐negative	   manner	   by	   limiting	   the	  ubiquitylation	  activity	  of	   the	  wild-­‐type	  protein.	   Indeed,	   expression	  of	   a	  mutant	  form	   of	   FBXW7/hCDC4	   in	   cells	   without	   FBXW7/hCDC4	   genetic	   alterations	   has	  been	  shown	  to	  repress	  substrate	  ubiquitylation	  [136,	  142,	  143].	  	  
FBXW7/hCDC4	   inactivation	   by	   mechanisms	   other	   than	   mutations	   have	  also	   been	   reported.	  Methylation	   of	   the	  FBXW7/hCDC4-­β	   gene	   promoter,	  which	  results	  in	  decreased	  expression,	  was	  found	  to	  be	  a	  frequent	  event	  in	  both	  breast	  cancer	  cell	  lines	  and	  primary	  tumors,	  demonstrating	  that	  promoter	  methylation	  is	  an	  alternative	  mechanism	  for	  the	  suppression	  of	  FBXW7/hCDC4	  activity	  [144].	  Finally,	  FBXW7/hCDC4	   is	  negatively	   regulated	  by	  microRNAs.	  Two	  microRNAs,	  miR223	  and	  miR27a,	  were	  recently	  implicated	  in	  cyclin	  E	  regulation	  through	  the	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post-­‐transcriptional	  repression	  of	  FBXW7/hCDC4	  [145,	  146].	  Overexpression	  of	  these	   microRNAs	   results	   in	   decreased	   FBXW7/hCDC4	   mRNA	   levels,	   with	  concomitant	  increases	  in	  cyclin	  E	  levels	  and	  stability,	  and	  DNA	  replication	  stress.	  Importantly,	   increased	   levels	  of	  miR27a	  expression,	  which	   correlated	  with	   low	  FBXW7/hCDC4	  levels,	  were	  found	  in	  pediatric	  B-­‐ALL	  [146].	  	  To	  conclude,	   the	  plethora	  of	  mutations	  and	  other	   types	  of	   alterations	  of	  the	  FBXW7/hCDC4	  gene	  found	  in	  cancers	  highlights	  the	  importance	  of	  this	  tumor	  suppressor	  in	  human	  malignancy.	  	  	  
	   28	  
2.5.	  THE	  MYC	  ONCOPROTEIN	  
 
	  
In	   the	   final	   part	   of	   this	   literature	   review,	   we	  will	   turn	   our	   attention	   to	   the	  Myc	  
protein.	  Although,	  as	  we	  learned,	  Myc	  is	  also	  an	  important	  substrate	  for	  ubiquitin-­
mediated	   degradation	   by	   FBXW7/hCDC4,	   this	   will	   not	   be	   the	   main	   focus	   of	   the	  
present	  section.	  Rather,	  we	  will	  concentrate	  on	  aspects	  of	  Myc	  function	  that	  are	  of	  
relevance	  to	  Paper	  III	  in	  this	  thesis.	  	  
	  
	  
2.5.1.	  Can’t	  do	  without	  Myc	  	  The	  Myc	  family	  of	  proto-­‐oncogenes	  (comprising	  c-­‐Myc,	  N-­‐Myc,	  and	  L-­‐Myc)	  play	  important	   roles	   in	   the	   regulation	   of	   normal	   cellular	   processes	   such	   as	   cell	  proliferation,	   growth,	  metabolism,	   survival,	   and	   differentiation.	   First	   identified	  as	   transforming	   factors	   transduced	   by	   avian	   retroviruses,	   Myc	   genes	   encode	  transcription	  factors	  that	  regulate	  the	  expression	  of	  an	  estimated	  10-­‐15%	  of	  all	  mammalian	   genes.	   Since	   Myc	   controls	   many	   pathways	   with	   key	   roles	   in	   the	  hallmarks	  of	  cancer,	  it	  is	  hardly	  surprising	  to	  find	  that	  Myc	  is	  deregulated	  in	  most	  tumors.	   Indeed,	   alterations	   in	   expression	   or	   activity	   of	   the	   Myc	   oncogenes	  contribute	   to	   the	   genesis	   of	   a	   wide	   range	   of	   human	   cancers	   including	  hematopoietic	  malignancies	  as	  well	  as	  various	  solid	  tumors	  ([44]	  and	  reviewed	  in	  [147,	  148]).	  	  	  
	  
2.5.2.	  MAXimizing	  transcription	  by	  Myc	  	  The	   Myc	   genes	   encode	   proteins	   of	   the	   basic	   region/helix-­‐loop-­‐helix/leucine	  zipper	   (bHLH/LZ)	   family	   that,	   upon	   heterodimerization	   with	   their	   obligate	  partner	  Max	  (Myc-­‐associated	  protein	  X),	  bind	  DNA	  and	  activate	  gene	  expression.	  Myc:Max	   complexes	   specifically	   recognize	   a	   so-­‐called	   E-­‐box	   sequence	   (5’-­‐CACGTG-­‐3’)	   in	   the	   promoters	   of	   target	   genes.	   Two	   main	   regions	   of	   the	   Myc	  protein	   are	   particularly	   important	   for	  Myc	   function.	   These	   include	   the	   amino-­‐terminal	   transactivation	   domain	   (TAD)	   and	   the	   carboxy-­‐terminal	   bHLH/LZ	  domain	   (Figure	  3).	   The	  TAD	   region	   contains	   the	   conserved	  Myc	  boxes	   I	   and	   II	  (MBI	  and	  MBII),	  which	  are	  critical	   for	  cofactor	  binding,	   transactivation	  activity,	  cellular	   transformation,	   and	   virtually	   all	   Myc-­‐dependent	   biological	   functions.	  Myc	  utilizes	   its	   helix-­‐loop-­‐helix	  domain	   to	  dimerize	  with	  Max,	  which	   results	   in	  the	   formation	   of	   a	   complex	   capable	   of	   binding	   DNA	   via	   the	   basic	   region.	   The	  bHLH/LZ	   is	   also	   essential	   for	   full	   transformation	   of	   primary	   and	   immortalized	  cells	  (reviewed	  in	  [147-­‐149]).	  Transcriptional	   activation	   by	   Myc	   is	   believed	   to	   occur	   through	  recruitment	  of	  a	  number	  of	  transcriptional	  cofactors	  involved	  in	  the	  modulation	  of	   chromatin	   structure	   including	  histone	  acetyl	   transferases	   (HATs),	   chromatin	  remodelling	   complexes,	   demethylases,	   and	   ubiquitin	   ligases.	   One	   such	   protein,	  TRRAP	  (transactivation/transformation	  associated	  protein),	  is	  recruited	  to	  Myc-­‐regulated	  gene	  promoters	  through	  binding	  to	  the	  MBII	  domain	  of	  Myc.	  TRRAP	  is	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the	   core	   subunit	   of	   the	   TIP60	   and	  GCN5	   histone	   acetyl	   transferase	   complexes,	  which	  are	  also	  recruited	  to	  promoters	  through	  association	  with	  TRRAP.	  Found	  in	  the	  TIP60	   complex	   are	   two	  ATPases,	   TIP48	   and	  TIP49,	  which	   are	   required	   for	  the	   function	   of	   several	   chromatin	   remodelling	   complexes.	   They	   bind	   the	  MBII	  region	   independently	  of	  TRRAP	   (reviewed	   in	   [150]).	   Furthermore,	   recruitment	  of	  the	  E3	  ubiquitin	  ligase	  SCFSKP2	  and	  proteasomal	  subunits	  have	  been	  shown	  to	  be	   required	   for	   transactivation	   of	   several	  Myc	   target	   genes	   [151].	   Not	   all	  Myc	  cofactors,	   however,	   require	  MBII	   for	   binding	   to	  Myc.	   Examples	   of	   this	   are	   the	  histone	  acetyltransferases	  CREB-­‐binding	  protein	  (CBP)	  and	  p300,	  which	  interact	  with	   the	   C-­‐terminal	   region	   of	   Myc.	   While	   GCN5	   and	   TIP60	   preferentially	  acetylate	   histones,	   it	   is	   believed	   that	   CBP/p300	   can	   also	   acetylate	   other	  substrates,	   including	   transcription	   factors,	   such	   as	   Myc	   itself	   [152,	   153]	   and	  subunits	   of	   the	   RNA	   polymerase	   [154,	   155].	   The	   action	   of	   Myc-­‐associated	  cofactors	  can	  therefore	  activate	  gene	  transcription	  by	  enhancing	  accessibility	  of	  chromatin	  for	  subsequent	  binding	  and	  activation	  by	  other	  transcription	  factors.	  While	  Myc	  has	  been	  predominantly	  associated	  with	  gene	  activation,	  there	  is	  also	  evidence	  for	  its	  involvement	  in	  gene	  repression.	  Although	  the	  mechanisms	  of	   repression	   are	   not	   as	  well	   studied	   as	   those	   resulting	   in	   gene	   activation,	   the	  present	   model	   suggests	   that	   Myc:Max	   complexes	   are	   recruited	   to	   non-­‐E-­‐box	  binding	  sites	  through	  the	   interaction	  with	  other	  transcription	  factors,	   including	  Miz-­‐1.	   Myc:Max	   dimers	   block	   transcriptional	   activation	   by	   Miz-­‐1	   both	   by	  blocking	   association	   between	   Miz-­‐1	   and	   p300,	   and	   by	   recruiting	   the	   histone	  methyltransferase	  DNMT3a	  (reviewed	  in	  [150,	  156]).	  The	   function	   of	   Myc	   as	   a	   transcription	   factor	   can	   be	   antagonized	   by	  competition	   with	   the	   Mad/Mnt	   family	   of	   transcriptional	   repressors.	   These	  families,	  composed	  of	  Mad1,	  Mxi1,	  Mad3,	  and	  Mad4;	  Mnt	  and	  Mga,	  are	  bHLH/LZ	  proteins	  that	  behave	  much	  like	  Myc	  in	  that	  they	  can	  readily	  heterodimerize	  with	  Max	   and	   bind	   DNA	   at	   E-­‐box	   sequences.	   The	   Mad:Max	   or	   Mnt:Max	   complexes	  	  repress	  transcription	  by	  recruiting	  histone	  deacetylases	  via	  the	  adaptor	  protein	  Sin3.	   Given	   that	  Max	   is	   a	   stable	   and	   constitutively	   expressed	   protein	   suggests	  that	   regulation	   of	   transcription	   is	   dependent	   on	   the	   abundance	   of	   Max-­‐associated	  transcription	  factors	  [156].	  	  	  
	  
	  
2.5.3.	  Myc’s	  many	  targets	  	  The	  number	  of	  genes	  that	  are	  regulated	  by	  Myc	  is	  unusually	   large	  compared	  to	  other	   transcription	   factors.	  Myc	  activities	   regulate	   the	  expression	  of	  genes	   that	  cover	  a	  broad	  range	  of	  biological	  functions,	  although	  some	  gene	  pathways	  seem	  to	  be	  overrepresented.	  Myc-­‐regulated	  genes,	   including	  protein	   coding	   genes	   as	  well	   as	   functional	   RNAs,	   are	   transcribed	   by	   all	   three	   RNA	   polymerases.	   Myc	  regulates	   cell	   growth	   by	   supplying	   the	   cell	  with	   a	   variety	   of	   building	   blocks.	   It	  activates	   the	   production	   of	   components	   important	   in	   protein	   biosynthesis,	  including	   ribosomal	   RNAs	   and	   proteins,	   as	   well	   as	   RNA	   processing	   and	  translation	  factors.	  Myc	  has	  also	  been	  shown	  to	  stimulate	  transcription	  of	  genes	  involved	   in	   metabolism	   and	   mitochondrial	   biogenesis,	   leading	   to	   increased	  energy	   production.	   Further,	   Myc	   regulates	   cell	   cycle	   progression	   by	  transactivating	   several	   genes,	   including	   cyclins	   and	   CDKs,	   while	   inhibiting	   the	  expression	   of	   genes	   that	   attenuate	   cell	   cycle	   progression,	   including	   cyclin-­‐
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dependent	   kinase	   inhibitors	   (CKIs),	   such	   as	   p21CIP1.	   Other	   genes	   that	   are	  commonly	   down-­‐regulated	   by	   Myc	   include	   those	   that	   promote	   differentiation,	  inhibit	   signal	   transduction	   pathways	   and	   reduce	   cell	   adhesion	   and	   cell-­‐cell	  communication	   (Reviewed	   in	   [147]).	   Thus,	   the	   ability	   of	  Myc	   to	   stimulate	   cell	  growth	  and	  proliferation,	  as	  well	  as	  to	  inhibit	  cell	  cycle	  arrest,	  makes	  Myc	  a	  very	  powerful	  gene	   that,	  when	  deregulated,	  contributes	   to	   the	   limitless	  proliferative	  potential	  characteristic	  of	  cancer	  cells.	  	   Paradoxically,	  Myc’s	   ability	   to	   induce	   cell	   proliferation	   is	   limited	   by	   the	  potential	  of	  Myc	  to	   induce	  apoptosis.	  Although	  the	  mechanisms	  of	  Myc-­‐induced	  cell	   death	   are	   not	   exactly	   known,	   two	   major	   pathways	   have	   been	   suggested	  (reviewed	   in	   [157,	   158]).	   The	   first	   involves	   the	   induction	   of	   p14ARF,	   which	  stabilizes	  p53	  by	  sequestering	  the	  E3	  ligase	  Mdm2	  which	  is	  responsible	  for	  p53	  degradation	   [159,	  160].	  When	   stabilized,	   p53	   can	  activate	  proapoptotic	   signals	  and	  induce	  cell	  death.	  The	  second	  mechanism	  involves	  the	  induction	  of	  the	  pro-­‐apoptotic	   protein	   Bim	   and	   simultaneous	   repression	   of	   anti-­‐apoptotic	   signals,	  contributing	   to	   the	   release	   of	   cytochrome	   c	   from	   the	  mitochondria	   [161,	   162].	  	  This	  implies	  that	  apoptosis	  is	  a	  major	  tumor	  barrier	  that	  needs	  to	  be	  overcome	  for	   Myc-­‐induced	   transformation.	   Indeed,	   loss	   of	   pro-­‐apoptotic	   genes	   including	  p14ARF,	   p53,	   or	   BIM,	   or	   overexpression	   of	   anti-­‐apoptotic	   genes	   facilitates	  myc-­‐induced	   tumorigenesis	   [160,	   163,	   164].	   However,	   it	   has	   been	   recently	   shown	  that,	  in	  normal	  cells,	  significantly	  higher	  levels	  of	  Myc	  are	  required	  for	  inducing	  apoptosis	  than	  are	  needed	  for	  driving	  proliferation,	  thus	  allowing	  Myc’s	  normal	  activities	  to	  proceed	  without	  resulting	  in	  cell	  death	  [165].	  	  Finally,	  Myc	  has	  also	  been	  reported	  to	  both	  suppress	  and	  promote	  cellular	  senescence,	   an	   irreversible	   arrest	  of	  proliferation	   [148].	  Myc	   is	   able	   to	   repress	  senescence	  and	   contribute	   to	   immortalization	  of	  primary	   cells	  by,	   for	   instance,	  promoting	   expression	   of	   hTERT,	   and	   inhibiting	   expression	   of	   important	  senescence-­‐promoting	  CKIs	  p21	  and	  p16	  [166,	  167].	  On	  the	  other	  hand,	  Myc	  can	  also	   promote	   senescence	   under	   conditions	   where	   protective	   factors	   such	   as	  WRN	  and	  CDK2	  are	  defective	  [168].	  	  
	  
	  
2.5.4.	  Regulation	  of	  the	  Myc	  protein:	  living	  a	  short	  sweet	  life	  	   	  The	  widespread	  binding	  of	  Myc	  to	  DNA	  and	  its	   involvement	  in	  many	  important	  cellular	  functions	  would	  give	  the	  impression	  that	  Myc	  is	  a	  very	  abundant	  protein.	  However,	   this	   is	   not	   the	   case.	   Myc	   is	   turned	   over	   at	   a	   very	   high	   rate	   via	   the	  ubiquitin-­‐proteasome	   system,	   involving	   at	   least	   four	   ubiquitin	   ligases,	   to	   date:	  SCFSKP2,	   SCFFBXW7/hCDC4,	   HectH9/Huwe1/Mule,	   and	   TRUSS.	   Moreover,	   the	   SCFβ-­‐TrCP	   complex	   and	   the	   ubiquitin-­‐specific	   protease	   USP28,	   have	   been	   shown	   to	  antagonize	  SCFFbxw7–mediated	  Myc	  turnover.	  Considerable	  effort	  has	  been	  made	  towards	  understanding	  whether	  an	  extended	  half-­‐life	  of	  Myc	  protein,	  stemming	  from	   inefficient	   protein	   turnover,	   lies	   behind	   the	   increased	   Myc	   protein	  commonly	  observed	  in	  cancers.	  Let	  us	  take	  a	  closer	  look	  at	  each	  of	  these	  factors,	  in	   particular	   how	   they	   alter	   Myc	   protein	   stability	   and	   their	   involvement	   in	  cancer.	  
	  
SCFSKP2:	  SKP2	   is	   a	   proto-­‐oncogene	   overexpressed	   in	   different	   cancers	   [169].	   It	  promotes	   the	   degradation	   of	   several	   negative	   regulators	   of	   the	   cell	   cycle,	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including	   the	   cyclin	   dependent	   kinase	   inhibitor	   p27Kip1,	   a	   tumor	   suppressor	  which	  is	  frequently	  inactivated	  in	  cancer	  cells	  [28]	  (for	  a	  review	  see	  [170]).	  SKP2	  was	  the	  first	   identified	  E3	  ubiquitin	   ligase	  to	  target	  Myc	  for	  ubiquitin-­‐mediated	  degradation.	  However,	  SKP2	  also	  promotes	  transactivation	  of	  Myc	  target	  genes,	  resulting	  in	  S-­‐phase	  transition;	  SKP2	  binds	  to	  Myc	  through	  the	  MBII	  and	  HLH/LZ	  regions	   and	   is	   considered	   to	   be	   a	   coactivator	   of	   Myc:Max	   transcriptional	  complexes	   [151,	   171].	   Interestingly,	   it	   has	   been	  demonstrated	   that	   subunits	   of	  the	  proteasome	   are	   recruited,	   along	  with	   SKP2,	   to	  Myc	   target	   gene	  promoters,	  implying	   an	   important	   relationship	   between	  Myc	   activation	   and	   the	   UPS	   [151,	  171].	  	  
	  
SCFFBXW7/hCDC4:	  The	  SCFFBXW7/hCDC4	   is	   considered	   to	  be	   a	  major	   regulator	  of	  Myc	  protein	   turnover,	   and	   has	   so	   far	   only	   been	   associated	   with	   the	   negative	  regulation	  of	  Myc	   function.	  Targeted	  destruction	  of	  Myc	  by	  FBXW7/hCDC4	   is	  a	  complex	  process	  that	  depends	  on	  GSK3-­‐β-­‐mediated	  phosphorylation	  at	  Thr58	  in	  the	   MBI	   region.	   GSK3-­‐β	   phosphorylation	   of	   Myc	   is	   primed	   by	   ERK-­‐mediated	  Ser62	   phosphorylation	   and	   also	   requires	   the	   activity	   of	   the	   cis-­trans	   prolyl	  isomerase	   Pin1.	   Interestingly,	   the	   action	   of	   Pin1	   has	   been	   reported	   to	   be	  required	  for	  recruitment	  of	  the	  protein	  phosphatase	  2A	  (PP2A)	  and	  subsequent	  dephosphorylation	  of	   the	  stabilizing	  Ser62	  phosphate	   in	  Myc.	  Remarkably,	   it	   is	  the	  nucleolar	  FBXW7/hCDC4-­‐γ	  isoform	  that	  finally	  targets	  Myc	  for	  ubiquitylation	  and	  proteasomal	  degradation	  [99,	  100,	  134,	  172,	  173].	  Several	  mechanisms	  can	  render	   Myc	   resistant	   to	   degradation	   by	   SCFFBXW7/hCDC4	   in	   human	   cancers;	   for	  instance,	  point	  mutations	  at	  Thr58	  of	  Myc	  have	  been	  found	  in	  lymphomas	  [174],	  and	   mutational	   inactivation	   of	   FBXW7/hCDC4	   in	   several	   cancers	   [175]	  (discussed	  in	  section	  2.4.6.).	  	  
	  
HectH9/Huwe1/Mule:	   The	   Hect-­‐domain	   ubiquitin	   ligase	   HectH9	   has	   been	  shown	  to	  promote	   transcriptional	  activation	  of	   c-­‐Myc	   through	   lysine	  63	   (K63)-­‐linked	   ubiquitylation.	   Adhikary	   et	   al.	   demonstrated	   that	   HectH9-­‐mediated	  ubiquitylation	   did	   not	   result	   in	   proteasomal	   degradation	   of	   Myc	   protein,	   but	  instead	  promoted	  transactivation	  of	  Myc	  target	  genes	  through	  recruitment	  of	  the	  coactivator	   p300	   [176].	   It	   is	  worth	   noting	   that	   a	   truncated	   version	   of	   HectH9,	  lacking	  the	  first	  2472	  amino	  acids,	  was	  used	  in	  this	  study.	  	  Interestingly,	   an	   independent	   study	   showed	   that	  HectH9	   (referred	   to	   as	  Huwe1)	   induced	   neural	   differentiation	   and	   proliferation	   arrest	   by	   the	  proteasomal-­‐mediated	   destruction	   of	   N-­‐Myc	   through	   K48-­‐linked	  polyubiquitylation	  [177].	  In	  this	  study,	  HectH9	  was	  able	  to	  bind	  and	  ubiquitylate	  both	   N-­‐Myc	   and	   c-­‐Myc	   in	   a	   K48-­‐linked	   fashion,	   albeit	   to	   different	   extents,	  suggesting	  that	  c-­‐Myc	  is	  also	  a	  substrate	  for	  degradation	  by	  HectH9.	  	  Whether	  HectH9	   is	  a	  potent	  activator	   [176],	  or	  even	  a	   repressor	  of	  Myc	  [177],	   remains	   to	   be	   determined.	   HECT-­‐domain	   containing	   E3	   ligases	   are	  thought	   to	   form	   only	   homogeneous	   ubiquitin	   chains	   on	   their	   substrates	   (i.e.,	  either	  K48-­‐	  or	  K63-­‐linked	  chains	  only)	  [178].	  In	  fact,	  HectH9	  has	  been	  shown	  to	  catalyze	   ubiquitylation	   of	   a	   number	   of	   substrates,	   including	   p53	   [179],	   Cdc6	  [180],	  Histone	  H2A	  [181],	  Mcl-­‐1	  [182],	  Miz-­‐1	  [183],	  as	  well	  as	  N-­‐Myc	  and	  c-­‐Myc	  described	  above,	  through	  the	  formation	  of	  K48-­‐linked	  ubiquitin	  chains.	  This	  is	  an	  important	  issue	  that	  yet	  needs	  to	  be	  further	  clarified.	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TRUSS/TRPC2AF:	   The	   tumor	   necrosis	   factor	   receptor-­‐associated	   ubiquitous	  scaffolding	  and	  signalling	  protein	  (TRUSS)	   is	  a	  receptor	  of	   the	  DDB1-­‐CUL4A	  E3	  ubiquitin	   ligase	  complex	   ,	  which	  belongs	   to	   the	   family	  of	   the	  cullin-­‐RING	  finger	  ligase	  complexes	  [184].	  TRUSS	  was	  recently	  shown	  to	  mediate	  ubiquitylation	  of	  both	   c-­‐Myc	   and	   N-­‐Myc	   and	   repress	   Myc-­‐dependent	   transcription	   and	   cellular	  transformation.	   Expression	   analyses	   in	   cancer	   cell	   lines	   demonstrated	   that	  TRUSS	   is	   downregulated	   in	   certain	   cell	   lines,	   suggesting	   that	   TRUSS-­‐mediated	  Myc	  degradation	  may	  be	  impaired	  in	  some	  cancer	  cells	  [185].	  	  
	  
SCFβ-­TrCP:	  The	   SCFβ-­‐TrCP	   ubiquitin	   ligase	   is	   one	   of	   the	  most	  well-­‐studied	   SCF	   E3	  ubiquitin	   ligases.	   β-­‐TrCP	   (FBXW1)	   plays	   important	   roles	   in	   diverse	   cellular	  pathways	   and	   a	   wealth	   of	   evidence	   indicates	   that	   β-­‐TrCP	   is	   mainly	   oncogenic	  (Review	  [86]).	  Its	  numerous	  targets	  can	  be	  mainly	  divided	  into	  two	  groups:	  cell	  cycle	   regulators	   and	   pro-­‐apoptotic	   regulators.	   Interestingly,	   a	   recent	   report	  showed	  that	  β-­‐TrCP	  stabilizes	  Myc	  during	  the	  S	  and	  G2	  phases	  of	  the	  cell	  cycle,	  by	  assembling	  heterotypic	  ubiquitin	  chains	  that	  carry	  different	  lysine	  linkages	  in	  the	   amino-­‐terminus	   of	   Myc,	   possibly	   around	   the	   same	   region	   important	   for	  FBXW7/hCDC4	   targeting	   of	   Myc.	   In	   this	   manner,	   β-­‐TrCP	   may	   antagonize	  ubiquitylation	  and	  degradation	  of	  Myc	  by	  the	  SCFFBXW7/hCDC4	  ligase	  [186].	  	  
	  





Figure	  3.	  Schematic	  representation	  of	  the	  functional	  domains	  of	  the	  Myc	  protein,	  and	  
regions	   that	   mediate	   binding	   of	   the	   different	   Myc	   co-­factors	   and	   E3	   ligases.	   If	   the	  
interaction	  results	  in	  Myc	  transcriptional	  repression,	  the	  domain	  is	  shown	  as	  a	  red	  bar,	  
if	   it	   results	   in	  Myc	  activation,	   it	   is	   shown	   in	  green,	  and	   if	   it	  mediates	  both	  activation	  
and	  repression,	  the	  domain	  is	  indicated	  by	  a	  dashed	  bar.	  I=MBI,	  II=MBII.	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   The	   fact	   that	   Myc	   is	   tightly	   regulated	   by	   ubiquitin-­‐dependent	   pathways	  reflects	  the	  importance	  of	  these	  processes	  in	  the	  control	  of	  Myc	  function.	  Paper	  
III	  deals	  with	  the	  discovery	  of	  SCFFBXO28,	  a	  novel	  E3	  ubiquitin	  ligase	  that	  regulates	  
cellular	  proliferation	  and	  Myc	  transactivation.	  	  
	  
	  
2.5.5.	  Myc-­‐induced	  transformation:	  too	  much	  of	  a	  good	  thing	  
	  As	   outlined	   above,	   Myc	   regulates	   a	   myriad	   of	   pathways	   that	   contribute	   to	  neoplasia.	  However,	  it	  should	  be	  noted	  that,	  like	  other	  oncogenes,	  Myc	  alone	  fails	  to	  transform	  normal	  cells	  and	  additional	  mutations	  in	  other	  oncogenic	  pathways,	  for	   example	   the	   Ras	   pathway,	   cooperate	   with	   Myc	   in	   cellular	   transformation	  (reviewed	   in	   [150]).	   As	   mentioned,	   deregulation	   of	   Myc	   activities	   can	   have	  devastating	   consequences	   to	   the	   cell,	   resulting	   in	   an	   enlarged	   population	   of	  highly	   proliferating,	   self-­‐renewing	   cells	   that	   are	   prone	   to	   acquiring	   further	  oncogenic	   changes	   to	   ultimately	   promote	   tumor	   formation.	   By	   modifying	   the	  expression	  of	  a	  large	  number	  of	  target	  genes,	  Myc	  activation	  increases	  the	  cell’s	  capacity	   to	   grow	  and	  proliferate,	   promoting	  migration	   and	   angiogenesis,	  while	  inhibiting	   terminal	   differentiation	   and	   senescence.	   Accordingly,	   increased	  Myc	  expression	  and/or	  activity	  is	  most	  likely	  a	  requirement	  for	  tumor	  development,	  and	  from	  this	  we	  could	  speculate	  that	  many	  other	  genes	  involved	  in	  regulation	  of	  Myc	  activity	  must	  also	  be	  deregulated	  in	  cancer	  cells.	  Given	   the	   crucial	   function	   of	   Myc	   in	   multiple	   biological	   pathways,	   it	   is	  clear	   that	   various	   fail-­‐safe	   mechanisms	   must	   keep	   Myc	   activities	   in	   check	   to	  prevent	  Myc	   from	   inducing	  cellular	   transformation.	  As	  mentioned,	  Myc	  has	   the	  ability	  to	  induce	  apoptosis	  under	  conditions	  of	  cellular	  stress	  or	  limited	  survival	  factors	   [188,	  189].	  However,	   in	  Myc-­‐driven	   tumors,	   certain	  mutations	  abrogate	  Myc	   induced	   apoptosis.	   Common	   mutations	   affect	   the	   function	   of	   the	   tumor	  suppressor	   genes	   p53	   and	   p14ARF.	   However,	  mutations	   in	  Myc	   itself	   have	   also	  been	  shown	  to	  be	  directly	  associated	  with	  decreased	  apoptotic	  potential	  of	  Myc.	  One	   example	   is	   the	  mutation	   of	   Thr58	   in	   the	   transactivation	   domain	   (MBI)	   of	  Myc	   found	   in	  Burkitt’s	   lymphomas.	  Since	  phosphorylation	  at	  Thr58	   is	  essential	  for	   proteasomal	   degradation	   of	   Myc,	   mutation	   at	   this	   site	   could	   result	   in	   Myc	  accumulation,	   which	   can	   contribute	   to	   tumorigenesis	   [174,	   190].	   However,	   a	  recent	  study	  demonstrated	  that	  Thr58	  mutation	  also	  abolished	  the	  ability	  of	  Myc	  to	  induce	  the	  pro-­‐apoptotic	  gene	  Bim	  in	  the	  absence	  of	  p53	  or	  p14ARF	  mutations	  [191].	  Therefore,	  either	  mutations	  of	  p53	  and	  p14ARF	  in	  combination	  with	  wild-­‐type	   Myc,	   or	   mutations	   of	   Myc	   that	   fail	   to	   transactivate	   Bim,	   are	   seemingly	  sufficient	  for	  escaping	  apoptosis	  and	  inducing	  tumorigenesis.	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3.	  AIMS	  OF	  THE	  THESIS	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Both	   SCFCdc4α	   and	   SCFCdc4γ	   are	   required	   for	   cyclin	   E	   turnover	   in	   cell	  
lines	  that	  do	  not	  overexpress	  cyclin	  E	  
	  
	  In	   this	   study,	   we	   have	   followed	   up	   on	   a	   previous	   study	   from	   our	   group	   and	  collaborators.	   The	   original	   observation	   that	   both	   the	   nuclear	   isoforms	   of	  FBXW7/hCDC4,	   hCDC4α	   and	   hCDC4γ,	   are	   required	   for	   cyclin	   E1	   turnover	  indicated	   that	   the	   different	   isoforms	   collaborate	   in	   cyclin	   E1	   ubiquitylation	  [119].	   In	  vitro	  ubiquitylation	  analysis	  showed	  that	   the	  role	  of	  hCDC4α	   in	  cyclin	  E1	   degradation,	   rather	   then	   ubiquitylation,	   is	   to	   serve	   as	   a	   cofactor	   for	  isomerization	   catalyzed	   by	   the	   prolyl	   isomerase	   Pin1	   of	   a	   non-­‐cannonical	  proline-­‐proline	   bond	   in	   the	   cyclin	   E1	   phosphodegron.	   This	   step	   was	   also	  demonstrated	  to	  be	  essential	  for	  the	  subsequent	  multiubiquitylation	  of	  cyclin	  E1	  by	  the	  hCDC4γ	  isoform.	  	  In	   this	   study,	   we	   asked	   whether	   this	   two-­‐step	   mechanism	   and	  requirement	  for	  two	  hCDC4	  isoforms	  is	  general	  in	  cells.	  To	  test	  this,	  we	  carried	  out	   RNAi-­‐mediated	   silencing	   experiments	   targeting	   each	   individual	   hCDC4	  isoform	   in	   a	   panel	   of	   human	   cell	   lines:	   2	   immortalized	   normal	   cell	   lines,	   five	  tumor-­‐derived	   cell	   lines,	   as	   well	   as	   the	   transformed	   293A	   cell	   line.	   Using	   a	  combination	  of	  Western	  blotting	  and	  quantitative	   immuofluorescence	  analyses,	  we	   observed	   accumulation	   of	   cyclin	   E1	   protein	   upon	   hCDC4α-­‐specific	   siRNA	  depletion	  in	  all	  cell	  lines	  analyzed.	  However,	  when	  hCDC4γ	  was	  siRNA	  depleted,	  cyclin	  E1	  was	  elevated	  in	  only	  a	  subset	  of	  these	  cell	  lines,	  including	  normal	  and	  non-­‐transformed	   cells.	   Increased	   cyclin	   E1	   levels	   were	   shown	   to	   be	   due	   to	  decreased	   turnover	   of	   cyclin	   E1	  protein,	   rather	   than	   to	   differences	   in	   isoform-­‐specific	  mRNA	  expression.	  Since	  cyclin	  E1	   levels	  are	  abnormally	  elevated	   in	  many	  cancer	  cell	   lines,	  we	  hypothesized	  that	  the	  differences	  in	  isoform	  requirement	  could	  be	  explained	  by	  the	  relative	  expression	  cyclin	  E1.	   Indeed,	  when	  comparing	  cyclin	  E1	  protein	  levels	   in	   different	   cell	   lines,	   it	   became	   apparent	   that	   the	   cell	   lines	   where	  depletion	   of	   either	   hCDC4	   isoform	   (hCDC4α	   or	   hCDC4γ)	   stabilized	   cyclin	   E1	  protein,	   expressed	   relatively	   low	   levels	  of	   cyclin	  E1.	   In	   contrast,	   cell	   lines	  with	  high	  levels	  of	  cyclin	  E1	  were	  only	  responsive	  to	  hCDC4α	  siRNA	  depletion.	  To	  test	  if	   high	   levels	   of	   cyclin	   E1	   can	   bypass	   the	   requirement	   for	   hCDC4γ,	   we	  overexpressed	  cyclin	  E1,	  while	  simultaneously	  silencing	  each	  hCDC4	  isoform,	  in	  cells	  that	  require	  both	  hCDC4α	  and	  hCDC4γ	  for	  cyclin	  E1	  turnover.	  Indeed,	  cyclin	  E1	  levels	  were	  no	  longer	  responsive	  to	  silencing	  of	  hCDC4γ,	  suggesting	  that	  the	  normal	  cyclin	  E1	  degradation	  pathway	  is	  not	  employed	  when	  cyclin	  E1	  levels	  are	  abnormally	  high.	  Because	  overexpression	  of	  cyclin	  E1	  abrogates	  the	  requirement	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SCFFbxw7/hCdc4	  targets	  cyclin	  E2	  for	  ubiquitin-­‐dependent	  proteolysis	  
	  
	  Cyclin	   E2	   is,	   like	   cyclin	   E1,	   often	   over-­‐expressed	   in	   human	   tumors,	   and	   this	  alteration	   is	   an	   independent	  prognostic	   factor	   for	  poor	  patient	  prognosis	   [128,	  192].	  Both	  E-­‐type	  cyclins	  display	  similar	  expression,	  peaking	  during	  late	  G1	  and	  progressively	  decreasing	  during	  S-­‐phase,	  due	  to	  a	  combination	  of	  transcriptional	  and,	  in	  the	  case	  of	  cyclin	  E1,	  targeted	  degradation	  by	  SCFFBXW7/hCDC4	  [39,	  40,	  103].	  Given	  the	  similarity	  between	  cyclin	  E1	  and	  cyclin	  E2,	   in	  this	  study	  we	  aimed	  to	  investigate	  whether	  cyclin	  E2	  is	  a	  novel	  SCFFBXW7/hCDC4	  substrate.	  	   To	   determine	   if	   FBXW7/hCDC4	   regulates	   the	   turnover	   of	   endogenous	  cyclin	   E2	   protein,	   we	   performed	   in	   vivo	   cycloheximide	   chase	   analysis	   and	  ubiquitylation	  experiments	  using	  RNAi-­‐mediated	  depletion	  or	  ectopic	  expression	  of	  FBXW7/hCDC4,	  respectively.	  Whereas	  cyclin	  E2	  protein	  was	  stabilized	  in	  cells	  where	   FBXW7/hCDC4	   was	   depleted,	   overexpression	   of	   FBXW7/hCDC4	  significantly	   increased	   ubiquitin-­‐conjugated	   cyclin	   E2.	   These	   results	   were	  confirmed	   in	   vitro	   using	   recombinant	   cyclin	   E2	   and	   SCFFBXW7/hCDC4	   complexes,	  indicating	   that	   cyclin	   E2	   is	   directly	   targeted	   for	   ubiquitylation	   by	   the	  SCFFBXW7/hCDC4	   ubiquitin	   ligase.	   To	   explore	   this	   in	  more	   detail,	   we	   investigated	  whether	  cyclin	  E2	  possesses	  a	  CDC4-­‐phosphodegron	  (CPD).	  Analogous	  to	  cyclin	  E1,	  we	   found	   two	  putative	  CPDs,	   one	  high-­‐affinity	   degron	   and	  one	   low-­‐affinity	  degron	  in	  cyclin	  E2,	  which	  correspond	  to	  the	  consensus	  CPDs	  found	  in	  cyclin	  E1.	  Mutation	   of	   these	   putative	   phosphorylated	   residues	   increased	   the	   stability	   of	  cyclin	  E2	  in	  vivo,	  likely	  abrogating	  ubiquitylation	  by	  SCFFBXW7/hCDC4.	  A	  surprising	  finding	  in	  this	  study	  was	  the	  apparent	  involvement	  of	  cyclin	  E1	  in	  the	  ubiquitin-­‐dependent	  degradation	  of	  cyclin	  E2.	  Whereas	  knockdown	  of	  cyclin	   E1	   caused	   an	   increase	   in	   the	   steady-­‐state	   levels	   of	   cyclin	   E2,	   ectopic	  expression	  of	   cyclin	  E1	   stimulated	   cyclin	  E2	  degradation	  and	  ubiquitylation	  by	  SCFFBXW7/hCDC4	   in	   vivo.	   This	   would	   imply	   that	   accumulation	   of	   cyclin	   E2	   would	  require	  that	  cyclin	  E1	  levels	  are	  low.	  Indeed,	  analysis	  of	  the	  expression	  profile	  of	  cyclin	  E2	  protein	  during	  the	  cell	  cycle	  demonstrated	  that	  expression	  of	  cyclin	  E2	  peaked	  slightly	   later	   than	  cyclin	  E1,	   and	  persisted	   into	  mitosis,	   suggesting	   that	  cyclin	  E2	  displays	  different	  windows	  of	  expression	  and	  degradation	  as	  compared	  to	  cyclin	  E1.	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The	  putative	   role	  of	   cyclin	  E1	   in	   the	   regulation	  of	   cyclin	  E2	  degradation	  could	   be	  mediated	   through	  phosphorylation	   of	   cyclin	  E2	   at	   CPDs	  by	   the	   cyclin	  E1-­‐CDK2	   complex,	   stimulating	   binding	   and	   ubiquitylation	   by	   FBXW7/hCDC4.	  Our	  studies	  also	  indicate	  that	  cyclin	  E1	  may	  compete	  with	  cyclin	  E2	  for	  binding	  to	   FBXW7/hCDC4	   during	   G1	   and	   early	   S-­‐phase.	   Thus,	   we	   propose	   that	   by	  regulating	   the	   abundance	   of	   cyclin	   E2,	   cyclin	   E1	   ensures	   prolonged	   cyclin	   E2-­‐CDK2	   activities,	   allowing	   it	   to	   perform	   non-­‐redundant	   functions	   in	   cell	   cycle	  control.	  However,	  further	  studies	  will	  be	  required	  to	  address	  the	  validity	  of	  these	  molecular	  mechanisms.	  To	  summarize,	   in	   this	  paper	  we	   report	   that	  SCFFBXW7/hCDC4	   targets	   cyclin	  E2	  for	  ubiquitin-­‐dependent	  proteolysis.	  Since	  FBXW7/hCDC4	  is	  often	  inactivated	  in	   several	   human	   cancers,	   alteration	   of	   this	   pathway	   could	   contribute	   to	   the	  deregulation	  of	  both	  E-­‐type	  cyclins,	  further	  promoting	  tumorigenesis.	  	   	  	  
PAPER	  III.	  
	  
The	   ubiquitin	   ligase	   SCFFBXO28	   regulates	   Myc-­‐driven	   transcription	  
through	   non-­‐proteolytic	   ubiquitylation	   and	   is	   required	   for	   cell	  
proliferation	  
	  
	  Given	   that,	   to	   date,	   the	   majority	   of	   F-­‐box	   proteins	   have	   remained	  uncharacterized,	  at	   the	  beginning	  of	   this	  study	  we	  aimed	  to	   identify	  new	  F-­‐box	  genes	   with	   potential	   roles	   in	   regulation	   of	   cell	   proliferation.	   Initially,	   we	  employed	  a	   functional	  RNAi	   screen	  using	   an	   siRNA	   library	   targeting	   the	   entire	  family	  of	  human	  F-­‐box	  genes,	  and	  assessed	  for	  effects	  on	  cell	  proliferation	  in	  four	  different	   tumor-­‐derived	   cell	   lines	   by	   immunofluorescence	   microscopy.	   From	  these	   analyses,	   several	   candidate	   F-­‐box	   genes	   were	   identified.	   These	   results	  were	   subsequently	   validated	   in	   a	   genome-­‐wide	   screen	   that	   included	   53	   F-­‐box	  genes.	   Interestingly,	   in	   both	   screens	   FBXO28	   was	   one	   of	   the	   top	   candidates	  affecting	   cell	   proliferation	   and	  was	   thus	   chosen	   for	   further	   in-­‐depth	   functional	  analysis.	  	   Examination	  of	   the	  amino	  acid	  sequence	  revealed	   that	  FBXO28	   is	  highly	  conserved	   in	  various	   species,	   supporting	  a	   critical	  biological	   function	  of	   this	  F-­‐box	   protein.	   FBXO28	   contains	   an	   F-­‐box	  motif	   capable	   of	   co-­‐precipitating	   with	  SCF	  core	  components	  SKP1	  and	  CUL1,	  demonstrating	  that	  FBXO28	  is	  part	  of	  an	  SCF	  E3	  ubiquitin	  ligase.	  To	  identify	  pathways	  that	  might	  be	  regulated	  by	  FBXO28,	  we	  carried	  out	  microarray	  expression	  analyses	  of	  HCT116	  cells	  transfected	  with	  FBXO28	   siRNAs.	   FBXO28	   depletion	   resulted	   in	   changes	   in	   the	   expression	   of	  multiple	   genes	   involved	   in	   important	   biological	   processes	   including	   cell	   cycle	  control	  and	  metabolism.	   Interestingly,	  detailed	  analyses	  of	   the	  gene	  expression	  data	   revealed	   that,	   among	   others,	   a	   considerable	   number	   of	   Myc	   target	   genes	  were	  significantly	  affected.	  	  To	  further	  investigate	  a	  potential	  relationship	  between	  FBXO28	  and	  Myc,	  we	   assessed	   for	   the	   ability	   of	   these	   two	   proteins	   to	   interact	   in	   vivo	   using	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Phosphorylation	  of	  the	  F-­‐box	  protein	  FBXO28	  is	  associated	  with	  poor	  
prognosis	  in	  patients	  with	  primary	  breast	  cancer	  
	  
	  In	   Paper	   III	   we	   showed	   that	   FBXO28	   regulates	   cell	   proliferation	   and	   Myc	  transcriptional	  activation.	  To	  gain	  further	  insight	  into	  the	  biological	  functions	  of	  FBXO28,	   we	   set	   out	   to	   investigate	   whether	   FBXO28	   itself	   is	   regulated,	   for	  instance	   by	   post-­‐translational	   modifications.	   Immunopurification	   of	   FBXO28,	  followed	  by	  mass	   spectrometric	   analysis,	   identified	   specific	  phosphorylation	  of	  FBXO28	   at	   serine	   344	   (S344).	   Additional	   experiments	   using	   phosphospecific	  FBXO28	   antibodies	   showed	   that	   pS344-­‐FBXO28	   resides	   in	   the	   nucleus	   and	   is	  phosphorylated	   in	   a	   cell-­‐cycle	   regulated	   fashion	   by	   the	   CDKs.	   Efficient	  phosphorylation	  of	  FBXO28	  in	  vitro	  was	  observed	  with	  cyclin	  A-­‐CDK2	  and	  cyclin	  B-­‐CDK1,	   but	   not	   cyclin	   E-­‐CDK2,	   arguing	   that	   FBXO28	   is	   a	   novel	   CDK1/2	  substrate.	  	   Given	   the	   previous	   findings	   that	   FBXO28	   is	   critical	   for	   cellular	  proliferation,	  we	  next	  sought	  to	  investigate	  the	  role	  of	  FBXO28	  phosphorylation	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on	   proliferation.	   Ectopic	   expression	   of	   a	   phosphorylation-­‐deficient	   mutant	   of	  FBXO28	   (S344A-­‐FBXO28)	   in	   tumor	   cell	   lines	   attenuated	   cell	   proliferation	   and,	  importantly,	   reduced	   the	   transforming	   potential	   of	  Myc	   in	   p53-­‐/-­‐	  MEFs.	   These	  results	   indicated	   that	   CDK	   phosphorylation	   of	   FBXO28	   at	   Ser344	   has	   an	  important	   role	   in	   cellular	   proliferation	   and	   possibly	   in	   Myc-­‐induced	  transformation.	  	   Encouraged	   by	   these	   observations,	   we	   set	   out	   to	   examine	   if	   FBXO28	  phosphorylation	  has	  clinical	  significance	  using	  immunohistochemistry	  on	  tissue	  microarrays	   (TMA).	   A	   panel	   of	   144	   primary	   breast	   cancers	   was	   analyzed	   for	  FBXO28	  phosphorylation	  using	   the	  pS344-­‐FBXO28	  antibody.	  The	  vast	  majority	  of	   the	  tumors	  displayed	  strong	  nuclear	   intensity.	  However,	   the	  nuclear	   fraction	  (NF)	   of	   pS344-­‐FBXO28	   was	   found	   to	   vary	   significantly	   between	   the	   different	  tumors.	  Indeed,	  a	  high	  NF	  of	  pS344-­‐FBXO28	  correlated	  with	  clinicopathological	  parameters	   associated	   with	   several	   established	   markers	   of	   poor	   patient	  outcome,	  including	  tumor	  size,	  high	  grade	  and	  ER-­‐negative	  status.	  Importantly,	  a	  strong	  association	  between	  high	  NF	  of	  pS344-­‐FBXO28	  and	  overall	  survival	  (OS),	  breast	   cancer	   specific	   survival	   (BCSS)	   and	   recurrence-­‐free	   survival	   (RFS)	  were	  found,	   and	  multivariate	   analyses	   further	   established	   that	   a	   high	   NF	   of	   pS344-­‐FBXO28	  as	  an	  independent	  predictor	  of	  poor	  OS	  in	  breast	  cancer.	  	   Additional	   analysis	   assessing	   pS344-­‐FBXO28	   in	   specific	   breast	   cancer	  subtypes	  revealed	  that	  a	  high	  NF	  of	  pS344-­‐FBXO28	  was	  significantly	  associated	  with	   decreased	   BCSS	   in	   the	   low	   proliferative	   luminal	   A	   tumor	   subtype,	  suggesting	   that	   FBXO28	   phosphorylation	   is	   not	   just	   a	   marker	   for	   highly	  proliferative	   luminal	   B	   tumors.	   Importantly,	   the	   prognostic	   impact	   of	  phosphorylated	  FBXO28	  was	  also	  revealed	  when	  FBXO28	  phosphorylation	  was	  analyzed	   in	   patients	  with	  moderate-­‐grade	   tumors,	   where	   a	   high	   NF	   of	   pS344-­‐FBXO28	  predicted	  poor	  OS.	  From	   this	   study	   we	   conclude	   that	   the	   nuclear	   fraction	   of	   FBXO28	  phosphorylation	  is	  an	  independent	  prognostic	  factor	  for	  poor	  survival	  in	  breast	  cancer.	  It	  will	  be	  important	  to	  confirm	  these	  findings	  in	  an	  independent	  patient	  cohort	   and	   to	   investigate	   whether	   FBXO28	   phosphorylation	   can	   be	   a	   valuable	  clinical	  tool	  as	  a	  prognostic	  biomarker	  in	  breast	  cancer,	  as	  well	  as	  other	  types	  of	  cancer.	   In	   the	   future,	   it	   will	   also	   be	   important	   to	   define	   the	   role	   of	   FBXO28	  phosphorylation	  in	  Myc-­‐induced	  transcription	  and	  cellular	  transformation.	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  I	  have	  come	  to	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   that	   I	  have	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   that	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  being	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  of	  CCK	  	  I	  have	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  been	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  to	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  on	  your	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  no	  matter	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  it	  was	  with	  lab	  matters	  or	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  stranded	  at	  the	  airport	  in	  New	  Jersey.	  Although	  you	  can	  be	  quite	   a	   control-­freak	   and	   meticulous	   with	   labwork,	   I	   want	   to	   thank	   you	   for	  always	  encouraging	  me	  to	   follow	  my	  gut	   feeling	  because,	  at	   the	  end	  of	   the	  day,	  science	   is	   much	   about	   believing	   in	   your	   data.	   I	   can’t	   think	   of	   a	   more	   caring,	  engaged	  and	  understanding	  supervisor	  than	  you.	  Thanks	  a	  lot	  for	  making	  me	  the	  scientist	  I	  am	  today!	  	  My	   co-­‐supervisor,	  Dan	  Grandér,	   thanks	   for	   always	  bringing	  up	  new	   ideas	   and	  perspectives	   to	   the	   project.	   You	   are	   such	   a	   great	   teacher	   and	   a	   good	   listener,	  provided	   that	  you	  get	   lots	  of	   coffee!	   It	   is	   inspiring	   to	   see	  you	  multitask	  and	  be	  great	  at	  everything.	  It’s	  been	  said	  that	  Dan	  Grandér’s	  graduates	  do	  really	  well	  in	  science…	  cross	  your	  fingers	  for	  me	  	  	  
Aljona,	  you	  have	  been	  my	  best	  friend	  in	  the	  lab	  and	  I	  so	  miss	  having	  you	  around.	  You	  are	  such	  a	  generous	  and	  caring	  person,	  and	  I	  always	  feel	  like	  I	  can	  talk	  to	  you	  about	  anything.	  Natalie,	  there’s	  a	  calmness	  about	  you	  that	  always	  makes	  me	  feel	  that	  no	  problem	  is	  worth	  stressing	  for.	  The	  time	  you	  and	  Aljona	  were	  at	  the	  lab	  was	  some	  of	   the	  best	  during	   these	  years…	  you	   two	  were	   like	  big	  sisters	   to	  me.	  Thanks	  for	  keeping	  the	  lab	  drama-­‐free!	  	  
Josefin,	  you	  are	  a	  great	  role–model.	   I	  have	  never	  met	  anyone	  so	  organized	  and	  efficient,	  bossy	  	  and	  fun	  as	  you	  are,	  and	  I	  hope	  that	  I	  could	  be	  some	  of	  that	  one	  day.	  Thanks	   for	  being	  such	  a	  great	  support	  and	  a	  good	   friend	   in	  and	  out	  of	   the	  lab.	  Our	  little	  Indian	  music	  box,	  Nimesh.	  There	  is	  no	  boring	  moment	  with	  you	  in	  the	  lab…	  you	  turned	  the	  lab	  into	  a	  Bollywood	  movie:	  happy,	  loud	  and	  colourful.	  I	  truly	   enjoyed	   our	   chats	   over	   breakfast	   and	   coffee	   breaks,	   but	   above	   all	   our	  common	  sense	  of	  humor	  ;-­‐).	  Who	  would	  have	  imagined	  that	  you	  and	  I	  could	  be	  such	   a	   good	   match!	   Keep	   singing	   and	   try	   no	   to	   lose	   your	   head	   trying	   to	   find	  substrates!	   Charis,	   I	   really	   appreciate	   your	   help	   with	   the	   various	   FBXO28	  projects	  that	  have	  come	  and	  gone	  during	  the	  past	  two	  years.	  Your	  great	  sense	  of	  integrity	  and	  determination	  are	  important	  in	  science,	  but	  also	  try	  to	  stay	  open	  to	  ideas	  that	  are	  sometimes	  “outside	  the	  box”.	  With	  you	  and	  Nimesh	  as	  a	  team,	  I	  can	  leave	  reassured	  that	  the	  project	  is	  in	  good	  hands!	  Shahab,	  you	  are	  the	  proof	  that	  perseverance	   can	   take	   you	   places!	   You	   have	   a	   great	   heart	   and	   such	   a	   unique	  laughter,	   and	   you	   are	   always	  willing	   to	   help	   out.	   Strangely,	   there	   seems	   to	   be	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more	  left-­‐over	  cake	  and	  Indian	  food	  ever	  since	  you	  left	  the	  lab.	  Elin,	  you	  were	  the	   first	   student	   I	   supervised	   and	   you	   really	  made	   it	   so	   easy	   for	  me!	   You	   are	  smart,	  and	  hard-­‐working,	  and	  a	  real	  blast	  at	  parties.	  Thanks	  for	  all	  the	  help	  with	  the	  MCM	  project	  and	  for	  keeping	  a	  positive	  attitude	  even	  though	  we	  had	  clearly	  hit	  a	  dead-­‐end.	  Azadeh,	   for	  nice	  chats,	  good	  pregnancy	  advise	  and	  input	  on	  the	  project.	  Also	  thanks	  to	  the	  students	  Angelina,	  Karim,	  and	  Yogesh	  for	  bringing	  a	  happy	  attitude	  to	  the	  lab.	  	  	  Members	  of	   the	  Grandér’s	  group,	   thanks	   for	  all	   the	   fun	  times	  at	  Castle	  kickoffs,	  midsummer	   lunches	   and	   Christmas	   dinners.	   Micke,	   you	   have	   the	   power	   of	  making	  it	  so	  easy	  to	  get	  things	  off	  one’s	  chest,	  especially	  when	  beer	  is	  involved!	  Thanks	  for	  all	  great	  times	  at	  the	  kickoffs	  and	  for	  always	  having	  all	  the	  answers!	  
Masako,	  for	  having	  a	  huge	  smile	  whenever	  we	  meet.	  	  Thank	  you	  for	  showing	  us	  Japan,	   you	   were	   a	   fantastic	   hostess!	   Per	   J.	   for	   always	   having	   time	   for	   a	   chat,	  
Katja	  and	  Lotte,	  for	  being	  so	  patient	  and	  helpful	  when	  we	  were	  sharing	  the	  same	  lab	  and	  for	  keeping	  everything	  running	  smoothly,	  Martin	  C.,	   for	  spicing	  up	  any	  discussion	  with	  a	  little	  bit	  of	  black	  humor.	  Past	  members	  Linn	  and	  Eva,	   I	  really	  admire	  that	  you	  dared	  to	  leave	  research	  to	  pursue	  something	  you	  really	  wanted.	  	  The	  Wiman’s	  group,	  of	  which	  I	  became	  an	  honorary	  member.	  Thanks	  for	  letting	  me	  crash	  parties,	  dinners,	  celebrations	  and	  even	  conference	  trips.	  You	  guys	  made	  my	  student	  life	  at	  CCK	  much	  more	  fun!	  In	  particular,	  I	  would	  like	  to	  thank	  some	  of	  the	  former	  members,	  Anna,	   the	  super-­‐smart	  redhead,	  for	  being	  a	  true	  friend	  to	  us.	  Our	  trip	  to	  China	  was	  unforgettable…	  we	  should	  do	  it	  again!	  Jin,	  I	  love	  your	  unique	  and	  honest	  personality.	   I	  can	  always	  count	  on	  you	  for	  a	  good	  laugh	  and	  great	   beauty	   advise.	   I	   am	   so	   happy	   to	   have	   you	   as	   Elvis’	   godmother	   and	   good	  friend,	  and	  I	  look	  forward	  to	  fun	  times	  in	  California!	  Ruby,	  I	  so	  miss	  all	  the	  great	  parties	  that	  we	  had	  when	  you	  were	  around.	  Susanne,	  thanks	  for	  all	  the	  help	  with	  the	  Northern	  blots	  and	  your	  youthful	  spirit.	  All	  the	  fun	  people,	  past	  and	  present,	  including	   Cinzia,	   Gregor,	   Jeremy,	   Magda,	   Nader,	   Vladimir,	   Emarn,	   Lidi,	  
Qiang,	  for	  being	  so	  kind	  and	  friendly.	  
	  
Elisabeth	  and	  Sofia	   for	  letting	  me	  into	  the	  little	  Farnebo’s	  triangle	  of	  trust!	  You	  two	   are	   a	   lot	   of	   fun	   to	   talk	   to!	   I	   have	   really	   enjoyed	   all	   the	   lunches	   and	  wine-­‐tasting	  parties.	  Elisabeth,	  I	  feel	  like	  I	  never	  thanked	  you	  enough	  for	  coming	  with	  me	   to	   look	   for	   a	  w-­‐dress.	   I	  was	   probably	   not	   the	   easiest!	  Marianne,	   it	   is	   very	  inspiring,	  and	  not	  surprising	  at	  all,	  to	  see	  you	  succeed	  in	  everything	  you	  do.	  I	  can	  see	  a	  lot	  of	  your	  tenacity	  in	  Salah,	  and	  I’m	  sure	  that’s	  a	  good	  sign!	  	  Members	  of	  the	  Olle	  Larsson’s	  group:	  Margherita,	  the	  sweet	  crazy	  Italian	  who	  always	  makes	  me	   laugh!	  Dudi,	   I	   could	   always	   count	   on	   you	  having	   everything	  from	  antibodies	   to	  plasmids.	  Thanks	   for	  being	  so	  generous	  with	   reagents!	  Also	  thanks	  to	  Sylvia,	  Thomas,	  and	  past	  members	  Bita,	  Linda,	  Sandra	  and	  Eric	   for	  keeping	  a	  nice	  atmosphere	  on	  the	  fourth	  floor.	  	  Many	   thanks	   to	   the	  people	   at	   CCK,	  who	   still	  make	  me	   feel	   that	   I	   belong	   at	   the	  department:	   Dali,	   Barry,	   Pádraig	   Markus,	   Jeroen,	   Martin	   A.,	   Natalie	   L.P.,	  
Amir,	  Aris,	  Alvaro,	   and	   Emma.	   Juan,	  many	  many	   thanks	   for	   helping	  me	  with	  FACS,	  and	  for	  giving	  me	  such	  a	  good	  reputation	  about	  my	  BrdU	  assays!	  Inga	  and	  
Tomadher,	  it’s	  always	  lovely	  to	  meet	  you	  at	  the	  occasional	  parties.	  You	  two	  are	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so	  much	  fun	  to	  talk	  to!	  Mikael	  Lindström,	  for	  your	  generous	  help	  with	  reagents	  and	  input.	  Anders	  Zetterberg	  and	  Pär	  L.	  for	  providing	  us	  with	  the	  ROMA	  data.	  	  Our	  neighbours	  at	  CMB;	  the	  Percipalle	  and	  Wrange	  groups,	  for	  contributing	  to	  a	  nice	  work	   atmosphere.	  Aishe,	   it’s	   so	   refreshing	   to	   chat	  with	   you!	   Keep	   up	   the	  happy	  spirit,	   it	  makes	  a	  difference!	  Sweet	  Nanaho,	   I	  hope	  to	  be	  as	  calm	  as	  you	  when	   I	   become	   a	   mom.	   Ales,	   talking	   to	   you	   was	   both	   enlightening	   and	  perplexing.	  I	  miss	  the	  entertaining	  discussions	  between	  you	  and	  Raju!	  Thanks	  to	   Piergiorgio	   for	   input	   on	   our	   nucleolar	   project	   and	   for	   being	   available	   for	  questions.	   Also	   thanks	   to	  Christine,	  Sergej	  B.	   and	  Örjan	   for	   being	   so	   friendly	  and	   for	   patiently	   allowing	   us	   to	   be	   noisy	   at	   times.	   Other	   people	   at	   CMB,	   in	  particular	   Javier	   and	   Teresa	   for	   being	   so	   kind	   and	   always	   greeting	   me	   with	  smiles.	  Thanks	  Javier	  for	  nice	  chats	  and	  for	  taking	  the	  time	  to	  help	  me	  with	  the	  FACS	   whenever	   I	   needed.	   Abrahan,	   for	   reminding	   me	   of	   how	   much	   I	   miss	  dancing	   salsa!	   The	   super	   sweet	   ladies	   at	   the	   autocleaving	   facility,	   Veronica,	  
Janet,	  Elisabeth	  V.	  and	  Rosa-­Amanda	  for	  always	  being	  so	  helpful	  and	  for	  doing	  your	  job	  with	  a	  smile!	  Zdravko	  and	  Irene	  for	  keeping	  CMB	  running	  and	  making	  it	  look	  like	  it’s	  an	  easy	  job.	  	  Our	  collaborators,	  Lars-­Gunnar	  Larsson,	  I	  wish	  I	  had	  listened	  the	  first	  time	  you	  said	   “it	   smells	   like	   Myc”!	   Thanks	   for	   sharing	   your	   endless	   knowledge	   on	   Myc	  with	  us	  and	   for	  helping	  out	  with	   the	  manuscript	  until	   the	   late	  night	  hours	   so	   I	  could	  meet	  my	  deadlines.	  Hamid,	  this	  project	  has	  been	  a	  rollercoaster	  for	  all	  of	  us	   involved!	   I	  am	  glad	  you	  didn’t	  quit	  after	  the	  WTF	   incident	  …unforgettable!	  
Helén,	  thanks	  for	  so	  good-­‐naturedly	  helping	  out	  with	  the	  project.	  It’s	  too	  bad	  you	  left	   before	   it	   got	   really	   interesting!	   Per	   H.	   for	   being	   so	   a	   caring	   and	   helpful.	  
Francesc	   Vinyals,	   Fredrik	   Pontén,	   Stina	   Magnusson,	   Juha	   Rantala,	   Erik	  
Fredlund	  and	  Steve	  Reed	  for	  great	  work	  and	  input.	  	  The	   San	   Diego	   crew:	   Chuck,	   for	   allowing	   me	   to	   spend	   some	   of	   the	   most	  productive	  three	  months	  of	  my	  PhD	  studies	  in	  your	  lab.	  YingMeei,	  you	  were	  such	  a	   great	   friend	   to	   me	   during	   my	   visit.	   Thanks	   for	   all	   the	   rides,	   long	   chats	   and	  dinners,	  and	  for	  introducing	  me	  to	  Mochi	  ice	  cream.	  Stefan,	  you	  and	  Melanie	  were	  such	  generous	  friends!	  I	  am	  so	  glad	  that	  even	  today	  I	  can	  write	  to	  you	  and	  you	   always	   reply	   as	   though	   no	   time	   has	   passed.	   Many	   thanks	   also	   to	   Sonia,	  
Zdenka	  and	  Dahui,	  for	  making	  me	  feel	  part	  of	  the	  group.	  	  	  The	   people	   at	   Zymenex:	   Claes,	   Annika,	   Helena,	   Stefan,	   Kerstin,	   Susanne,	  
Magnus,	  and	  Pia,	  and	  the	  resident	  seagulls,	   it	  was	  a	  pleasure	  to	  be	  an	  intern	  at	  your	   company	   during	   this	   summer.	   Thanks	   for	   teaching	   me	   how	   to	   work	  efficiently	  and	  still	  have	  two	  fika-­‐breaks	  per	  day.	  	  	  	  The	   party	   friends:	  Mehdi,	   looove,	   I	   feel	   like	   you	   are	   almost	   a	   little	   brother	   to	  Salah	  and	  I	  so	  enjoy	  making	  fun	  of	  you!	  Thank	  you	  for	  always	  being	  so	  protective,	  respectful	  and	  caring	  towards	  me.	  We’ll	  be	  waiting	  for	  you	  in	  SF!	  Chia	  and	  Sergej	  
P.,	  no	  party	  has	  beaten	  the	  tequila	  party	  we	  had	  at	  Rackarberget!	  Thanks	  for	  all	  the	  good	  times	  and	  for	  remaining	  such	  great	  friends	  after	  all	  these	  years.	  Chiara,	  my	  favourite	  Italian	  cook,	  your	  food	  is	  just	  heavenly!	  Thanks	  for	  taking	  such	  good	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care	  of	  our	  little	  Elvis.	  Yuko,	  I	  am	  very	  glad	  that	  Sergej	  found	  such	  a	  sweet	  girl.	  I	  look	  forward	  to	  visiting	  you	  guys	  in	  Japan.	  	  My	   family	   in	   Sweden:	   Sunday	   lunches	   are	   a	   real	   treat	   and	   the	   best	   way	   to	  recharge	   batteries.	   Thanks	   for	   adopting	  me	   into	   your	   small	   family.	  Mehri	   and	  
Farman,	  you	  are	  the	  most	  ideal	  parents-­‐in-­‐law	  one	  can	  ask	  for,	  always	  so	  loving	  and	  caring!	  Thank	  you	   for	   the	   support	  and	   trust	  during	   these	  years.	  Azziz,	   the	  heart	  of	  the	  family!	  No	  words	  in	  any	  language	  can	  express	  how	  much	  your	  love	  and	   devotion	   means	   to	   us.	   Safa,	   for	   gastronomic	   adventures	   and	   memorable	  trips.	  You	  are	  not	  only	  Salah’s	  brother	  but	  also	  a	  great	  friend	  to	  us.	  Thanks	  for	  all	  the	  fun	  times!	  Parastoo,	  you	  are	  such	  a	  good-­‐natured,	  generous,	  happy	  person,	  and	  a	  great	  cook.	  You	  complement	  Safa	  in	  so	  many	  good	  ways!	  	  My	   family:	  my	  wonderful	   parents,	  Carlos	   and	  Flor	  Alba,	   for	   giving	  me	   all	   the	  tools	   and	   confidence	   to	   chose	  my	   own	   path.	  With	   your	   never-­‐ending	   love	   and	  support	   I	  have	  always	   felt	   that	   I	   could	  accomplish	  anything.	  Thanks	   for	  always	  being	  so	  proud	  of	  the	  small	  and	  big	  accomplishments.	  I	  miss	  you	  every	  day!	  My	  beautiful	  sisters	  and	  best	  friends:	  Lina,	  most	  people	  describe	  you	  as	  a	  talker,	  but	  you	  are	  also	  a	  great	  listener.	  Talking	  to	  you	  about	  anything	  and	  everything	  is	  the	  best	  therapy	  after	  a	  long	  day	  at	  work!	  I	  truly	  admire	  your	  strength	  as	  a	  woman	  and	   a	  mother.	   Thanks	   for	   always	   being	   around.	   My	   little	   sis,	  Andreita,	   in	  my	  mind	   you	   will	   always	   be	   the	   13-­‐year-­‐old	   girl	   whom	   I	   had	   to	   say	   good-­‐bye	   to	  when	   I	   went	   away	   to	   Canada.	   It’s	   sad	   that	   we	   never	   get	   to	   live	   in	   the	   same	  continent	   for	   too	   long,	   but	   I	   hope	   to	   make	   up	   for	   that	   when	   we	   move	   to	  California.	  You	  have	  always	  looked	  up	  to	  us	  but	  do	  know	  that	  I	  am	  very	  proud	  of	  you.	   I	   love	   the	   four	   of	   you!	   My	   lovely	   little	   nephew	   Carlos	   “Chiky”,	   I	   never	  thought	  I	  could	  get	  so	  attached	  to	  you…	  you	  made	  me	  believe	  in	  love	  at	  first	  sight	  
.	  You	  have	  enriched	  my	  life	  in	  so	  many	  ways	  in	  the	  past	  two	  years!	  Please	  don’t	  grow	  up	  so	  fast!	  Danil,	  thanks	  for	  being	  part	  of	  all	  our	  special	  events	  in	  the	  past	  year.	  I	  hope	  you	  guys	  move	  to	  US	  soon	  for	  some	  baby-­‐seating	  payback!	  The	  rest	  of	  my	  big	  Cepeda/Caycedo	  family,	  thanks	  for	  being	  proud	  of	  me.	  	  My	  growing	   little	   family:	   little	   furry	  ball,	  Elvis.	  Getting	  you	  was	  one	  of	   the	  best	  decisions	   I	  ever	  made!	  You	  are	  a	  great	  companion	  and	  such	  a	   loving	  cat!	  Being	  greeted	  enthusiastically	  by	  you	  when	  I	  come	  home	  at	  the	  end	  of	  the	  day	  always	  makes	  me	   feel	   better.	   You	   and	   I	   have	   a	   special	   connection,	   even	   though	   Salah	  thinks	  I’m	  crazy...	  he’s	  just	  jealous.	  You’ll	  always	  be	  my	  first	  fuzzy	  baby!	  
	  
Salah,	  my	   love…	  you	  are	  my	  absolute	  everything.	  There	   is	  no	  way	   I	   could	  have	  made	  it	  this	  far	  without	  you,	  not	  to	  mention	  the	  huge	  help	  and	  support	  you	  have	  been	   to	  me	   throughout	   the	   past	   few	  months.	   You	   are	   the	   true	   kanelbulle	   that	  made	  me	  return	  to	  Sweden	  and	  I’m	  still	  enjoying	  every	  bite	  of	  it.	  I	  am	  a	  happier	  person	  by	  your	  side	  and	  you	  really	  bring	  out	   the	  best	   in	  me!	  Thanks	   for	   loving	  me	  during	  all	  these	  wonderful	  years.	  I	  love	  you	  sooooo	  much,	  you	  have	  no	  idea!	  	  Finally,	  a	  special	  thanks	  to	  my	  little	  bulle	  (who’s	  still	  in	  the	  oven),	  for	  giving	  me	  the	   calm,	   strength	   and	   focus	   to	   get	   through	   all	   this.	   Thanks	   for	   these	   amazing	  seven	  months…	  you	  mean	  the	  world	  to	  us	  and	  we	  can’t	  wait	  to	  finally	  meet	  you!
	   44	  
6.	  REFERENCES	  
	  
	  1.	   Hanahan,	  D.	  and	  R.A.	  Weinberg,	  Hallmarks	  of	  cancer:	  the	  next	  generation.	  Cell,	  2011.	  144(5):	  p.	  646-­‐74.	  2.	   Beckmann,	   M.W.,	   et	   al.,	   Multistep	   carcinogenesis	   of	   breast	   cancer	   and	  
tumour	  heterogeneity.	  J	  Mol	  Med	  (Berl),	  1997.	  75(6):	  p.	  429-­‐39.	  3.	   Nass,	   S.J.	   and	   R.B.	   Dickson,	   Defining	   a	   role	   for	   c-­Myc	   in	   breast	  
tumorigenesis.	  Breast	  Cancer	  Res	  Treat,	  1997.	  44(1):	  p.	  1-­‐22.	  4.	   Ormandy,	   C.J.,	   et	   al.,	   Cyclin	   D1,	   EMS1	   and	   11q13	   amplification	   in	   breast	  
cancer.	  Breast	  Cancer	  Res	  Treat,	  2003.	  78(3):	  p.	  323-­‐35.	  5.	   Owens,	  M.A.,	  B.C.	  Horten,	  and	  M.M.	  Da	  Silva,	  HER2	  amplification	  ratios	  by	  
fluorescence	   in	   situ	   hybridization	   and	   correlation	   with	  
immunohistochemistry	  in	  a	  cohort	  of	  6556	  breast	  cancer	  tissues.	  Clin	  Breast	  Cancer,	  2004.	  5(1):	  p.	  63-­‐9.	  6.	   Knudson,	  A.G.,	  Jr.,	  Mutation	  and	  cancer:	  statistical	  study	  of	  retinoblastoma.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1971.	  68(4):	  p.	  820-­‐3.	  7.	   Antoniou,	  A.,	   et	  al.,	  Average	  risks	  of	  breast	  and	  ovarian	  cancer	  associated	  
with	   BRCA1	   or	   BRCA2	   mutations	   detected	   in	   case	   Series	   unselected	   for	  
family	  history:	  a	   combined	  analysis	  of	  22	   studies.	  Am	   J	  Hum	  Genet,	  2003.	  
72(5):	  p.	  1117-­‐30.	  8.	   Bloom,	   H.J.	   and	  W.W.	   Richardson,	  Histological	   grading	   and	   prognosis	   in	  
breast	  cancer;	  a	  study	  of	  1409	  cases	  of	  which	  359	  have	  been	  followed	  for	  15	  
years.	  Br	  J	  Cancer,	  1957.	  11(3):	  p.	  359-­‐77.	  9.	   Elston,	  C.W.	  and	  I.O.	  Ellis,	  Pathological	  prognostic	  factors	  in	  breast	  cancer.	  
I.	  The	  value	  of	  histological	  grade	  in	  breast	  cancer:	  experience	  from	  a	  large	  
study	  with	  long-­term	  follow-­up.	  Histopathology,	  1991.	  19(5):	  p.	  403-­‐10.	  10.	   Yager,	   J.D.	  and	  N.E.	  Davidson,	  Estrogen	  carcinogenesis	   in	  breast	  cancer.	  N	  Engl	  J	  Med,	  2006.	  354(3):	  p.	  270-­‐82.	  11.	   Clemons,	  M.	  and	  P.	  Goss,	  Estrogen	  and	   the	  risk	  of	  breast	  cancer.	  N	  Engl	   J	  Med,	  2001.	  344(4):	  p.	  276-­‐85.	  12.	   Pardee,	   A.B.,	   A	   restriction	   point	   for	   control	   of	   normal	   animal	   cell	  
proliferation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1974.	  71(4):	  p.	  1286-­‐90.	  13.	   Zetterberg,	  A.,	  O.	  Larsson,	  and	  K.G.	  Wiman,	  What	   is	   the	  restriction	  point?	  Curr	  Opin	  Cell	  Biol,	  1995.	  7(6):	  p.	  835-­‐42.	  14.	   Morgan,	   D.O.,	   Cyclin-­dependent	   kinases:	   engines,	   clocks,	   and	  
microprocessors.	  Annu	  Rev	  Cell	  Dev	  Biol,	  1997.	  13:	  p.	  261-­‐91.	  15.	   Ekholm,	  S.V.	  and	  S.I.	  Reed,	  Regulation	  of	  G(1)	  cyclin-­dependent	  kinases	   in	  
the	  mammalian	  cell	  cycle.	  Curr	  Opin	  Cell	  Biol,	  2000.	  12(6):	  p.	  676-­‐84.	  16.	   Ajchenbaum,	  F.,	  et	  al.,	  Independent	  regulation	  of	  human	  D-­type	  cyclin	  gene	  
expression	  during	  G1	  phase	  in	  primary	  human	  T	  lymphocytes.	  J	  Biol	  Chem,	  1993.	  268(6):	  p.	  4113-­‐9.	  17.	   Ohtsubo,	  M.,	  et	  al.,	  Human	  cyclin	  E,	  a	  nuclear	  protein	  essential	   for	  the	  G1-­
to-­S	  phase	  transition.	  Mol	  Cell	  Biol,	  1995.	  15(5):	  p.	  2612-­‐24.	  18.	   Girard,	   F.,	   et	   al.,	   Cyclin	   A	   is	   required	   for	   the	   onset	   of	   DNA	   replication	   in	  
mammalian	  fibroblasts.	  Cell,	  1991.	  67(6):	  p.	  1169-­‐79.	  
	   45	  
19.	   Walker,	  D.H.	  and	  J.L.	  Maller,	  Role	  for	  cyclin	  A	  in	  the	  dependence	  of	  mitosis	  
on	  completion	  of	  DNA	  replication.	  Nature,	  1991.	  354(6351):	  p.	  314-­‐7.	  20.	   King,	   R.W.,	   P.K.	   Jackson,	   and	   M.W.	   Kirschner,	  Mitosis	   in	   transition.	   Cell,	  1994.	  79(4):	  p.	  563-­‐71.	  21.	   Sherr,	  C.J.	  and	  J.M.	  Roberts,	  CDK	  inhibitors:	  positive	  and	  negative	  regulators	  
of	  G1-­phase	  progression.	  Genes	  Dev,	  1999.	  13(12):	  p.	  1501-­‐12.	  22.	   Carnero,	  A.	  and	  G.J.	  Hannon,	  The	  INK4	   family	  of	  CDK	   inhibitors.	  Curr	  Top	  Microbiol	  Immunol,	  1998.	  227:	  p.	  43-­‐55.	  23.	   Russo,	   A.A.,	   et	   al.,	   Structural	   basis	   for	   inhibition	   of	   the	   cyclin-­dependent	  
kinase	   Cdk6	   by	   the	   tumour	   suppressor	   p16INK4a.	   Nature,	   1998.	  
395(6699):	  p.	  237-­‐43.	  24.	   Bartek,	  J.,	  J.	  Bartkova,	  and	  J.	  Lukas,	  The	  retinoblastoma	  protein	  pathway	  in	  
cell	  cycle	  control	  and	  cancer.	  Exp	  Cell	  Res,	  1997.	  237(1):	  p.	  1-­‐6.	  25.	   Frolov,	   M.V.	   and	   N.J.	   Dyson,	   Molecular	   mechanisms	   of	   E2F-­dependent	  
activation	   and	   pRB-­mediated	   repression.	   J	   Cell	   Sci,	   2004.	   117(Pt	   11):	   p.	  2173-­‐81.	  26.	   Lundberg,	   A.S.	   and	   R.A.	   Weinberg,	   Functional	   inactivation	   of	   the	  
retinoblastoma	   protein	   requires	   sequential	   modification	   by	   at	   least	   two	  
distinct	  cyclin-­cdk	  complexes.	  Mol	  Cell	  Biol,	  1998.	  18(2):	  p.	  753-­‐61.	  27.	   Montagnoli,	  A.,	  et	  al.,	  Ubiquitination	  of	  p27	  is	  regulated	  by	  Cdk-­dependent	  
phosphorylation	  and	  trimeric	  complex	  formation.	  Genes	  Dev,	  1999.	  13(9):	  p.	  1181-­‐9.	  28.	   Carrano,	  A.C.,	  et	  al.,	  SKP2	  is	  required	  for	  ubiquitin-­mediated	  degradation	  of	  
the	  CDK	  inhibitor	  p27.	  Nat	  Cell	  Biol,	  1999.	  1(4):	  p.	  193-­‐9.	  29.	   den	  Elzen,	  N.	  and	   J.	  Pines,	  Cyclin	  A	   is	  destroyed	   in	  prometaphase	  and	  can	  
delay	   chromosome	   alignment	   and	   anaphase.	   J	   Cell	   Biol,	   2001.	  153(1):	   p.	  121-­‐36.	  30.	   Furuno,	   N.,	   N.	   den	   Elzen,	   and	   J.	   Pines,	   Human	   cyclin	   A	   is	   required	   for	  
mitosis	  until	  mid	  prophase.	  J	  Cell	  Biol,	  1999.	  147(2):	  p.	  295-­‐306.	  31.	   Lindon,	   C.,	  Control	   of	  mitotic	   exit	   and	   cytokinesis	   by	   the	   APC/C.	   Biochem	  Soc	  Trans,	  2008.	  36(Pt	  3):	  p.	  405-­‐10.	  32.	   Sullivan,	  M.	  and	  D.O.	  Morgan,	  Finishing	  mitosis,	  one	  step	  at	  a	  time.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2007.	  8(11):	  p.	  894-­‐903.	  33.	   Weinberg,	   R.A.,	   The	   retinoblastoma	   protein	   and	   cell	   cycle	   control.	   Cell,	  1995.	  81(3):	  p.	  323-­‐30.	  34.	   Massague,	  J.,	  G1	  cell-­cycle	  control	  and	  cancer.	  Nature,	  2004.	  432(7015):	  p.	  298-­‐306.	  35.	   Bloom,	  J.	  and	  M.	  Pagano,	  Deregulated	  degradation	  of	  the	  cdk	  inhibitor	  p27	  
and	  malignant	  transformation.	  Semin	  Cancer	  Biol,	  2003.	  13(1):	  p.	  41-­‐7.	  36.	   Pagano,	  M.,	  et	  al.,	  Role	  of	   the	  ubiquitin-­proteasome	  pathway	   in	  regulating	  
abundance	   of	   the	   cyclin-­dependent	   kinase	   inhibitor	   p27.	   Science,	   1995.	  
269(5224):	  p.	  682-­‐5.	  37.	   Nakayama,	  K.I.	  and	  K.	  Nakayama,	  Regulation	  of	   the	  cell	   cycle	  by	  SCF-­type	  
ubiquitin	  ligases.	  Semin	  Cell	  Dev	  Biol,	  2005.	  16(3):	  p.	  323-­‐33.	  38.	   Schraml,	   P.,	   et	   al.,	   Cyclin	   E	   overexpression	   and	   amplification	   in	   human	  
tumours.	  J	  Pathol,	  2003.	  200(3):	  p.	  375-­‐82.	  39.	   Moberg,	  K.H.,	  et	  al.,	  Archipelago	  regulates	  Cyclin	  E	  levels	  in	  Drosophila	  and	  
is	  mutated	  in	  human	  cancer	  cell	  lines.	  Nature,	  2001.	  413(6853):	  p.	  311-­‐6.	  
	   46	  
40.	   Strohmaier,	   H.,	   et	   al.,	   Human	   F-­box	   protein	   hCdc4	   targets	   cyclin	   E	   for	  
proteolysis	   and	   is	   mutated	   in	   a	   breast	   cancer	   cell	   line.	   Nature,	   2001.	  
413(6853):	  p.	  316-­‐22.	  41.	   Bouchard,	  C.,	  et	  al.,	  Direct	  induction	  of	  cyclin	  D2	  by	  Myc	  contributes	  to	  cell	  
cycle	  progression	  and	  sequestration	  of	  p27.	  EMBO	  J,	  1999.	  18(19):	  p.	  5321-­‐33.	  42.	   Sears,	   R.,	   K.	   Ohtani,	   and	   J.R.	   Nevins,	   Identification	   of	   positively	   and	  
negatively	   acting	   elements	   regulating	   expression	   of	   the	   E2F2	   gene	   in	  
response	  to	  cell	  growth	  signals.	  Mol	  Cell	  Biol,	  1997.	  17(9):	  p.	  5227-­‐35.	  43.	   Hermeking,	  H.,	  et	  al.,	  Identification	  of	  CDK4	  as	  a	  target	  of	  c-­MYC.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2000.	  97(5):	  p.	  2229-­‐34.	  44.	   Nesbit,	  C.E.,	  J.M.	  Tersak,	  and	  E.V.	  Prochownik,	  MYC	  oncogenes	  and	  human	  
neoplastic	  disease.	  Oncogene,	  1999.	  18(19):	  p.	  3004-­‐16.	  45.	   Reed,	   S.I.,	   Ratchets	   and	   clocks:	   the	   cell	   cycle,	   ubiquitylation	   and	   protein	  
turnover.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2003.	  4(11):	  p.	  855-­‐64.	  46.	   Sun,	  L.	  and	  Z.J.	  Chen,	  The	  novel	  functions	  of	  ubiquitination	  in	  signaling.	  Curr	  Opin	  Cell	  Biol,	  2004.	  16(2):	  p.	  119-­‐26.	  47.	   Ciechanover,	  A.	  and	  K.	  Iwai,	  The	  ubiquitin	  system:	  from	  basic	  mechanisms	  
to	  the	  patient	  bed.	  IUBMB	  Life,	  2004.	  56(4):	  p.	  193-­‐201.	  48.	   Varshavsky,	  A.,	  Regulated	  protein	  degradation.	  Trends	  Biochem	  Sci,	  2005.	  
30(6):	  p.	  283-­‐6.	  49.	   Jentsch,	   S.,	  W.	   Seufert,	   and	  H.P.	   Hauser,	  Genetic	   analysis	   of	   the	   ubiquitin	  
system.	  Biochim	  Biophys	  Acta,	  1991.	  1089(2):	  p.	  127-­‐39.	  50.	   Dantuma,	  N.P.,	  et	  al.,	  A	  dynamic	  ubiquitin	  equilibrium	  couples	  proteasomal	  
activity	  to	  chromatin	  remodeling.	  J	  Cell	  Biol,	  2006.	  173(1):	  p.	  19-­‐26.	  51.	   Ciechanover,	   A.,	   Proteolysis:	   from	   the	   lysosome	   to	   ubiquitin	   and	   the	  
proteasome.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2005.	  6(1):	  p.	  79-­‐87.	  52.	   Giles,	  J.,	  Chemistry	  Nobel	  for	  trio	  who	  revealed	  molecular	  death-­tag.	  Nature,	  2004.	  431(7010):	  p.	  729.	  53.	   Varshavsky,	   A.,	   The	   N-­end	   rule	   pathway	   of	   protein	   degradation.	   Genes	  Cells,	  1997.	  2(1):	  p.	  13-­‐28.	  54.	   Chen,	   Z.J.	   and	   L.J.	   Sun,	   Nonproteolytic	   functions	   of	   ubiquitin	   in	   cell	  
signaling.	  Mol	  Cell,	  2009.	  33(3):	  p.	  275-­‐86.	  55.	   Glickman,	  M.H.	   and	  A.	  Ciechanover,	  The	  ubiquitin-­proteasome	  proteolytic	  
pathway:	   destruction	   for	   the	   sake	   of	   construction.	   Physiol	   Rev,	   2002.	  
82(2):	  p.	  373-­‐428.	  56.	   Pickart,	   C.M.,	  Mechanisms	   underlying	   ubiquitination.	   Annu	   Rev	   Biochem,	  2001.	  70:	  p.	  503-­‐33.	  57.	   Borden,	  K.L.,	  RING	  domains:	  master	  builders	  of	  molecular	   scaffolds?	   J	  Mol	  Biol,	  2000.	  295(5):	  p.	  1103-­‐12.	  58.	   Honda,	   R.,	   H.	   Tanaka,	   and	   H.	   Yasuda,	   Oncoprotein	   MDM2	   is	   a	   ubiquitin	  
ligase	  E3	  for	  tumor	  suppressor	  p53.	  FEBS	  Lett,	  1997.	  420(1):	  p.	  25-­‐7.	  59.	   Nakayama,	  K.I.	   and	  K.	  Nakayama,	  Ubiquitin	   ligases:	   cell-­cycle	   control	  and	  
cancer.	  Nat	  Rev	  Cancer,	  2006.	  6(5):	  p.	  369-­‐81.	  60.	   Burton,	   J.L.	  and	  M.J.	  Solomon,	  D	  box	  and	  KEN	  box	  motifs	   in	  budding	  yeast	  
Hsl1p	   are	   required	   for	   APC-­mediated	   degradation	   and	   direct	   binding	   to	  
Cdc20p	  and	  Cdh1p.	  Genes	  Dev,	  2001.	  15(18):	  p.	  2381-­‐95.	  61.	   Guardavaccaro,	  D.,	  et	  al.,	  Control	  of	  meiotic	  and	  mitotic	  progression	  by	  the	  
F	  box	  protein	  beta-­Trcp1	  in	  vivo.	  Dev	  Cell,	  2003.	  4(6):	  p.	  799-­‐812.	  
	   47	  
62.	   Margottin-­‐Goguet,	   F.,	   et	   al.,	   Prophase	   destruction	   of	   Emi1	   by	   the	  
SCF(betaTrCP/Slimb)	   ubiquitin	   ligase	   activates	   the	   anaphase	   promoting	  
complex	  to	  allow	  progression	  beyond	  prometaphase.	  Dev	  Cell,	  2003.	  4(6):	  p.	  813-­‐26.	  63.	   Bashir,	   T.,	   et	   al.,	   Control	   of	   the	   SCF(Skp2-­Cks1)	   ubiquitin	   ligase	   by	   the	  
APC/C(Cdh1)	  ubiquitin	  ligase.	  Nature,	  2004.	  428(6979):	  p.	  190-­‐3.	  64.	   Vodermaier,	  H.C.,	  APC/C	  and	  SCF:	  controlling	  each	  other	  and	  the	  cell	  cycle.	  Curr	  Biol,	  2004.	  14(18):	  p.	  R787-­‐96.	  65.	   Hicke,	  L.,	  Protein	  regulation	  by	  monoubiquitin.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2001.	  
2(3):	  p.	  195-­‐201.	  66.	   Haglund,	   K.,	   P.P.	   Di	   Fiore,	   and	   I.	   Dikic,	  Distinct	  monoubiquitin	   signals	   in	  
receptor	  endocytosis.	  Trends	  Biochem	  Sci,	  2003.	  28(11):	  p.	  598-­‐603.	  67.	   Chau,	   V.,	   et	   al.,	   A	   multiubiquitin	   chain	   is	   confined	   to	   specific	   lysine	   in	   a	  
targeted	  short-­lived	  protein.	  Science,	  1989.	  243(4898):	  p.	  1576-­‐83.	  68.	   Thrower,	   J.S.,	   et	   al.,	   Recognition	   of	   the	   polyubiquitin	   proteolytic	   signal.	  EMBO	  J,	  2000.	  19(1):	  p.	  94-­‐102.	  69.	   Ikeda,	   F.	   and	   I.	   Dikic,	   Atypical	   ubiquitin	   chains:	   new	   molecular	   signals.	  
'Protein	  Modifications:	  Beyond	  the	  Usual	  Suspects'	  review	  series.	  EMBO	  Rep,	  2008.	  9(6):	  p.	  536-­‐42.	  70.	   Haglund,	  K.	   and	   I.	  Dikic,	  Ubiquitylation	  and	   cell	   signaling.	   EMBO	   J,	   2005.	  
24(19):	  p.	  3353-­‐9.	  71.	   Bennett,	  E.J.	  and	  J.W.	  Harper,	  DNA	  damage:	  ubiquitin	  marks	  the	  spot.	  Nat	  Struct	  Mol	  Biol,	  2008.	  15(1):	  p.	  20-­‐2.	  72.	   Amerik,	   A.Y.	   and	   M.	   Hochstrasser,	   Mechanism	   and	   function	   of	  
deubiquitinating	  enzymes.	  Biochim	  Biophys	  Acta,	  2004.	  1695(1-­‐3):	  p.	  189-­‐207.	  73.	   Wenzel,	   T.	   and	   W.	   Baumeister,	   Conformational	   constraints	   in	   protein	  
degradation	   by	   the	   20S	   proteasome.	   Nat	   Struct	   Biol,	   1995.	  2(3):	   p.	   199-­‐204.	  74.	   Bai,	  C.,	  et	  al.,	  SKP1	  connects	  cell	  cycle	  regulators	  to	  the	  ubiquitin	  proteolysis	  
machinery	  through	  a	  novel	  motif,	  the	  F-­box.	  Cell,	  1996.	  86(2):	  p.	  263-­‐74.	  75.	   Jin,	   J.,	   et	   al.,	   Systematic	   analysis	   and	   nomenclature	   of	   mammalian	   F-­box	  
proteins.	  Genes	  Dev,	  2004.	  18(21):	  p.	  2573-­‐80.	  76.	   Cenciarelli,	  C.,	  et	  al.,	  Identification	  of	  a	  family	  of	  human	  F-­box	  proteins.	  Curr	  Biol,	  1999.	  9(20):	  p.	  1177-­‐9.	  77.	   Winston,	  J.T.,	  et	  al.,	  A	  family	  of	  mammalian	  F-­box	  proteins.	  Curr	  Biol,	  1999.	  
9(20):	  p.	  1180-­‐2.	  78.	   Skowyra,	  D.,	  et	  al.,	  F-­box	  proteins	  are	  receptors	  that	  recruit	  phosphorylated	  
substrates	  to	  the	  SCF	  ubiquitin-­ligase	  complex.	  Cell,	  1997.	  91(2):	  p.	  209-­‐19.	  79.	   Cardozo,	   T.	   and	   M.	   Pagano,	   The	   SCF	   ubiquitin	   ligase:	   insights	   into	   a	  
molecular	  machine.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2004.	  5(9):	  p.	  739-­‐51.	  80.	   Sutterluty,	  H.,	  et	  al.,	  p45SKP2	  promotes	  p27Kip1	  degradation	  and	  induces	  S	  
phase	  in	  quiescent	  cells.	  Nat	  Cell	  Biol,	  1999.	  1(4):	  p.	  207-­‐14.	  81.	   Tsvetkov,	   L.M.,	   et	   al.,	   p27(Kip1)	   ubiquitination	   and	   degradation	   is	  
regulated	   by	   the	   SCF(Skp2)	   complex	   through	   phosphorylated	   Thr187	   in	  
p27.	  Curr	  Biol,	  1999.	  9(12):	  p.	  661-­‐4.	  82.	   Yu,	   Z.K.,	   J.L.	   Gervais,	   and	   H.	   Zhang,	   Human	   CUL-­1	   associates	   with	   the	  
SKP1/SKP2	  complex	  and	  regulates	  p21(CIP1/WAF1)	  and	  cyclin	  D	  proteins.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1998.	  95(19):	  p.	  11324-­‐9.	  
	   48	  
83.	   Bornstein,	  G.,	  et	  al.,	  Role	  of	  the	  SCFSkp2	  ubiquitin	  ligase	  in	  the	  degradation	  
of	  p21Cip1	  in	  S	  phase.	  J	  Biol	  Chem,	  2003.	  278(28):	  p.	  25752-­‐7.	  84.	   Kamura,	  T.,	  et	  al.,	  Degradation	  of	  p57Kip2	  mediated	  by	  SCFSkp2-­dependent	  
ubiquitylation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2003.	  100(18):	  p.	  10231-­‐6.	  85.	   Bhattacharya,	   S.,	   et	   al.,	   SKP2	   associates	   with	   p130	   and	   accelerates	   p130	  
ubiquitylation	  and	  degradation	  in	  human	  cells.	  Oncogene,	  2003.	  22(16):	  p.	  2443-­‐51.	  86.	   Frescas,	   D.	   and	  M.	   Pagano,	  Deregulated	   proteolysis	   by	   the	   F-­box	   proteins	  
SKP2	   and	   beta-­TrCP:	   tipping	   the	   scales	   of	   cancer.	   Nat	   Rev	   Cancer,	   2008.	  
8(6):	  p.	  438-­‐49.	  87.	   Tung,	   J.J.,	   et	   al.,	   A	   role	   for	   the	   anaphase-­promoting	   complex	   inhibitor	  
Emi2/XErp1,	   a	   homolog	   of	   early	   mitotic	   inhibitor	   1,	   in	   cytostatic	   factor	  
arrest	  of	  Xenopus	  eggs.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2005.	  102(12):	  p.	  4318-­‐23.	  88.	   Watanabe,	   N.,	   et	   al.,	   M-­phase	   kinases	   induce	   phospho-­dependent	  
ubiquitination	  of	  somatic	  Wee1	  by	  SCFbeta-­TrCP.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2004.	  101(13):	  p.	  4419-­‐24.	  89.	   Busino,	  L.,	  et	  al.,	  Degradation	  of	  Cdc25A	  by	  beta-­TrCP	  during	  S	  phase	  and	  in	  
response	  to	  DNA	  damage.	  Nature,	  2003.	  426(6962):	  p.	  87-­‐91.	  90.	   Jin,	   J.,	   et	   al.,	   SCFbeta-­TRCP	   links	   Chk1	   signaling	   to	   degradation	   of	   the	  
Cdc25A	  protein	  phosphatase.	  Genes	  Dev,	  2003.	  17(24):	  p.	  3062-­‐74.	  91.	   Kanemori,	   Y.,	   K.	   Uto,	   and	   N.	   Sagata,	   Beta-­TrCP	   recognizes	   a	   previously	  
undescribed	   nonphosphorylated	   destruction	   motif	   in	   Cdc25A	   and	   Cdc25B	  
phosphatases.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2005.	  102(18):	  p.	  6279-­‐84.	  92.	   Zhang,	  W.	  and	  D.M.	  Koepp,	  Fbw7	  isoform	  interaction	  contributes	  to	  cyclin	  E	  
proteolysis.	  Mol	  Cancer	  Res,	  2006.	  4(12):	  p.	  935-­‐43.	  93.	   Matsumoto,	   A.,	   et	   al.,	   Fbxw7beta	   resides	   in	   the	   endoplasmic	   reticulum	  
membrane	   and	   protects	   cells	   from	   oxidative	   stress.	   Cancer	   Sci,	   2011.	  
102(4):	  p.	  749-­‐55.	  94.	   Orlicky,	  S.,	  et	  al.,	  Structural	  basis	  for	  phosphodependent	  substrate	  selection	  
and	  orientation	  by	  the	  SCFCdc4	  ubiquitin	  ligase.	  Cell,	  2003.	  112(2):	  p.	  243-­‐56.	  95.	   Hao,	   B.,	   et	   al.,	   Structure	   of	   a	   Fbw7-­Skp1-­cyclin	   E	   complex:	   multisite-­
phosphorylated	   substrate	   recognition	   by	   SCF	   ubiquitin	   ligases.	   Mol	   Cell,	  2007.	  26(1):	  p.	  131-­‐43.	  96.	   Verma,	  R.,	  R.M.	  Feldman,	  and	  R.J.	  Deshaies,	  SIC1	  is	  ubiquitinated	  in	  vitro	  by	  
a	  pathway	   that	   requires	  CDC4,	  CDC34,	  and	  cyclin/CDK	  activities.	  Mol	  Biol	  Cell,	  1997.	  8(8):	  p.	  1427-­‐37.	  97.	   Henchoz,	   S.,	   et	   al.,	  Phosphorylation-­	  and	  ubiquitin-­dependent	  degradation	  
of	  the	  cyclin-­dependent	  kinase	  inhibitor	  Far1p	  in	  budding	  yeast.	  Genes	  Dev,	  1997.	  11(22):	  p.	  3046-­‐60.	  98.	   Wei,	   W.,	   et	   al.,	   The	   v-­Jun	   point	   mutation	   allows	   c-­Jun	   to	   escape	   GSK3-­
dependent	  recognition	  and	  destruction	  by	  the	  Fbw7	  ubiquitin	  ligase.	  Cancer	  Cell,	  2005.	  8(1):	  p.	  25-­‐33.	  99.	   Yada,	   M.,	   et	   al.,	   Phosphorylation-­dependent	   degradation	   of	   c-­Myc	   is	  
mediated	  by	  the	  F-­box	  protein	  Fbw7.	  EMBO	  J,	  2004.	  23(10):	  p.	  2116-­‐25.	  100.	   Welcker,	  M.,	  et	  al.,	  The	  Fbw7	  tumor	  suppressor	  regulates	  glycogen	  synthase	  
kinase	  3	  phosphorylation-­dependent	   c-­Myc	  protein	  degradation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2004.	  101(24):	  p.	  9085-­‐90.	  
	   49	  
101.	   Oberg,	   C.,	   et	   al.,	   The	   Notch	   intracellular	   domain	   is	   ubiquitinated	   and	  
negatively	  regulated	  by	  the	  mammalian	  Sel-­10	  homolog.	  J	  Biol	  Chem,	  2001.	  
276(38):	  p.	  35847-­‐53.	  102.	   Gupta-­‐Rossi,	   N.,	   et	   al.,	   Functional	   interaction	   between	   SEL-­10,	   an	   F-­box	  
protein,	   and	   the	   nuclear	   form	   of	   activated	   Notch1	   receptor.	   J	   Biol	   Chem,	  2001.	  276(37):	  p.	  34371-­‐8.	  103.	   Koepp,	  D.M.,	  et	  al.,	  Phosphorylation-­dependent	  ubiquitination	  of	  cyclin	  E	  by	  
the	  SCFFbw7	  ubiquitin	  ligase.	  Science,	  2001.	  294(5540):	  p.	  173-­‐7.	  104.	   Drury,	   L.S.,	   G.	   Perkins,	   and	   J.F.	   Diffley,	  The	   Cdc4/34/53	   pathway	   targets	  
Cdc6p	  for	  proteolysis	  in	  budding	  yeast.	  EMBO	  J,	  1997.	  16(19):	  p.	  5966-­‐76.	  105.	   Gudas,	   J.M.,	   et	   al.,	   Cyclin	   E2,	   a	   novel	   G1	   cyclin	   that	   binds	   Cdk2	   and	   is	  
aberrantly	  expressed	  in	  human	  cancers.	  Mol	  Cell	  Biol,	  1999.	  19(1):	  p.	  612-­‐22.	  106.	   Zariwala,	  M.,	   J.	   Liu,	   and	  Y.	  Xiong,	  Cyclin	  E2,	  a	  novel	  human	  G1	   cyclin	  and	  
activating	   partner	   of	   CDK2	   and	   CDK3,	   is	   induced	   by	   viral	   oncoproteins.	  Oncogene,	  1998.	  17(21):	  p.	  2787-­‐98.	  107.	   Lauper,	   N.,	   et	   al.,	   Cyclin	   E2:	   a	   novel	   CDK2	   partner	   in	   the	   late	   G1	   and	   S	  
phases	  of	  the	  mammalian	  cell	  cycle.	  Oncogene,	  1998.	  17(20):	  p.	  2637-­‐43.	  108.	   Moroy,	  T.	  and	  C.	  Geisen,	  Cyclin	  E.	   Int	   J	  Biochem	  Cell	  Biol,	  2004.	  36(8):	  p.	  1424-­‐39.	  109.	   Moore,	  J.D.,	  et	  al.,	  Nuclear	  import	  of	  Cdk/cyclin	  complexes:	  identification	  of	  
distinct	  mechanisms	  for	  import	  of	  Cdk2/cyclin	  E	  and	  Cdc2/cyclin	  B1.	   J	  Cell	  Biol,	  1999.	  144(2):	  p.	  213-­‐24.	  110.	   Winston,	  J.T.,	  C.	  Chu,	  and	  J.W.	  Harper,	  Culprits	  in	  the	  degradation	  of	  cyclin	  
E	  apprehended.	  Genes	  Dev,	  1999.	  13(21):	  p.	  2751-­‐7.	  111.	   Geng,	   Y.,	   et	   al.,	   Regulation	   of	   cyclin	   E	   transcription	   by	   E2Fs	   and	  
retinoblastoma	  protein.	  Oncogene,	  1996.	  12(6):	  p.	  1173-­‐80.	  112.	   Le	   Cam,	   L.,	   et	   al.,	   Timing	   of	   cyclin	   E	   gene	   expression	   depends	   on	   the	  
regulated	   association	   of	   a	   bipartite	   repressor	   element	   with	   a	   novel	   E2F	  
complex.	  EMBO	  J,	  1999.	  18(7):	  p.	  1878-­‐90.	  113.	   Ohtani,	  K.,	  J.	  DeGregori,	  and	  J.R.	  Nevins,	  Regulation	  of	  the	  cyclin	  E	  gene	  by	  
transcription	   factor	   E2F1.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A,	   1995.	   92(26):	   p.	  12146-­‐50.	  114.	   Zhang,	  H.S.,	  et	  al.,	  Exit	  from	  G1	  and	  S	  phase	  of	  the	  cell	  cycle	  is	  regulated	  by	  
repressor	   complexes	   containing	   HDAC-­Rb-­hSWI/SNF	   and	   Rb-­hSWI/SNF.	  Cell,	  2000.	  101(1):	  p.	  79-­‐89.	  115.	   Clurman,	   B.E.,	   et	   al.,	   Turnover	   of	   cyclin	   E	   by	   the	   ubiquitin-­proteasome	  
pathway	   is	   regulated	   by	   cdk2	   binding	   and	   cyclin	   phosphorylation.	   Genes	  Dev,	  1996.	  10(16):	  p.	  1979-­‐90.	  116.	   Welcker,	   M.,	   et	   al.,	  Multisite	   phosphorylation	   by	   Cdk2	   and	   GSK3	   controls	  
cyclin	  E	  degradation.	  Mol	  Cell,	  2003.	  12(2):	  p.	  381-­‐92.	  117.	   Won,	   K.A.	   and	   S.I.	   Reed,	   Activation	   of	   cyclin	   E/CDK2	   is	   coupled	   to	   site-­
specific	  autophosphorylation	  and	  ubiquitin-­dependent	  degradation	  of	  cyclin	  
E.	  EMBO	  J,	  1996.	  15(16):	  p.	  4182-­‐93.	  118.	   Ye,	  X.,	  et	  al.,	  Recognition	  of	  phosphodegron	  motifs	  in	  human	  cyclin	  E	  by	  the	  
SCF(Fbw7)	  ubiquitin	  ligase.	  J	  Biol	  Chem,	  2004.	  279(48):	  p.	  50110-­‐9.	  119.	   van	   Drogen,	   F.,	   et	   al.,	   Ubiquitylation	   of	   cyclin	   E	   requires	   the	   sequential	  
function	   of	   SCF	   complexes	   containing	   distinct	   hCdc4	   isoforms.	   Mol	   Cell,	  2006.	  23(1):	  p.	  37-­‐48.	  
	   50	  
120.	   Reed,	   S.I.,	   Cooperation	   between	   different	   Cdc4/Fbw7	   isoforms	   may	   be	  
associated	  with	  2-­step	   inactivation	  of	  SCF(Cdc4)	   targets.	  Cell	  Cycle,	  2006.	  
5(17):	  p.	  1923-­‐4.	  121.	   Akama,	   Y.,	   et	   al.,	   Frequent	   amplification	   of	   the	   cyclin	   E	   gene	   in	   human	  
gastric	  carcinomas.	  Jpn	  J	  Cancer	  Res,	  1995.	  86(7):	  p.	  617-­‐21.	  122.	   Ekholm-­‐Reed,	   S.,	   et	   al.,	  Deregulation	   of	   cyclin	   E	   in	   human	   cells	   interferes	  
with	   prereplication	   complex	   assembly.	   J	   Cell	   Biol,	   2004.	   165(6):	   p.	   789-­‐800.	  123.	   Willmarth,	   N.E.,	   D.G.	   Albertson,	   and	   S.P.	   Ethier,	   Chromosomal	   instability	  
and	  lack	  of	  cyclin	  E	  regulation	  in	  hCdc4	  mutant	  human	  breast	  cancer	  cells.	  Breast	  Cancer	  Res,	  2004.	  6(5):	  p.	  R531-­‐9.	  124.	   Spruck,	   C.H.,	   K.A.	   Won,	   and	   S.I.	   Reed,	   Deregulated	   cyclin	   E	   induces	  
chromosome	  instability.	  Nature,	  1999.	  401(6750):	  p.	  297-­‐300.	  125.	   Mussman,	   J.G.,	   et	   al.,	   Synergistic	   induction	   of	   centrosome	  
hyperamplification	   by	   loss	   of	   p53	   and	   cyclin	   E	   overexpression.	   Oncogene,	  2000.	  19(13):	  p.	  1635-­‐46.	  126.	   Nielsen,	  N.H.,	  et	  al.,	  Cyclin	  E	  overexpression,	  a	  negative	  prognostic	  factor	  in	  
breast	   cancer	   with	   strong	   correlation	   to	   oestrogen	   receptor	   status.	   Br	   J	  Cancer,	  1996.	  74(6):	  p.	  874-­‐80.	  127.	   Keyomarsi,	  K.,	  et	  al.,	  Cyclin	  E	  and	  survival	  in	  patients	  with	  breast	  cancer.	  N	  Engl	  J	  Med,	  2002.	  347(20):	  p.	  1566-­‐75.	  128.	   Payton,	  M.,	  et	  al.,	  Deregulation	  of	  cyclin	  E2	  expression	  and	  associated	  kinase	  
activity	  in	  primary	  breast	  tumors.	  Oncogene,	  2002.	  21(55):	  p.	  8529-­‐34.	  129.	   Geng,	  Y.,	  et	  al.,	  Expression	  of	  cyclins	  E1	  and	  E2	  during	  mouse	  development	  
and	  in	  neoplasia.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2001(98):	  p.	  13138-­‐13143.	  130.	   Haas,	  K.,	  et	  al.,	  Malignant	  transformation	  by	  cyclin	  E	  and	  Ha-­Ras	  correlates	  
with	   lower	   sensitivity	   towards	   induction	   of	   cell	   death	   but	   requires	  
functional	  Myc	  and	  CDK4.	  Oncogene,	  1997.	  15(21):	  p.	  2615-­‐23.	  131.	   Rajagopalan,	   H.,	   et	   al.,	   Inactivation	   of	   hCDC4	   can	   cause	   chromosomal	  
instability.	  Nature,	  2004.	  428(6978):	  p.	  77-­‐81.	  132.	   Spruck,	   C.H.,	   et	   al.,	  hCDC4	   gene	  mutations	   in	   endometrial	   cancer.	   Cancer	  Res,	  2002.	  62(16):	  p.	  4535-­‐9.	  133.	   Yeh,	  E.S.,	  B.O.	  Lew,	  and	  A.R.	  Means,	  The	   loss	  of	  PIN1	  deregulates	   cyclin	  E	  
and	  sensitizes	  mouse	  embryo	  fibroblasts	  to	  genomic	  instability.	  J	  Biol	  Chem,	  2006.	  281(1):	  p.	  241-­‐51.	  134.	   Yeh,	   E.,	   et	   al.,	   A	   signalling	   pathway	   controlling	   c-­Myc	   degradation	   that	  
impacts	  oncogenic	  transformation	  of	  human	  cells.	  Nat	  Cell	  Biol,	  2004.	  6(4):	  p.	  308-­‐18.	  135.	   Popov,	  N.,	  et	  al.,	  The	  ubiquitin-­specific	  protease	  USP28	  is	  required	  for	  MYC	  
stability.	  Nat	  Cell	  Biol,	  2007.	  9(7):	  p.	  765-­‐74.	  136.	   Akhoondi,	  S.,	  et	  al.,	  FBXW7/hCDC4	  is	  a	  general	  tumor	  suppressor	  in	  human	  
cancer.	  Cancer	  Res,	  2007.	  67(19):	  p.	  9006-­‐12.	  137.	   Mao,	   J.H.,	   et	  al.,	  Fbxw7/Cdc4	   is	  a	  p53-­dependent,	  haploinsufficient	   tumour	  
suppressor	  gene.	  Nature,	  2004.	  432(7018):	  p.	  775-­‐9.	  138.	   Kominami,	  K.,	   I.	  Ochotorena,	  and	  T.	  Toda,	  Two	  F-­box/WD-­repeat	  proteins	  
Pop1	  and	  Pop2	  form	  hetero-­	  and	  homo-­complexes	  together	  with	  cullin-­1	  in	  
the	   fission	   yeast	   SCF	   (Skp1-­Cullin-­1-­F-­box)	   ubiquitin	   ligase.	   Genes	   Cells,	  1998.	  3(11):	  p.	  721-­‐35.	  
	   51	  
139.	   Seibert,	   V.,	   et	   al.,	   Combinatorial	   diversity	   of	   fission	   yeast	   SCF	   ubiquitin	  
ligases	   by	   homo-­	   and	   heterooligomeric	   assemblies	   of	   the	   F-­box	   proteins	  
Pop1p	  and	  Pop2p.	  BMC	  Biochem,	  2002.	  3:	  p.	  22.	  140.	   Tang,	  X.,	  et	  al.,	  Suprafacial	  orientation	  of	  the	  SCFCdc4	  dimer	  accommodates	  
multiple	   geometries	   for	   substrate	   ubiquitination.	   Cell,	   2007.	   129(6):	   p.	  1165-­‐76.	  141.	   Welcker,	   M.	   and	   B.E.	   Clurman,	   Fbw7/hCDC4	   dimerization	   regulates	   its	  
substrate	  interactions.	  Cell	  Div,	  2007.	  2:	  p.	  7.	  142.	   O'Neil,	  J.,	  et	  al.,	  FBW7	  mutations	  in	  leukemic	  cells	  mediate	  NOTCH	  pathway	  
activation	  and	  resistance	  to	  gamma-­secretase	  inhibitors.	   J	  Exp	  Med,	  2007.	  
204(8):	  p.	  1813-­‐24.	  143.	   Davis,	   H.,	   et	   al.,	   FBXW7	  mutations	   typically	   found	   in	   human	   cancers	   are	  
distinct	   from	   null	   alleles	   and	   disrupt	   lung	   development.	   J	   Pathol,	   2011.	  
224(2):	  p.	  180-­‐9.	  144.	   Akhoondi,	   S.,	   et	   al.,	   Inactivation	   of	   FBXW7/hCDC4-­beta	   expression	   by	  
promoter	   hypermethylation	   is	   associated	   with	   favorable	   prognosis	   in	  
primary	  breast	  cancer.	  Breast	  Cancer	  Res,	  2010.	  12(6):	  p.	  R105.	  145.	   Xu,	   Y.,	   et	   al.,	   MicroRNA-­223	   regulates	   cyclin	   E	   activity	   by	   modulating	  
expression	   of	   F-­box	   and	   WD-­40	   domain	   protein	   7.	   J	   Biol	   Chem,	   2010.	  
285(45):	  p.	  34439-­‐46.	  146.	   Lerner,	   M.,	   et	   al.,	  MiRNA-­27a	   controls	   FBW7/hCDC4-­dependent	   cyclin	   E	  
degradation	  and	  cell	  cycle	  progression.	  Cell	  Cycle,	  2011.	  10(13):	  p.	  2172-­‐83.	  147.	   Eilers,	  M.	  and	  R.N.	  Eisenman,	  Myc's	  broad	  reach.	  Genes	  Dev,	  2008.	  22(20):	  p.	  2755-­‐66.	  148.	   Larsson,	  L.G.	  and	  M.A.	  Henriksson,	  The	  Yin	  and	  Yang	  functions	  of	  the	  Myc	  
oncoprotein	  in	  cancer	  development	  and	  as	  targets	  for	  therapy.	  Exp	  Cell	  Res,	  2010.	  316(8):	  p.	  1429-­‐37.	  149.	   Meyer,	  N.	  and	  L.Z.	  Penn,	  Reflecting	  on	  25	  years	  with	  MYC.	  Nat	  Rev	  Cancer,	  2008.	  8(12):	  p.	  976-­‐90.	  150.	   Adhikary,	  S.	  and	  M.	  Eilers,	  Transcriptional	   regulation	  and	   transformation	  
by	  Myc	  proteins.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2005.	  6(8):	  p.	  635-­‐45.	  151.	   von	   der	   Lehr,	   N.,	   et	   al.,	   The	   F-­box	   protein	   Skp2	   participates	   in	   c-­Myc	  
proteosomal	   degradation	   and	   acts	   as	   a	   cofactor	   for	   c-­Myc-­regulated	  
transcription.	  Mol	  Cell,	  2003.	  11(5):	  p.	  1189-­‐200.	  152.	   Vervoorts,	   J.,	   et	   al.,	   Stimulation	   of	   c-­MYC	   transcriptional	   activity	   and	  
acetylation	  by	  recruitment	  of	   the	  cofactor	  CBP.	  EMBO	  Rep,	  2003.	  4(5):	  p.	  484-­‐90.	  153.	   Faiola,	  F.,	  et	  al.,	  Dual	  regulation	  of	  c-­Myc	  by	  p300	  via	  acetylation-­dependent	  
control	   of	   Myc	   protein	   turnover	   and	   coactivation	   of	   Myc-­induced	  
transcription.	  Mol	  Cell	  Biol,	  2005.	  25(23):	  p.	  10220-­‐34.	  154.	   Chan,	   H.M.	   and	   N.B.	   La	   Thangue,	   p300/CBP	   proteins:	   HATs	   for	  
transcriptional	  bridges	  and	  scaffolds.	  J	  Cell	  Sci,	  2001.	  114(Pt	  13):	  p.	  2363-­‐73.	  155.	   Goodman,	  R.H.	  and	  S.	  Smolik,	  CBP/p300	  in	  cell	  growth,	  transformation,	  and	  
development.	  Genes	  Dev,	  2000.	  14(13):	  p.	  1553-­‐77.	  156.	   Grandori,	   C.,	   et	   al.,	   The	   Myc/Max/Mad	   network	   and	   the	   transcriptional	  
control	  of	  cell	  behavior.	  Annu	  Rev	  Cell	  Dev	  Biol,	  2000.	  16:	  p.	  653-­‐99.	  
	   52	  
157.	   Meyer,	   N.,	   S.S.	   Kim,	   and	   L.Z.	   Penn,	   The	   Oscar-­worthy	   role	   of	   Myc	   in	  
apoptosis.	  Semin	  Cancer	  Biol,	  2006.	  16(4):	  p.	  275-­‐87.	  158.	   Dang,	   C.V.,	   A.	   O'Donnell	   K,	   and	   T.	   Juopperi,	   The	   great	   MYC	   escape	   in	  
tumorigenesis.	  Cancer	  Cell,	  2005.	  8(3):	  p.	  177-­‐8.	  159.	   Zindy,	  F.,	  et	  al.,	  Myc	  signaling	  via	  the	  ARF	  tumor	  suppressor	  regulates	  p53-­
dependent	   apoptosis	   and	   immortalization.	   Genes	   Dev,	   1998.	   12(15):	   p.	  2424-­‐33.	  160.	   Eischen,	   C.M.,	   et	   al.,	   Disruption	   of	   the	   ARF-­Mdm2-­p53	   tumor	   suppressor	  
pathway	   in	   Myc-­induced	   lymphomagenesis.	   Genes	   Dev,	   1999.	   13(20):	   p.	  2658-­‐69.	  161.	   Egle,	  A.,	   et	   al.,	  Bim	   is	  a	   suppressor	  of	  Myc-­induced	  mouse	  B	   cell	   leukemia.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2004.	  101(16):	  p.	  6164-­‐9.	  162.	   Juin,	  P.,	  et	  al.,	  c-­Myc-­induced	  sensitization	  to	  apoptosis	  is	  mediated	  through	  
cytochrome	  c	  release.	  Genes	  Dev,	  1999.	  13(11):	  p.	  1367-­‐81.	  163.	   Haupt,	  Y.,	  et	  al.,	  bmi-­1	  transgene	  induces	  lymphomas	  and	  collaborates	  with	  
myc	  in	  tumorigenesis.	  Oncogene,	  1993.	  8(11):	  p.	  3161-­‐4.	  164.	   Schmitt,	  C.A.,	  et	  al.,	  INK4a/ARF	  mutations	  accelerate	  lymphomagenesis	  and	  
promote	   chemoresistance	   by	   disabling	   p53.	   Genes	   Dev,	   1999.	   13(20):	   p.	  2670-­‐7.	  165.	   Murphy,	   D.J.,	   et	   al.,	  Distinct	   thresholds	   govern	   Myc's	   biological	   output	   in	  
vivo.	  Cancer	  Cell,	  2008.	  14(6):	  p.	  447-­‐57.	  166.	   Hydbring,	  P.,	  et	  al.,	  Phosphorylation	  by	  Cdk2	  is	  required	  for	  Myc	  to	  repress	  
Ras-­induced	   senescence	   in	   cotransformation.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A,	  2010.	  107(1):	  p.	  58-­‐63.	  167.	   Zhuang,	   D.,	   et	   al.,	   C-­MYC	   overexpression	   is	   required	   for	   continuous	  
suppression	  of	  oncogene-­induced	  senescence	  in	  melanoma	  cells.	  Oncogene,	  2008.	  27(52):	  p.	  6623-­‐34.	  168.	   Campaner,	  S.,	  et	  al.,	  Cdk2	  suppresses	  cellular	  senescence	   induced	  by	   the	  c-­
myc	  oncogene.	  Nat	  Cell	  Biol,	  2010.	  12(1):	  p.	  54-­‐9;	  sup	  pp	  1-­‐14.	  169.	   Gstaiger,	  M.,	  et	  al.,	  Skp2	  is	  oncogenic	  and	  overexpressed	  in	  human	  cancers.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2001.	  98(9):	  p.	  5043-­‐8.	  170.	   DeSalle,	   L.M.	   and	  M.	   Pagano,	  Regulation	   of	   the	   G1	   to	   S	   transition	   by	   the	  
ubiquitin	  pathway.	  FEBS	  Lett,	  2001.	  490(3):	  p.	  179-­‐89.	  171.	   Kim,	  S.Y.,	  et	  al.,	  Skp2	  regulates	  Myc	  protein	  stability	  and	  activity.	  Mol	  Cell,	  2003.	  11(5):	  p.	  1177-­‐88.	  172.	   Sears,	  R.,	  et	  al.,	  Multiple	  Ras-­dependent	  phosphorylation	  pathways	  regulate	  
Myc	  protein	  stability.	  Genes	  Dev,	  2000.	  14(19):	  p.	  2501-­‐14.	  173.	   Gregory,	  M.A.,	  Y.	  Qi,	  and	  S.R.	  Hann,	  Phosphorylation	  by	  glycogen	  synthase	  
kinase-­3	   controls	   c-­myc	   proteolysis	   and	   subnuclear	   localization.	   J	   Biol	  Chem,	  2003.	  278(51):	  p.	  51606-­‐12.	  174.	   Bahram,	   F.,	   et	   al.,	   c-­Myc	   hot	   spot	   mutations	   in	   lymphomas	   result	   in	  
inefficient	   ubiquitination	   and	   decreased	   proteasome-­mediated	   turnover.	  Blood,	  2000.	  95(6):	  p.	  2104-­‐10.	  175.	   Tan,	  Y.,	  O.	  Sangfelt,	  and	  C.	  Spruck,	  The	  Fbxw7/hCdc4	  tumor	  suppressor	   in	  
human	  cancer.	  Cancer	  Lett,	  2008.	  271(1):	  p.	  1-­‐12.	  176.	   Adhikary,	   S.,	   et	   al.,	  The	   ubiquitin	   ligase	   HectH9	   regulates	   transcriptional	  
activation	   by	  Myc	   and	   is	   essential	   for	   tumor	   cell	   proliferation.	   Cell,	   2005.	  
123(3):	  p.	  409-­‐21.	  
	   53	  
177.	   Zhao,	   X.,	   et	   al.,	  The	  HECT-­domain	   ubiquitin	   ligase	  Huwe1	   controls	   neural	  
differentiation	   and	   proliferation	   by	   destabilizing	   the	   N-­Myc	   oncoprotein.	  Nat	  Cell	  Biol,	  2008.	  10(6):	  p.	  643-­‐53.	  178.	   Kim,	  H.T.,	   et	  al.,	  Certain	  pairs	  of	  ubiquitin-­conjugating	  enzymes	   (E2s)	  and	  
ubiquitin-­protein	   ligases	   (E3s)	   synthesize	   nondegradable	   forked	   ubiquitin	  
chains	   containing	   all	   possible	   isopeptide	   linkages.	   J	   Biol	   Chem,	   2007.	  
282(24):	  p.	  17375-­‐86.	  179.	   Chen,	   D.,	   et	   al.,	   ARF-­BP1/Mule	   is	   a	   critical	   mediator	   of	   the	   ARF	   tumor	  
suppressor.	  Cell,	  2005.	  121(7):	  p.	  1071-­‐83.	  180.	   Hall,	   J.R.,	   et	   al.,	  Cdc6	   stability	   is	   regulated	   by	   the	   Huwe1	   ubiquitin	   ligase	  
after	  DNA	  damage.	  Mol	  Biol	  Cell,	  2007.	  18(9):	  p.	  3340-­‐50.	  181.	   Liu,	  Z.,	  R.	  Oughtred,	  and	  S.S.	  Wing,	  Characterization	  of	  E3Histone,	  a	  novel	  
testis	   ubiquitin	   protein	   ligase	   which	   ubiquitinates	   histones.	   Mol	   Cell	   Biol,	  2005.	  25(7):	  p.	  2819-­‐31.	  182.	   Zhong,	  Q.,	   et	   al.,	  Mule/ARF-­BP1,	   a	  BH3-­only	  E3	  ubiquitin	   ligase,	   catalyzes	  
the	  polyubiquitination	  of	  Mcl-­1	  and	  regulates	  apoptosis.	  Cell,	  2005.	  121(7):	  p.	  1085-­‐95.	  183.	   Yang,	  Y.,	  et	  al.,	  E3	  ubiquitin	  ligase	  Mule	  ubiquitinates	  Miz1	  and	  is	  required	  
for	   TNFalpha-­induced	   JNK	   activation.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A,	   2010.	  
107(30):	  p.	  13444-­‐9.	  184.	   Petroski,	   M.D.	   and	   R.J.	   Deshaies,	   Function	   and	   regulation	   of	   cullin-­RING	  
ubiquitin	  ligases.	  Nat	  Rev	  Mol	  Cell	  Biol,	  2005.	  6(1):	  p.	  9-­‐20.	  185.	   Choi,	  S.H.,	  et	  al.,	  Myc	  protein	  is	  stabilized	  by	  suppression	  of	  a	  novel	  E3	  ligase	  
complex	  in	  cancer	  cells.	  Genes	  Dev,	  2010.	  24(12):	  p.	  1236-­‐41.	  186.	   Popov,	  N.,	  et	  al.,	  Ubiquitylation	  of	  the	  amino	  terminus	  of	  Myc	  by	  SCF(beta-­
TrCP)	   antagonizes	   SCF(Fbw7)-­mediated	   turnover.	   Nat	   Cell	   Biol,	   2010.	  
12(10):	  p.	  973-­‐81.	  187.	   Popov,	  N.,	  et	  al.,	  Fbw7	  and	  Usp28	  regulate	  myc	  protein	  stability	  in	  response	  
to	  DNA	  damage.	  Cell	  Cycle,	  2007.	  6(19):	  p.	  2327-­‐31.	  188.	   Evan,	  G.I.,	  et	  al.,	  Induction	  of	  apoptosis	  in	  fibroblasts	  by	  c-­myc	  protein.	  Cell,	  1992.	  69(1):	  p.	  119-­‐28.	  189.	   Harrington,	  E.A.,	  et	  al.,	  c-­Myc-­induced	  apoptosis	  in	  fibroblasts	  is	  inhibited	  by	  
specific	  cytokines.	  EMBO	  J,	  1994.	  13(14):	  p.	  3286-­‐95.	  190.	   Salghetti,	  S.E.,	  S.Y.	  Kim,	  and	  W.P.	  Tansey,	  Destruction	  of	  Myc	  by	  ubiquitin-­
mediated	   proteolysis:	   cancer-­associated	   and	   transforming	   mutations	  
stabilize	  Myc.	  EMBO	  J,	  1999.	  18(3):	  p.	  717-­‐26.	  191.	   Hemann,	  M.T.,	   et	   al.,	  Evasion	   of	   the	   p53	   tumour	   surveillance	   network	   by	  
tumour-­derived	  MYC	  mutants.	  Nature,	  2005.	  436(7052):	  p.	  807-­‐11.	  192.	   Sieuwerts,	   A.M.,	   et	   al.,	  Which	   cyclin	   E	   prevails	   as	   prognostic	   marker	   for	  
breast	  cancer?	  Results	  from	  a	  retrospective	  study	  involving	  635	  lymph	  node-­
negative	   breast	   cancer	   patients.	   Clin	   Cancer	   Res,	   2006.	   12(11	   Pt	   1):	   p.	  3319-­‐28.	  	  
 
	   54	  
7.	  ORIGINAL	  PUBLICATIONS	  AND	  MANUSCRIPTS 
	  
	  
